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Abstract 
Human papillomaviruses (HPVs) are responsible for approximately 4.5% of the global cancer 
burden. Virtually all cervical cancers (CESC) are caused by HPVs, as well as a subset of head 
and neck squamous cell carcinomas (HNSC). Our studies began by using data from over 800 
CESC and HNSC samples from The Cancer Genome Atlas (TCGA) to test a model proposed 
from in vitro studies of an HPV-dependent deregulation of the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) locus. Similar to the proposed models, we found that the HPV+ 
TMEs—regardless of tissue of origin—expressed significantly higher levels of KDM6A which 
demethylates the repressive tri-methylated lysine 27 on histone 3—critical for tightly 
regulating expression from the aforementioned locus. Furthermore, we also found that CpG 
methylation of the CDKN2A locus was consistently altered in HPV-positive (HPV+) tumors. 
We next wanted to test another in vitro model that proposed an HPV-dependent transcriptional 
downregulation of genes that encode for essential products of the class I major 
histocompatibility complex I (MHC-I) antigen presentation system. Utilizing the same large 
TCGA cohorts, we unexpectedly found that these genes were expressed at high levels in HPV+ 
tumors. The high mRNA levels of the MHC-I antigen presentation apparatus could be a 
consequence of the higher intratumoral levels of interferon-gamma (IFNγ) observed in HPV+ 
carcinomas, which correlated with signatures of increased infiltration by T- and NK-cells. In 
addition, we also found increased expression of the class II MHC antigen presentation system 
in HPV+ HNSC. Furthermore, we observed that HPV+ HNSC TMEs exhibited a strong bias 
towards a Th1 response which was characterized by increased infiltration with multiple types 
of immune cells and expression of their effector molecules. Moreover, the HPV+ HNSC TME 
also expressed high levels of multiple T-cell exhaustion markers that were indicative of a T-
cell-inflamed phenotype. Overall, these analyses have provided significant insight into the 
validity of models proposed from experiments conducted in relatively artificial in vitro culture 
systems. Importantly, these studies have illustrated, in great detail, the strikingly profound 
differences in both the epigenetic and immune landscapes between the tumor 
microenvironments of HPV+ and HPV-negative carcinomas.
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Summary for Lay Audience 
Human papillomaviruses (HPVs) are responsible for approximately 4.5% of the global cancer 
burden. Virtually all cervical cancers (CESC) are caused by HPVs, as well as a subset of head 
and neck squamous cell carcinomas (HNSC). CESC and HNSC are the 4th and 7th most 
common cancers worldwide, respectively. The distinctive etiological factors that are involved 
in CESC and HNSC tumorigenesis—such as the expression of exogenous oncogenic viral 
antigens in HPV-positive (HPV+), but not HPV-negative (HPV–), carcinomas—provides us 
with a unique opportunity to study differences in the tumor microenvironments of HPV+ and 
HPV– carcinomas in 2 distinct anatomical regions. Much of the existing literature that 
underpins the foundation for this body of work utilizes artificial in vitro model systems. 
However, their lack of heterogeneity, tumor microenvironment, and infiltrating immune cells 
severely limit their ability to recapitulate actual human cancers. Therefore, this work 
capitalizes on genomic and transcriptomic “big” data acquired through next-generation “-
omics” technologies from actual human tumors, which allow for an insightful elucidation of 
mechanistic processes under the influence of a native heterogeneous environment. Utilizing 
computational methods, this work explores and profiles the epigenetic and immune landscapes 
between the tumor microenvironments of HPV+ and HPV– carcinomas present in actual 
human malignancies. The studies presented in this thesis identify strikingly profound 
differences in the epigenetic and immune landscapes of the tumor microenvironments of these 
2 etiologically-distinct carcinomas, regardless of their tissue of origin. Furthermore, they also 
provide insight into the validity of 2 important models of high-risk HPV-mediated sabotage of 
intracellular epigenetic and immune networks that were previously proposed from artificial in 
vitro culture studies. In addition, these studies identify potentially useful therapeutic targets 
and advocate for the utility of novel immunotherapy treatment modalities. Moreover, they also 
identify potentially predictive biomarkers of clinical outcomes that could have implications for 
treatment deintensification.  
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 Out of the night that covers me, 
        Black as the pit from pole to pole, 
 I thank whatever gods may be 
       For my unconquerable soul. 
 
  In the fell clutch of circumstance 
                                            I have not winced nor cried aloud. 
  Under the bludgeonings of chance 
        My head is bloody, but unbowed. 
      
  Beyond this place of wrath and tears 
        Looms but the Horror of the shade, 
  And yet the menace of the years 
        Finds, and shall find, me unafraid. 
 
  It matters not how strait the gate, 
        How charged with punishments the scroll, 
  I am the master of my fate: 
        I am the captain of my soul. 
     
        -Invictus 
         by William Ernest Henley 
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Chapter 1  
1 Introduction 
 
1.1 A Brief History of Papillomavirus Research 
The earliest evidence of human papillomavirus (HPV) infections came from ancient Greek 
and Roman texts that described lesions akin to present-day genital warts. At the time, such 
lesions were associated with sexual promiscuity, which hinted at their infectious etiology 
(Bafverstedt, 1967; zur Hausen, 2009).  However, it wasn’t until the start of the 20th century 
that the viral origins and contagious nature of warts were explicitly demonstrated through 
cell-free transmission experiments conducted in Italy (reviewed in Syrjanen and Syrjanen, 
2008). In the 1930s, landmark experiments conducted by Richard Shope identified the first 
animal papillomavirus (PV)—the cottontail rabbit papillomavirus (CRPV)—through the 
isolation and characterization of contagious cutaneous papillomas that grew on wild 
cottontail rabbits (Shope and Hurst, 1933). In addition to causing benign lesions, some 
CRPV-induced papillomas progressed to carcinomas (Rous and Beard, 1935). This 
fundamental observation led to the identification of CRPV as the first DNA tumor virus.  
Up until the 1950s, CRPV infection of rabbits served as an important model for the study 
of viral carcinogenesis (reviewed in Syrjanen and Syrjanen, 2008). However, the discovery 
of polyomaviruses (PyVs) replaced CRPV as a model of virally-induced tumorigenesis, 
since they were easily propagated in culture, could transform cells in vitro, and were 
tumorigenic to other experimental animals (Javier and Butel, 2008). With the dawn of 
molecular cloning in the 1970s, scientists were now able to study the biochemical 
properties of PVs through the cloning of their genomes. Specifically, open reading frames 
(ORFs) were being identified as putative viral genes, and their functions elucidated through 
reverse genetics (Chen et al., 1982; Danos et al., 1982).  
Anecdotal reports regarding the spontaneous conversion of genital warts into squamous 
cell carcinomas initiated extensive experiments in which the aim was to establish an 
association between HPV infection and cancer (zur Hausen, 1977; zur Hausen et al., 1974). 
2 
 
Indeed, in 1982 the first three reports of HPV sequences isolated from human tumors were 
published (Gissmann et al., 1982; Green et al., 1982; Zachow et al., 1982). Shortly 
thereafter, in situ DNA hybridization experiments on genital cancer biopsies and cervical 
cancer-derived cell lines identified two novel HPV genotypes—HPV type 16 (HPV16) and 
HPV type 18 (HPV18)—which were subsequently confirmed to be present in virtually all 
cervical cancers (Boshart et al., 1984; Durst et al., 1983). These ground-breaking 
discoveries definitively identified HPV16 and 18 as the causative agents of cervical cancer.  
In the 1990s, a large-scale epidemiological study provided evidence that various HPV 
types—HPV16, 18, 31, 33, and 35—were the main risk factors for cervical cancer (Munoz 
et al., 1992). In the early 2000s, a seminal paper by Gillison et al., showed evidence of a 
causal association between HPV infection and a subset of head and neck cancers (Gillison 
et al., 2000). Today, it is well-established that infection with specific HPV types can give 
rise to cervical, other anogenital, and head and neck cancers (zur Hausen, 2002). Through 
almost a century of research initiatives, certain HPV types have emerged as potent human 
biological carcinogens. 
1.2 Papillomaviruses at a Glance 
PVs are ubiquitous entities, having successfully infected and co-evolved with at least 54 
different non-human host species—mostly mammals, but also birds and reptiles (Rector 
and Van Ranst, 2013). Their ability to transmit through direct physical contact and general 
inability to cause fatal disease have allowed PVs to establish successful niches and co-
evolve with their host-species (Chen et al., 2018). Typically, infections with PVs—
regardless of the host species they infect—causes papillomas (warts), which are simply 
benign hyperplastic growths of epithelial cells (Rector and Van Ranst, 2013). However, in 
some instances, papillomas can progress to carcinomas, and this phenomenon of malignant 
progression is in part responsible for PVs being some of the most intensively researched 
viruses in the world, specifically those that infect humans. 
In humans, there are currently over 200 established HPV types that have been isolated, 
sequenced, and their clones deposited to the International HPV Reference Center (Muhr et 
al., 2018). This diverse group of human-specific PVs all share an exclusive tropism for 
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either cutaneous or mucosal epithelia. The cutaneous HPV types are responsible for the 
development of common warts (papillomas), which are typically self-limiting, small and 
grainy growths that occur most often on hands (Mammas et al., 2009). In extremely rare 
cases, individuals with an autosomal recessive genetic mutation are profoundly susceptible 
to infection with certain cutaneous HPV types that can lead to a skin disorder that is 
clinically termed epidermodysplasia verruciformis (EV) (Gewirtzman et al., 2008). 
Patients with EV have a genetic defect in two genes that are critical for cutaneous 
immunity, illustrating the importance of the immune system in keeping HPV infections 
under control (Lane et al., 2003). Symptomatically, patients succumb to a lifelong battle 
with uncontrollable growth of scaly macules (skin discoloration) and papules (inflamed 
cutaneous lesions) that can undergo malignant transformation (de Oliveira et al., 2003). 
In contrast, mucosal HPV types are responsible for mucosal lesions that occur in the 
anogenital or oral tracts (Doorbar et al., 2012). These mucosal warts, like their 
aforementioned cutaneous counterparts, are typically benign or low-grade and are often 
self-limiting. However, in some instances, infection with certain types of HPVs can lead 
to the formation of lesions that have a much higher propensity to progress to carcinomas. 
These epitheliotropic viruses are highly transmissible, with the highest incidence occurring 
at the onset of sexual activity (Cutts et al., 2007). In fact, mucosal HPVs are the most 
common sexually transmitted viral infection worldwide and it is estimated that most 
sexually active individuals, regardless of sex, will acquire it at some point during their life 
(Crosbie et al., 2013; Dunne et al., 2007). Accordingly, these mucosa-associated HPV 
types are designated as either low-risk (LR) or high-risk (HR) based on their oncogenic 
potential (Tommasino, 2014). The prototypical LR HPVs, HPV6 and 11, are responsible 
for the majority of anogenital and oral warts with about 90% being cleared naturally within 
2 years (Bharti et al., 2013). Whereas, the prototypical HR HPV types 16 and 18 are 
responsible for a small number of mucosal lesions, but the frequency of progression to 
premalignant lesions that further develop into carcinomas is much higher compared to their 
low-risk counterparts (Doorbar et al., 2012). Indeed, 12 HR HPV types—including HPV16 
and 18— are designated by the World Health Organization’s (WHO) International Agency 
for Research on Cancer (IARC) as Group 1 biological agents: “carcinogenic to humans” 
(Bouvard et al., 2009). In contrast, LR HPV types are classified by IARC as having 
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inadequate evidence of carcinogenicity (Group 3). These differences in carcinogenic 
potential between LR and HR HPV infections can be attributed to variations in viral 
oncoprotein functions, along with differences in viral promoter activities and gene 
expression patterns (Doorbar et al., 2012; Klingelhutz and Roman, 2012). 
1.3 Human Papillomavirus Biology 
HPVs belong to the Papillomaviridae family of viruses and are divided into five 
phylogenetic genera—designated Alpha, Beta, Gamma, Mu, and Nu—based on DNA 
sequence analysis (Bernard et al., 2010). The majority of research initiatives have focused 
on the Alphapapillomaviruses because of their impact on human health. This genus 
includes the mucosal wart causing LR types as well as the HR types that cause cancer. At 
the population level, HPV16 is the most frequently detected Alphapapillomavirus, and its 
high association with carcinogenesis makes this type the most clinically relevant 
(Schiffman et al., 2016). Indeed, because of its potent carcinogenicity, HPV16 is the best-
studied PV and will henceforth be considered in this thesis as the archetypal example. 
HPV16 is a small DNA tumor virus with a non-enveloped icosahedral capsid that is 
approximately 55 nm in diameter (Figure 1.1A). This naked capsid is primarily composed 
of the major capsid protein L1, and to a much smaller extent the minor capsid protein L2. 
(Doorbar et al., 2015). The virions consist of a single, double-stranded circular DNA 
genome that is made up of 7,908 base pairs (bp) that contains 8 open reading frames (ORFs) 
encoded on one DNA strand (Figure 1.1B). The genome is organized into 3 major regions: 
(i) a non-coding region, called the upstream regulatory region (URR)—alternatively called 
the long control region (LCR)—that contains cis-regulatory elements essential for viral 
DNA replication and controlling gene expression; (ii) an early region that encodes for the 
early genes—E1, E2, E4, E5, E6, and E7—that are involved in a plethora of functions 
including viral replication and cell transformation; and (iii) a late region that encodes for 
the major (L1) and minor (L2) capsid proteins (Tommasino, 2014). Select functions of the 
early and late gene products are summarized in Figure 1.1C. Furthermore, due to their 
relatively small genome size and subsequent limited coding capacity, viral gene expression 
is coordinated by multiple promoters that create a complex configuration of mRNA 
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Figure 1.1. The HPV16 capsid and genome organization with select functions 
highlighted. 
Schematic representation of the HPV16 icosahedral capsid (A) and genome organization 
(B). Summary of select functions of the viral products encoded by HPV16 (C). Regions 
with similar functions are indicated with similar colors: the non-coding region is in gray, 
the early region that encodes for the early genes involved in viral replication is in green, 
the early region that encodes for the early genes involved in cellular transformation is in 
red, and the late region that encodes for the capsid proteins is in blue. Adapted from 
Tommasino, 2014.
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transcripts that undergo extensive alternative splicing that enables viral gene products to 
be expressed at different phases throughout the viral replicative cycle (Graham, 2010). 
The replicative cycle of HPVs is unique because of the intimate link to the differentiation 
program of epidermal keratinocytes (Figure 1.2). In order for HPVs to successfully 
replicate, they require access to the basal layer cells of the epithelium through micro-
wounds or hair follicles (Doorbar et al., 2012). Once at the basal layer, entry into the host 
cell is mediated by the viral L1 major capsid protein interacting with heparan sulfate 
proteoglycans on the cell surface (Shafti-Keramat et al., 2003). This interaction triggers the 
internalization of the virion via a clathrin-dependent endocytic mechanism (Day et al., 
2003). Once internalized, the virus undergoes endosomal transport and subsequent 
uncoating in the late endosomes. The low pH environment found in late endosomes triggers 
viral egress by promoting the interaction between the viral L2 minor capsid protein and 
cellular protein SNX17 (Bergant Marusic et al., 2012). Importantly, the L2 protein—
complexed with viral DNA—ensures the correct entry of the viral genome into the host 
cell nucleus (Doorbar et al., 2012; Schelhaas et al., 2012). Once in the nucleus, there is an 
initial phase of viral genome amplification that is followed by maintenance of the viral 
episome at a low-copy number—often proposed to be around 50-200 copies per cell 
(McBride, 2008; Parish et al., 2006; Pyeon et al., 2009). Viral replication is mediated 
through the usurpation of the host cells’ high-fidelity cellular polymerases. Whereas 
maintenance of viral genome integrity and accurate segregation to daughter cells during 
mitosis is ensured by the E1 and E2 viral proteins, which are both necessary and sufficient 
for PV replication (McBride, 2017). 
As the basal layer cells migrate upwards, they begin to differentiate and stop proliferating. 
During differentiation, the cells undergo several biochemical changes in order to produce 
the protective, semi-permeable outer layer of skin that is an essential environmental barrier 
necessary for all terrestrial life (Madison, 2003). It is during this growth-arrested, 
differentiation stage that the viral E6 and E7 proteins deregulate cell cycle control and force 
the quiescent cell to re-enter S phase (Bravo and Felez-Sanchez, 2015; Cheng et al., 1995; 
Sherman et al., 1997). This forced re-entry results in viral genome amplification and 
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Figure 1.2. The replicative cycle of human papillomaviruses. 
HPVs infect keratinocytes present at the basal layer of the epithelium that are exposed 
through microwounds. Normal epithelium is shown on the left and HPV-infected 
epithelium is shown on the right. The replicative cycle of HPVs is intimately linked to the 
differentiation program of epidermal keratinocytes. Once in the basal layer cells, the HPV 
genome is established in the nucleus as a low-copy number episome. As the basal layer 
cells migrate upwards, they begin to differentiate and stop proliferating. During this 
growth-arrested, differentiation stage, the viral E6 and E7 proteins deregulate cell cycle 
control and force the quiescent cell to re-enter S phase. Following differentiation, the viral 
genome is amplified to a high-copy number. In the upper layers of the epithelium, the L1 
and L2 capsid proteins are produced and the viral genome is encapsidated. Newly 
assembled virions (purple) are shed into the environment. The different epithelial layers 
are indicated on the left. Viral progression through the epithelium is indicated on the right. 
Epithelium was created with BioRender. Adapted from Moody and Laimins, 2010.
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hyperproliferation of cells that would have normally exited the cell cycle. Consequently, 
deregulated cell cycle progression results in the accumulation of mutations that can lead to 
the development of HPV-associated cancers (Bravo and Felez-Sanchez, 2015). Following 
differentiation, the expression of E1, E2, E4, and E5 increases substantially, which results 
in an amplification of viral genome copy number from 50-200 copies to several 1000s of 
copies per cell (Bedell et al., 1991). Finally, in the upper layers of the epithelium, the L1 
and L2 capsid proteins are produced and the viral genome is encapsidated. Newly 
assembled virions are shed into the environment through the normal epithelial process of 
desquamation—shedding of the outermost layer of skin (Bodily and Laimins, 2011; 
Madison, 2003). This process occurs in the absence of lysis or necrosis, thereby avoiding 
inflammation and contributing to viral persistence. 
1.4 Human Papillomavirus Oncogenes and Transformation 
The E6 and E7 genes encoded by HR HPVs have been designated as “viral oncogenes” 
due to their fundamental roles in cellular transformation. The first evidence of their 
carcinogenic properties came from studies on cell lines derived from cervical cancers 
(Schwarz et al., 1985). These cervical cancer-derived cells had HR HPV DNA randomly 
integrated into their genome, with the E6 and E7 ORFs intact and several other viral genes 
disrupted. Their role in carcinogenesis was further highlighted by studies that demonstrated 
their ability to induce transformation and immortalize both rodent fibroblasts and human 
keratinocytes (Mansur and Androphy, 1993). Indeed, it is now widely accepted that the 
products of E6 and E7—often designated as viral oncoproteins—deregulate vital cellular 
processes, such as differentiation, cell cycle, DNA repair, senescence, and apoptosis 
(Tommasino, 2014). This deregulation facilitates the accumulation of DNA damage that 
contributes to the progression of the transformed phenotype. Importantly, the continuous 
expression of the E6 and E7 oncogenes seems necessary to maintain the malignant 
transformed phenotype, as silencing of E6 and/or E7 expression induces rapid growth 
arrest, senescence, or apoptosis in HPV-positive (HPV+) cervical and oral cancer-derived 
cell lines. (Goodwin and DiMaio, 2000; Goodwin et al., 2000; Jiang and Milner, 2002; 
Rampias et al., 2009; Sima et al., 2008). 
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The E7 ORF encodes for a small, acidic phosphoprotein of 98 amino acids (Vousden, 
1993). This viral oncoprotein has no enzymatic or DNA-binding activities, instead it 
associates with a wide variety of cellular regulatory proteins to inhibit or retarget their 
functions (McLaughlin-Drubin et al., 2012; Moody and Laimins, 2010). The HPV E7 
oncoprotein is subdivided into three domains: conserved regions 1–3 (CR1–3), based on 
amino acid sequence similarities between different HPV types (Phelps et al., 1988). The 
CR1 and CR2 are intrinsically disordered, allowing adaptability in their interactions with 
a plethora of cellular targets (Dyson and Wright, 2005; Ohlenschlager et al., 2006). 
Interestingly, CR1 and CR2 are structurally and functionally similar to certain domains 
found in the otherwise unrelated adenovirus E1A and simian vacuolating virus 40 (SV40) 
large T antigen (Dyson et al., 1992; Phelps et al., 1988; Vousden and Jat, 1989). Indeed, 
all 3 contain the LXCXE motif—where X is any amino acid—that is essential for the 
interaction with the retinoblastoma tumor suppressor and related family members (Rb) 
(Munger et al., 1989). 
The Rb protein (pRb) and related family members, p107 and p130, comprise the “pocket 
protein” family of cell cycle regulators that control the G1–S phase transition through the 
regulation of the E2F family of transcription factors (Dyson, 1998). In general, E2F 
transcription factors will localize and bind to E2F-binding sites that are found within the 
promoters of numerous genes involved in regulating cell cycle progression, differentiation, 
and apoptosis (DeGregori and Johnson, 2006). In the context of a normal cell, the Rb 
pocket protein complex directly binds to the transactivation domain of E2F, thereby 
repressing transcription from E2F-dependent promoters (Harbour and Dean, 2000). In late 
G1, the phosphorylation of Rb by cyclin-dependent kinases (CDKs) leads to its 
disassociation from E2F which results in the transcriptional activation of S phase-specific 
genes (Stevaux and Dyson, 2002). During HR HPV infection, the E7 oncoprotein will bind 
to Rb—mediated by the aforementioned LXCXE motif—disrupting the Rb–E2F complex 
and subsequently targeting Rb for proteasomal degradation through the ubiquitin-
dependent pathway (Boyer et al., 1996; Chellappan et al., 1992; Jones et al., 1997). This 
forced disassociation from E2F results in the constitutive expression of E2F-responsive 
genes, such as cyclin A and cyclin E, that stimulate premature entry into S phase, thereby 
reactivating DNA replication (Cheng et al., 1995; Zerfass et al., 1995). Furthermore, E7-
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mediated degradation of Rb also abrogates other Rb-specific activities that are 
fundamentally involved in DNA repair and maintaining host genome integrity (Moody and 
Laimins, 2010). 
In addition, HR HPV E7 also induces epigenetic changes on the host cell transcriptome. 
Specifically, E7 expression stimulates the activation of the histone methyltransferase 
EZH2, which catalyzes the tri-methylation (me3) of H3K27 (Holland et al., 2008; Hyland 
et al., 2011; McLaughlin-Drubin et al., 2011). Furthermore, in vitro studies have also 
observed an E7-dependent activation of the histone demethylases KDM6A and KDM6B 
that convert H3K27me3 to the di- or mono-methylated forms (Hyland et al., 2011; 
McLaughlin-Drubin et al., 2011). This E7-mediated induction of KDMs was also shown, 
in vitro, to induce the activation of the tumor suppressor p16, which is a product of the 
CDKN2A locus and functions as a negative regulator of the cell cycle via CDK inhibition 
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013; Rayess et al., 2012). 
Consequently, p16 is found to be expressed at high levels in nearly all HPV-induced 
tumors, and is therefore used as a surrogate biomarker of HPV status during pathological 
assessment (Hoffmann et al., 2010; Klaes et al., 2001; Sano et al., 1998). In Chapter 2, we 
explore the epigenetic landscape by utilizing next-generation “-omics” data from over 800 
primary human cervical and head and neck tumors to assess the impact of HPV status on 
the transcript levels of key regulators of H3K27 methylation, including EZH2, KDM6A, 
and KDM6B. Additionally, we also examine HPV-specific effects on gene expression and 
DNA methylation across the entire CDKN2A and adjacent CDKN2B genomic regions. 
The E6 ORF encodes for a basic and cysteine-rich protein of 158 amino acids. The main 
structural feature of this oncoprotein is the zinc-binding domains present at both the amino 
and carboxyl termini (Tommasino, 2014). The two zinc domains, together with an alpha-
helical structure in between them, form a binding pocket that strictly binds to cellular 
targets that contain the LXXLL motif (Nomine et al., 2006; Zanier et al., 2013; Zanier et 
al., 2012). Interestingly, even though it can bind to a vast number of cellular targets across 
the entirety of its structured surface, all of its primary interactors contain  
an LXXLL motif (Vande Pol and Klingelhutz, 2013). The ability to bind to this 
aforementioned motif is essential for its intracellular functions, as studies have shown that 
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mutants of E6 that fail to bind LXXLL are rendered functionally defective (Cooper et al., 
2003; Zanier et al., 2013). Indeed, this motif plays a central role in E6’s best characterized 
role: the ability to induce the degradation of the tumor suppressor p53 (Scheffner et al., 
1990). 
A major consequence from the E7-mediated forced re-entry into an unscheduled S phase 
is the elevation in the levels of p53, which impedes cell growth and induces apoptosis 
(Demers et al., 1994; Jones et al., 1997). The tumor suppressor p53 is a transcription factor 
that controls the expression of numerous genes that encode for products that are 
instrumental in regulating the cell cycle, DNA repair, and apoptosis. During cellular stress, 
such as DNA damage or hypoxia, p53 will trigger cell cycle arrest or apoptosis in order to 
safeguard cellular genomic integrity (Levine and Oren, 2009). This strategy of blocking 
the cell cycle ensures that damaged DNA does not get replicated and allows the cell to 
repair the damage before entering S phase. In some instances, the accumulated damage 
may be too great to repair, therefore p53 will induce apoptosis in order to prevent the 
generation of potentially transformed daughter cells. During an HPV infection, to 
counteract E7-induced cellular suicide, the E6 oncoprotein will interfere with the functions 
of p53 (Moody and Laimins, 2010). It accomplishes this feat by binding to the E3 ubiquitin 
ligase, E6-associated protein (E6AP), via the conserved cellular LXXLL motif and forming 
a trimeric complex with p53, which ultimately leads to the ubiquitylation and subsequent 
proteasomal degradation of this indispensable tumor suppressor (Huibregtse et al., 1991; 
Scheffner et al., 1993; Scheffner et al., 1990). Indeed, this abrogation of p53’s function 
combined with the E7-mediated forced re-entry into S phase, facilitates productive viral 
replication. However, due to the persistent nature of an HPV infection, it can result in the 
accumulation of DNA damage—that would have otherwise been repaired—leading to 
genomic instability that has consequences for tumor development (Moody and Laimins, 
2010). 
As mentioned previously, the two virally encoded oncoproteins, E6 and E7, are necessary 
for maintaining the transformed phenotype; however, the functions highlighted above are 
not sufficient to directly transform infected cells (Moody and Laimins, 2010). Therefore, 
additional carcinogenic events such as genomic instability must occur for malignant 
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transformation to develop. Genomic instability can occur over time with a persistent HPV 
infection due to the accumulation of DNA damage that results from the degradation of 
tumor suppressor proteins Rb and p53 (White et al., 1994). In addition, genomic instability 
has also been shown to occur through an anti-HPV response that is mediated by the 
antiviral apolipoprotein B messenger RNA-editing, enzyme-catalytic, polypeptide-like 3 
(APOBEC3) family of DNA cytidine deaminases that inadvertently mutate the host cell 
genome, resulting in the accumulation of DNA damage over time (Warren et al., 2017). 
This is in agreement with the prolonged latency observed between initial HPV infection 
and tumor development (Schiffman et al., 2007). This accidental induction of genomic 
instability is characteristic of HR HPV-induced malignancies. In fact, the majority of HPV-
associated cancers have numerous chromosomal defects such as aneuploidy—gain or loss 
of entire chromosomes—and chromosomal rearrangements (Moody and Laimins, 2010; 
White et al., 1994; zur Hausen, 1999). Indeed, this genetic instability is thought to be a 
precursor to tumor development, occurring before the integration of viral DNA into the 
host cell genome (Duensing et al., 2001). 
One of the fundamental events in facilitating progression to an HPV-mediated transformed 
phenotype is the integration of HR viral DNA into the host cell genome (Moody and 
Laimins, 2010). This integration event is generally thought of as a chance event that can 
cause the disruption of viral genes that are essential for maintaining normal viral gene 
expression (Doorbar et al., 2012; Thorland et al., 2003). Indeed, the integration breakpoints 
often occur in the viral genomic area that encodes for the early E2 gene, which plays a 
central role in the negative feedback control of the viral oncogenes E6 and E7. Furthermore, 
the E6 and E7 ORFs are consistently found to be preserved in a successful oncogenic-
promoting integration event (Parfenov et al., 2014; zur Hausen, 2002) (Figure 1.3). 
Consequently, disruption of E2 leads to the deregulated expression of the aforementioned 
oncogenes, subsequently furthering aberrant cellular proliferation through the abrogation 
of cell cycle checkpoints and fostering the accumulation of DNA damage that accelerates 
genetic instability. These viral oncoprotein-mediated effects are exacerbated through 
integration, causing cells to have a selective growth advantage that promotes 
carcinogenesis (Jeon et al., 1995; McBride and Warburton, 2017). In addition, integration 
can also lead to the activation of nearby cellular proto-oncogenes or inactivation of tumor 
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Figure 1.3. Integration of the HPV16 viral genome into host cell DNA. 
During progression to a malignant phenotype, the viral DNA genome often integrates into 
host cell DNA. The integration breakpoints often disrupt the viral genomic areas that 
encode for E2, E4, E5, and L2. The non-coding regulatory region LCR and the E6 and E7 
oncogenes are consistently found to be preserved in a successful oncogenic-promoting 
integration event. Adapted from zur Hausen, 2002.
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suppressor genes, as well as aberrant replication issues that lead to the amplification of host 
genes around the site of integration (Parfenov et al., 2014; Peter et al., 2006; Thorland et 
al., 2003). Moreover, HPV-associated malignancies become reliant on the expression of 
the integrated viral oncogenes for sustained proliferation and survival (Goodwin and 
DiMaio, 2000; Goodwin et al., 2000; Jiang and Milner, 2002; Rampias et al., 2009; Sima 
et al., 2008). While many HPV+ cancers are found to contain integrated copies of the HPV 
genome, this is not a universal phenomenon. Indeed, HPV+ carcinomas, such as anogenital 
and oral cancers, can contain either extrachromosomal HPV DNA, integrated viral DNA, 
or a combination of both (Kristiansen et al., 1994; McBride and Warburton, 2017). 
Importantly, unlike other viruses that integrate into the host cell genome, HPV integration 
is not a part of its normal replicative cycle, instead it is an accidental “dead-end” event that 
abolishes prospective production of viral progeny (McBride, 2017). 
1.5 Human Papillomavirus Cancer and Prevention 
The WHO’s IARC group have conclusively defined 12 HR HPV types as potent biological 
human carcinogens—HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 (Bouvard et al., 
2009). Of the estimated 14 million cancers that occurred worldwide in 2012, 640,000 were 
caused by an HPV infection (Plummer et al., 2016). HR HPVs sexually-transmitted mode 
of infection plays a significant role in causing approximately 4.5% of the global cancer 
burden, of which more than 80% occur in underdeveloped or developing nations (de Martel 
et al., 2012). Indeed, persistent infection by HR HPVs are responsible for virtually all cases 
of cervical cancers and other anogenital cancers that include vaginal, vulvar, penile, and 
anal carcinomas, as well as a significant fraction of head and neck cancers (Mesri et al., 
2014) (Table 1.1). Interestingly, the fraction of cancers attributed to HR HPV infection is 
much higher in women (8.6%) than in men (<1%) because of the unique susceptibility of 
the cervix to HPV-induced carcinogenesis (Schiffman et al., 2016). Furthermore, the 
fraction of cancers induced by HPV also varies significantly by geographical region and 
level of economic development (Roden and Stern, 2018). This variation can be partly 
explained by the quality of cervical cancer screening initiatives and access to preventative 
vaccination programs (Schiffman et al., 2016). 
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Table 1.1. Global estimated fraction of new cancers caused by HPV infection in 2012. 
Adapted from Schiffman et al., 2016.
Cancer Site New cases (n) 
Attributable 
to HPV (n) 
Attributable 
to HPV (%) 
Attributable by sex (n) 
Male Female 
Cervix 528,000 528,000 100 – 528,000 
Anus 40,000 35,000 88 17,000 18,000 
Vagina and vulva 49,000 20,000 41 – 20,000 
Penis 26,000 13,000 51 13,000 – 
Oropharynx 96,000 29,000 31 24,000 6,000 
Oral cavity and 
larynx 358,000 9,000 2.4 7,000 2,000 
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The causal link between HR HPV infection of the cervix and development of cancer is one 
of the most important scientific discoveries of all time. Indeed, for his seminal work in this 
ground-breaking discovery, Dr. Harald zur Hausen was awarded the 2008 Nobel Prize in 
Physiology or Medicine. Worldwide, cervical cancer is the 4th most frequently diagnosed 
cancer and the 4th leading cause of death in women, with approximately 570,000 new cases 
and 311,000 deaths in 2018 (Bray et al., 2018). The highest regional incidence and 
mortality rates are observed in economically disadvantaged areas, such as countries in sub-
Saharan Africa. In comparison, there is an estimated 7 to 10 times lower incidence and 18 
times lower mortality rates in countries with a high Human Development Index, such as 
Canada, USA, Australia, and New Zealand (Bray et al., 2018; Small et al., 2017). In fact, 
there is an inverse correlation between the income level of a country and cervical cancer 
rates (Schiffman et al., 2016). The main etiological factor is infection with HR HPVs, with 
99% of cervical cancers containing HR HPV DNA, of which HPV16 accounts for 50–60%, 
HPV18 accounts for approximately 20%, and the remaining fraction being caused by the 
other oncogenic types mentioned above (Roden and Stern, 2018). In countries with state-
of-the-art staging and treatment, 3-year local control rates for all stages ranged from 74–
95%. In contrast, for many underdeveloped countries the 3- to 5-year survival rate for all 
stages combined was less than 50% (Small et al., 2017). This huge disparity in prevalence 
and mortality rates between high-income and low- to middle-income nations, illustrates the 
need for effective screening and vaccination programs that have the potential to virtually 
eliminate the burden of cervical cancer from every country, regardless of wealth (Bosch et 
al., 2016). 
Over a decade ago the WHO’s IARC group definitively established HR HPVs as being the 
biological carcinogens responsible for a subset of head and neck squamous cell carcinomas 
(HNSC) (Gillison et al., 2015). Indeed, since the seminal study that causally linked HPV 
infection with the development of HNSC was published in 2000 (Gillison et al., 2000), it 
is now explicitly recognized that infection with HR HPVs causes a significant and 
increasing fraction of these carcinomas. HNSC is an umbrella term that encompasses a 
heterogenous group of malignancies in the head and neck region that include the oral 
cavity, oropharynx, hypopharynx, and larynx (Figure 1.4) (Leemans et al., 2018). HNSC
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Figure 1.4. Subsites of the head and neck region. 
Schematic of the subsites present in the head and neck region. The region of the 
hypopharynx is highlighted in red, the region of the oropharynx is highlighted in purple, 
and the region of the nasopharynx is highlighted in light blue. Head template was created 
with BioRender.
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is the 7th most commonly diagnosed cancer worldwide, with approximately 890,000 new 
cases and 453,000 deaths in 2018 (Bray et al., 2018). The classical etiological agents 
responsible for the majority of these carcinomas are smoking and excessive alcohol 
consumption, with HPV infection accounting for approximately 25% of all cases (Kreimer 
et al., 2005; Leemans et al., 2018). Accordingly, HNSC can be divided into either HPV+ 
or HPV-negative (HPV–) malignancies based on their respective carcinogenic origins. The 
majority of HPV+ cases in the head and neck region occur in the oropharynx (30.8%), with 
a much smaller percentage occurring in the other subsites such as the larynx (2.4%) and 
oral cavity (2.2%) (de Martel et al., 2017). Furthermore, HPV16 is the most common HPV 
type associated with these carcinomas, with an estimated 83% of HPV+ HNSC being 
caused by the potent biological carcinogen (Leemans et al., 2018).  
Alarmingly, the global frequency of HPV+ oropharyngeal cancers has increased to 
epidemic proportions, from 7.2% in the period of 1990–1994 to 32.7% in the period of 
2010–2012, which is most likely a consequence of changes in sexual behavior (D'Souza et 
al., 2007). Interestingly, this increase in HPV+ oropharyngeal cancers has been mostly 
observed in high-income countries with a concomitant decline in tobacco smoking 
(Chaturvedi et al., 2011). In agreement, our group has identified a similar epidemic increase 
in Southwestern Ontario, with the fraction of HPV+ oropharyngeal cancers increasing from 
25% in the period of 1993–1999 to 62% in the period of 2006–2011 (Nichols et al., 2013a; 
Nichols et al., 2013b). In terms of demographic and clinical characteristics, HPV+ HNSC 
occurs more frequently in males, affects a younger demographic, and generally patients 
exhibit markedly better clinical outcomes compared to their HPV– counterparts (Kang et 
al., 2015; Leemans et al., 2018). Indeed, several studies with various cohort sizes have 
shown that patients with HPV+ HNSC had a 2- to 5-year overall survival rate that ranged 
from 62–95% (Ang et al., 2010; Fakhry et al., 2008; Lassen et al., 2011; Posner et al., 2011; 
Rischin et al., 2010). In comparison—from the same aforementioned studies—patients 
with HPV– HNSC only had a 2- to 5-year overall survival rate that ranged from 35–74%. 
In essence, HPV+ HNSC is considered a distinct epidemiological, molecular, and clinical 
entity that is caused by an epitheliotropic sexually transmitted virus and is increasing at an 
epidemic rate, specifically in the Western world (Kang et al., 2015; Leemans et al., 2018). 
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In the early 1990s, scientists observed that expression of recombinant HPV L1 proteins—
the major capsid protein—in a range of in vitro systems, self-assembled into virus-like 
particles (VLPs) that were devoid of potentially carcinogenic viral DNA (Deschuyteneer 
et al., 2010; Roden and Stern, 2018). These “ghost particles” were immunologically similar 
to their native counterparts and were able to elicit high and durable titers of neutralizing 
antibodies in experimental animal models challenged with infectious, wildtype virus. 
Furthermore, these studies illustrated that the protection elicited by these VLPs were type-
restricted, which indicated that in order to achieve broad protection against other types of 
HPVs, VLPs generated from several major carcinogenic types were necessary (Breitburd 
et al., 1995; Suzich et al., 1995). Indeed, these studies provided the proof-of-concept 
necessary for the development of the first prophylactic HPV vaccine. Since the initiation 
of those pioneering studies, there have been 3 HPV VLP vaccines licensed: (i) Cervarix 
(GlaxoSmithKline), a bivalent vaccine targeting both HR HPV16 and 18, which are the 
two types responsible for most HPV+ cancers; (ii) Gardasil (Merck Inc.), a quadrivalent  
vaccine that targets HR HPV16 and 18, as well as the two most common LR types that 
cause the majority of genital warts, HPV6 and 11; and (iii) Gardasil9 (Merck Inc.), a 
nonavalent vaccine targeting HPV6, 11, 16, 18 and the next 5 most carcinogenic types—
HPV31, 33, 45, 52, and 58 (de Martel et al., 2017). All 3 vaccines have been shown to be 
remarkably safe and highly effective for protection against new infections and 
precancerous lesions (Schiffman et al., 2016). Furthermore, all 3 vaccines underwent large, 
phase III randomized controlled trials in young women (15–26 years), where they were 
shown to be more than 90% effective against genital warts, persistent infections, and 
precancerous lesions (Castellsague et al., 2011; Lehtinen et al., 2012; Munoz et al., 2010; 
Schiller et al., 2012). It is estimated that 118 million women aged 10–20 have been targeted 
by HPV vaccination programs, but unfortunately only 1% of these are in less developed 
countries (Bruni et al., 2016). Moreover, these HPV vaccines have the ability to prevent 
70–90% of all HPV+ cancers and have been projected to dramatically reduce the global 
burden of cervical cancer after 2050 (de Martel et al., 2017; Jit et al., 2014). 
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1.6 The Tumor Microenvironment 
Normal tissues maintain homeostasis through a dynamic complex of intercellular 
communication that ensures a strict balance of cellular proliferation and death. In order to 
achieve and maintain normal physiology a plethora of cells need to work in concert. Each 
of these cells have an intracellular program that restricts them in their role, location, and 
number. In contrast, cancers have lost these internal restraints through activating mutations 
in oncogenes and deactivating mutations in tumor suppressor genes. Nevertheless, these 
tumor cells are still able to dynamically communicate with diverse non-malignant cellular 
populations and extracellular infrastructure within their local environment (Joyce and 
Pollard, 2009). Indeed, as these cancerous cells divide and form tumors, they provoke 
dramatic molecular, cellular, and physical changes on the surrounding tissue in which they 
grow, giving rise to the tumor microenvironment (TME). The TME is comprised of a 
convoluted milieu of stroma that includes blood and lymphatic endothelial cells, 
fibroblasts, mesenchymal cells, and pericytes, as well as immune cells and the extracellular 
matrix (Turley et al., 2015). The diverse biological elements within the TME interact 
intimately with tumor cells, often influencing tumor cell survival, invasiveness, and 
metastatic dissemination, as well as therapeutic response (Joyce and Pollard, 2009; 
Nakasone et al., 2012; Polyak et al., 2009). 
While the cellular composition of the TME varies across different cancer types, some 
common features seem to be consistent throughout most solid tumors. For example, most 
tumors are highly vascularized by disorganized, tortuous and leaky vessels. Furthermore, 
the TME often contains infiltration from various innate and adaptive immune cell 
populations that can promote both protumor and antitumor effects (Turley et al., 2015). 
The utilization of next-generation “-omics” technologies, such as bulk tissue RNA-
sequencing (RNA-seq), have deconvoluted the composition of the immune landscape 
present within the TME (Ali et al., 2016; Aran et al., 2017; Newman et al., 2015). This has 
led to the broad classification of the TME immune landscape into 2 classes (Binnewies et 
al., 2018) (Figure 1.5). The 1st class is termed infiltrated–excluded, which is defined as 
lacking cytotoxic T lymphocytes (CTLs) and proinflammatory mediators in the tumor core, 
instead they contain tumor-associated macrophages along the tumor margins that have been 
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hypothesized to prevent CTL infiltration (Beatty et al., 2015; Binnewies et al., 2018). These 
tumors have been classified as being immunologically “cold” or alternatively, non-T-cell-
inflamed (Binnewies et al., 2018; Spranger, 2016) (Figure 1.5A). The 2nd class is termed 
infiltrated–inflamed, which is characterized by high infiltration of CTLs that express 
elevated levels of immune-dampening T-cell exhaustion markers such as LAG3, PD1, 
TIGIT, and TIM3 (Binnewies et al., 2018; Wherry, 2011). Moreover, they also contain T-
cell activation markers and proinflammatory mediators. These types of tumors are 
considered to be immunologically “hot” or alternatively, T-cell-inflamed (Binnewies et al., 
2018; Spranger, 2016) (Figure 1.5B). These broad classes of immune landscape 
classifications of the TME illustrate the possible different dynamic interactions that can 
occur between malignant and non-malignant cells that can have a substantial impact  
on both tumor status and therapeutic response (Binnewies et al., 2018). Indeed, 
characterization of the immune landscape of tumors is helping guide the rational design of 
therapies that mobilize the immune system to induce long-term remission in cancers 
previously considered to be terminal (Byrne and Fisher, 2017; Costa et al., 2018; George 
et al., 2017; Holzel et al., 2013). In Chapters 3, 4, and 5 we utilize large datasets generated 
by next-generation “-omics” technologies to explore and profile the immune landscapes 
between HPV+ and HPV– TMEs originating from either the cervical or head and neck 
regions. 
1.7 The Cancer Genome Atlas 
Historically, tumor-infiltrating leukocyte (TIL) detection within the TMEs of solid tumors 
has been primarily performed using immunohistochemistry or flow cytometry (Llosa et al., 
2015). Both of these techniques have taught us a great deal about the tumor immune profile, 
but they require antibodies to specific phenotypic markers of cell type or activation status, 
can be challenging to standardize, difficult to implement with small tissue samples, and 
expensive to perform for the dozens of markers necessary for a comprehensive view of the 
immune landscape of a given TME. More recent alternatives capitalize on the plunging 
costs of next-generation “-omics” technologies, including next-generation sequencing for 
genomics and transcriptomics, as well as genome-wide methylome analysis using high-
density arrays. Indeed, massive collaborative efforts such as The Cancer Genome Atlas 
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Figure 1.5. General classification of the types of immune landscapes present in tumor 
microenvironments. 
The tumor microenvironment can be divided into 2 broad classes based on their immune 
landscape. The tumor core of infiltrated–excluded environments lack cytotoxic T 
lymphocyte infiltration (CTL) and proinflammatory mediators but contain tumor-
associated macrophages (A). In contrast, the environments of infiltrated–inflamed are 
characterized by high infiltration with CTLs that express elevated levels of T-cell 
exhaustion markers and proinflammatory mediators (B). Created with BioRender. Adapted 
from Binnewies et al., 2018.
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(TCGA) have generated genomic, transcriptomic, and methylomic data for over 11,000 
tumor samples from 33 cancer types and subtypes (Liu et al., 2018). Capitalizing on this 
freely available data, it is possible to estimate the detailed composition and activation status 
of tumor-infiltrating immune cells into the TMEs of solid tumors from bulk tissue RNA-
seq data using computational approaches based on a set of immune-specific marker genes 
or expression signatures that correlate with distinct leukocyte populations (Bindea et al., 
2013; Danaher et al., 2017; Gameiro et al., 2018; Gameiro et al., 2019; Gameiro et al., 
2017; Newman et al., 2015; Rooney et al., 2015; Wolf and Samuels, 2018). 
The TCGA was a large-scale collaboration between the National Cancer Institute (NCI) 
and the National Human Genome Research Institute (NHGRI) to comprehensively 
characterize the molecular events in primary cancers and provide these data to the public 
for use by cancer researchers worldwide (Liu et al., 2018). This effort, which ended in 
2017, generated publicly available, comprehensive, multidimensional maps of genomic 
changes in more than 11,000 tumor samples. The TCGA dataset encompasses 33 types of 
human tumors, all processed via a uniform genomic data analysis pipeline that collected, 
selected, and analyzed these cancer samples in detail. These analyses included whole 
exome and/or whole genome sequencing, mRNA sequencing, microRNA sequencing, 
DNA copy number profiling, DNA methylation profiling, and reverse-phase protein array 
expression profiling. Although comprehensive clinical annotation was not possible for 
every TCGA sample, substantial clinical data are available, allowing comparison of many 
clinical variables and, in most cases, reasonably robust outcomes assessment. Furthermore, 
the quality and quantity of the TCGA molecular datasets have resulted in studies that have 
significantly advanced our understanding of cancer biology (The Cancer Genome Atlas 
Research Network, 2015; The Cancer Genome Atlas Research Network, 2017). 
The TCGA project provides an abundant source of free data available for mining by cancer 
researchers in many different ways. Importantly, many other questions unrelated to tumor 
immunity can be similarly addressed, such as correlations between gene expression and 
chemotherapy response, alterations induced by oncogenic pathogens, or expression of 
markers of differentiation, proliferation, or tumor aggressiveness. Additionally, batch-wise 
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analysis of this valuable data set for various correlations can also generate novel hypotheses 
that can be pursued experimentally. Literally, the seeds of thousands of important analyses 
await discovery in this collection of “big” data. 
1.8 Thesis Overview 
The work presented in this thesis capitalizes on novel state-of-the-art methods that are 
being utilized in both the fields of tumor virology and cancer biology. The utilization of 
next-generation “-omics” provides genomic and transcriptomic data derived from bulk 
tumors that illuminate the dynamic molecular landscapes of tumors under the influence of 
their local surroundings. Indeed, these types of analyses provide us with unique insights 
into the complexities of the TME that would have otherwise been missed by classical 2-
dimensional approaches, such as in vitro cell culture systems. By utilizing “big” data 
generated from the TCGA, we ensure a globally-uniform process for patient selection, 
sample collection, and data acquisition that minimizes artifactual experimental 
heterogeneity that can often occur without standardized protocols. Instead, the 
heterogeneity in these datasets are restricted to just the patients and cancers from which 
they are derived. Utilizing these computational methods, I explore and profile the 
epigenetic and immune landscapes between the tumor microenvironments of HPV+ and 
HPV– carcinomas present in actual human malignancies. Furthermore, I hypothesize that 
the epigenetic and immune landscapes between these 2 etiologically-distinct tumor 
microenvironments are profoundly different, regardless of their anatomical origins. 
As previously detailed above, HR HPVs cause cancer at multiple distinct anatomical 
locations. Regardless of the tissue of origin, most HPV+ cancers show highly upregulated 
expression of the p16 product of the CDKN2A gene (Klaes et al., 2001; Sano et al., 1998). 
Paradoxically, HPV+ tumor cells require continuous expression of this tumor suppressor 
for survival (McLaughlin-Drubin et al., 2013). Thus, restoration of normal p16 regulation 
has potential therapeutic value against HPV-induced cancers. Normally, p16 transcription 
is tightly controlled at the epigenetic level via polycomb repressive complex-mediated tri-
methylation of H3K27 (Popov and Gil, 2010). Although a mechanism by which HPV 
induces p16 has been previously proposed based on in vitro tissue culture models 
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013), it has not been 
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extensively validated in actual human tumors. Indeed, these cell culture-based experiments 
have allowed for a detailed elucidation of the biological factors involved in HPV-mediated 
upregulation of p16; however, an analysis of these HPV-specific epigenetic effects has not 
been done in any large cohorts of HPV-induced cancers under the influence of their 
respective native heterogenous environments. Therefore, my objective was to determine if 
the epigenetic changes involved in p16 upregulation observed in artificial culture systems 
were recapitulated in actual primary HPV+ tumors from different anatomical locations. 
In Chapter 2, I used genomic and transcriptomic data from over 800 human cervical and 
head and neck tumors from The Cancer Genome Atlas to test this model. I sought out to 
determine the impact of HPV status on expression from the CDKN2A locus, the adjacent 
CDKN2B locus, and transcript levels of key epigenetic regulators of these loci. As 
expected, HPV+ tumors from both anatomical sites exhibited high levels of p16. 
Furthermore, HPV+ tumors expressed higher levels of KDM6A, which demethylates 
H3K27me3. In addition, analysis of CpG methylation also detected two sites in the 
CDKN2A locus with consistently altered methylation in HPV+ tumors compared to their 
HPV– counterparts. Taken together, this data validates previous tissue culture studies and 
identifies remarkable similarities between the effects of HPV on gene expression and DNA 
methylation in both cervical and head and neck tumors from large human cohorts. 
Moreover, these results support a model whereby HPV-mediated deregulation of CDKN2A 
transcription requires KDM6A, a potentially druggable target. 
I next wanted to use the same computational methodology to validate another tissue culture 
model that proposed an HPV-mediated transcriptional downregulation of the class I major 
histocompatibility complex (MHC I) antigen presentation system (Georgopoulos et al., 
2000; Heller et al., 2011; Li et al., 2010). Indeed, this proposed downregulation could 
contribute to viral persistence and allow the infected or transformed cells to evade the 
adaptive immune response. In Chapter 3, I utilized the same genomic and transcriptomic 
data from Chapter 2, to determine the impact of HPV status on the mRNA expression of 
all six MHC-I heavy chain genes (HLA-A, -B, -C, -E, -F, and -G), and the β2 microglobulin 
light chain in actual HPV-induced carcinomas. Unexpectedly, these genes were all 
expressed at high levels in HPV+ cancers compared with normal control tissues. Indeed, 
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many of these genes were expressed at significantly enhanced levels in HPV+ tumors. 
Similarly, the transcript levels of several other components of the MHC-I peptide-loading 
complex were also high in HPV+ cancers. The coordinated expression of high mRNA 
levels of the MHC-I antigen presentation apparatus could be a consequence of the higher 
intratumoral levels of interferon-gamma (IFNγ) observed in HPV+ carcinomas, which 
correlated with signatures of increased infiltration by T- and NK-cells. These data, which 
were obtained from both cervical and head and neck carcinomas in large human cohorts, 
indicate that HPV oncoproteins do not efficiently suppress the transcription of the MHC-I 
antigen presentation system in actual human tumors as proposed by in vitro cell culture 
models. 
Given the observation of higher levels of intratumoral IFNγ and increased infiltration by 
T- and NK-cells into the HPV+ TME, a mechanistic and detailed characterization of 
immune cell presence and status between the 2 anatomically-similar, etiologically-different 
HNSC types were warranted. In Chapter 4, I utilized an immunogenomic approach on 
transcriptomic and clinical data to compare the immune landscape between the TMEs of 
HPV+ and HPV– HNSC and their influence on clinical outcomes. I found that HPV+ 
HNSC exhibited a strong Th1 response characterized by increased infiltration with multiple 
types of immune cells—CD4+, CD8+, and regulatory T-cells—and expression of their 
effector molecules. HPV+ HNSC also expressed higher levels of CD39 and multiple T-cell 
exhaustion markers including LAG3, PD1, TIGIT, and TIM3 compared to their HPV– 
counterparts. Importantly, patients with higher expression of these exhaustion markers—
indicative of a T-cell-inflamed tumor—correlated with markedly improved survival in 
HPV+, but not HPV–, HNSC. Thus, profound differences exist between the immune 
landscape of HPV+ and HPV– HNSC. In addition, these results suggest that immune 
checkpoint inhibitor therapy is a promising treatment strategy for HPV+ HNSC, and that 
expression of immune checkpoint molecules could also serve as predictive biomarkers of 
patient outcome. 
In the final data chapter of this thesis, I complete my profiling of the immune landscape 
between the TMEs of HPV+ and HPV– HNSC by determining the impact of HPV status 
on the expression of class II major histocompatibility complex (MHC-II) genes and related 
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genes involved in their regulation, antigen presentation, and T-cell co-stimulation. 
Expression of MHC-II is typically restricted to antigen presenting cells (APCs) (van den 
Elsen et al., 2004). However, during inflammation, epithelial cells can be induced to 
express MHC-II and function as accessory APCs (Boss and Jensen, 2003; Collins et al., 
1984; Kim et al., 2009). As done previously, I utilized RNA-seq data from over 500 HNSC 
patients from the TCGA and found that expression of virtually all MHC-II genes was 
significantly upregulated in HPV+ carcinomas compared to HPV– or normal control 
tissues. Similarly, genes that encode products involved in MHC-II-specific antigen 
presentation were also significantly upregulated in the HPV+ cohort. In addition, the 
expression of CIITA and RFX5—regulators of MHC-II transcription—were significantly 
upregulated in HPV+ tumors. This coordinated upregulation of MHC-II genes was found 
to be correlated with higher intratumoral levels of IFNγ in HPV+ carcinomas. Furthermore, 
genes that encode for various co-stimulatory molecules involved in T-cell activation and 
survival were also significantly upregulated in HPV+ tumors. Collectively, these results 
suggest a previously unappreciated role for epithelial cells in antigen presentation that 
functionally contributes to the highly immunogenic tumor microenvironment observed in 
HPV+ HNSC. 
Taken together, these analyses have provided insight into the validity of certain models 
proposed from artificial in vitro culture systems, as well as illustrating the profound 
differences in the epigenetic and immune landscapes between the tumor 
microenvironments of HPV+ and HPV– carcinomas. These studies also identify a 
potentially useful therapeutic target in KDM6A and advocate for the use of promising 
immunotherapy strategies in the treatment of HPV+ HNSC. Furthermore, I also show that 
expression of immune checkpoint molecules could serve as predictive biomarkers of 
clinical outcomes that could allow for treatment deintensification. Moreover, the novel 
hypotheses that have been generated by this work will feedback into the laboratory and 
allow for further exploration in an experimental setting where relevant models can be 
generated and biologically manipulated. Lastly, I hope that the accumulated knowledge 
gained from these studies will advance the field of tumor virology and have a positive 
impact on patients with these devastating HPV-induced malignancies. 
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Chapter 2  
2 Human Papillomavirus Dysregulates the Cellular 
Apparatus Controlling the Methylation Status of H3K27 
in Different Human Cancers to Consistently Alter Gene 
Expression Regardless of Tissue of Origin 
 
2.1 Introduction 
Human papillomaviruses (HPV) that infect mucosal tissues are classified as low- or high-
risk based on the frequency with which they are associated with cancer. Although both 
types dysregulate normal cell growth, infection by high-risk HPV is a causative agent for 
cancers at multiple distinct anatomical subsites (zur Hausen, 1996; zur Hausen, 2002). 
HPV was first recognized as the cause of virtually all cervical carcinomas and was then 
subsequently found to contribute to other anogenital cancers as well (Alemany et al., 2016; 
Crosbie et al., 2013; Guimera et al., 2017; zur Hausen, 2002). More recently, HPV infection 
was recognized as the agent responsible for an epidemic of oropharyngeal cancers (Gillison 
et al., 2000; Syrjanen, 2005). HPV has also been suggested to cause a subset of lung, 
prostate, bladder, and breast cancers (Lawson et al., 2015; The Cancer Genome Atlas 
Research Network, 2014; Singh et al., 2015; Zhai et al., 2015). Taken together, HPV 
infection is thought to be responsible for at least 5% of human cancers worldwide (Forman 
et al., 2012). 
HPV encodes two main oncogenes, E6 and E7 (Doorbar et al., 2012). Both are 
constitutively expressed in HPV-positive (HPV+) tumors, and suppression of expression 
of either of these two viral proteins causes HPV-dependent tumor cells to senesce and die 
(Deng et al., 2013; Goodwin and DiMaio, 2000; Goodwin et al., 2000; Jiang and Milner, 
2002; Rampias et al., 2009; Sima et al., 2008; zur Hausen, 1996). Both E6 and E7 perform 
multiple functions in an infected and/or cancerous cell. These two viral oncoproteins 
function by interacting with multiple key cellular regulatory proteins to dysregulate gene 
expression and growth (Doorbar et al., 2012). For example, p53 is bound and degraded by 
E6, while the retinoblastoma protein (Rb) and family members are important targets of E7 
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(Dyson et al., 1992; Kessis et al., 1993). Rb controls exit from the G1 phase of the cell 
cycle, and the interaction and subsequent degradation of Rb by E7 induces inappropriate 
cell cycle progression in HPV infected cells (Boyer et al., 1996; Brehm et al., 1998). In 
high-risk HPV infections, viral oncoproteins function to uncouple cell growth and 
differentiation and contribute to the formation of epithelial dysplasia, which may progress 
to carcinoma if the infection is not resolved (Doorbar et al., 2012). 
The HPV E7 oncoproteins alter the regulation of many host cellular genes and much effort 
has been devoted to understanding the mechanisms by which this occurs (Munger et al., 
2001). A subset of the effects of E7 on the cellular transcriptome are mediated by epigenetic 
changes (Durzynska et al., 2017). Specifically, E7 expression has been reported to reduce 
the global levels of tri-methylated lysine 27 on histone 3 (H3K27me3), a mark of 
transcriptionally silenced chromatin (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin 
et al., 2008; Schwartz and Pirrotta, 2007). Paradoxically, several cell culture studies have 
shown that HPV induces a significant upregulation in the expression level of the enhancer 
of zeste homolog 2 (EZH2) component of the polycomb repressive complex 2 (PRC2) 
(Holland et al., 2008; Hyland et al., 2011; McLaughlin-Drubin et al., 2011)—which is the 
methyltransferase responsible for mono-, di-, and tri-methylation of H3K27 (Popov and 
Gil, 2010; Schwartz and Pirrotta, 2007). Both studies also observed an HPV-dependent 
increase in lysine demethylase 6A (KDM6A) or lysine demethylase 6B (KDM6B)—the 
demethylases that convert H3K27me3 to the di-methylated or mono-methylated forms 
(Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Thus, HPV increases expression of 
the enzymes responsible for creating and removing H3K27me3, complicating our 
understanding of how the global decrease in H3K27me3 is achieved in an HPV infection. 
Mechanistic studies of these HPV-dependent changes on epigenetic regulators of gene 
expression have focused on altered p16 expression, which is present at high levels in nearly 
all HPV-induced tumors (Klaes et al., 2001; Sano et al., 1998). Indeed, p16 was commonly 
used as a surrogate marker of HPV status during pathological assessment of tumors, but 
this method to determine HPV status has largely been superseded by the implementation 
of molecularly-based diagnostics (Burd, 2016; Hoffmann et al., 2010; Klaes et al., 2001). 
The p16 and p14 products of the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene 
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locus normally function as negative regulators of the cell cycle. The p16 tumor suppressor 
induces cell cycle arrest and senescence by inhibiting E2F-mediated transcription, whereas 
p14 induces cell cycle arrest and apoptosis by facilitating p53 function (Zhang et al., 1998). 
Neither of these products inhibit cell cycle progression in HPV-induced cancers, as the p53 
and Rb pathways have been abrogated by E6 and E7, respectively (Dyson et al., 1992; 
Kessis et al., 1993). However, transcription from the CDKN2A locus is tightly regulated 
by epigenetic changes, with PRC2 serving a key role in repressing expression by catalyzing 
tri-methylation of H3K27 across this locus. Subsequently, the polycomb repressive 
complex 1 (PRC1) is recruited to maintain a transcriptionally repressive chromatin 
environment that is typically reflected by a local increase in DNA methylation (Popov and 
Gil, 2010). Thus, this well-characterized locus serves as a good model of epigenetic 
dysregulation induced by HPV infection (Kanao et al., 2004; Schlecht et al., 2015). 
In a detailed series of tissue culture-based experiments, evidence was obtained to suggest 
that the HPV-mediated reduction in H3K27me3 and subsequent transcriptional activation 
of p16 required E7 to induce expression of the H3K27-specific demethylases KDM6A and 
KDM6B (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). Knockdown 
of either KDM6A or KDM6B in HPV+ cervical carcinoma cell lines not only reduced p16 
expression, but also induced cell death (McLaughlin-Drubin et al., 2011; McLaughlin-
Drubin et al., 2013). Subsequent experiments showed that E7 expression in cell lines 
induced an acute dependence on KDM6B for growth. E7 expressing cells were similarly 
dependent on p16 expression, as treatment with a KDM6 selective small molecule inhibitor 
was cytotoxic in multiple cervical carcinoma cell lines (McLaughlin-Drubin et al., 2011; 
McLaughlin-Drubin et al., 2013). Thus, HPV E7 expressing cells are uniquely vulnerable 
to a targeted agent affecting an epigenetic regulator of cellular gene expression. 
While most of this work was done in tissue culture models, similar changes in expression 
of H3K27me3 regulators were reported in individual cervical carcinomas (Holland et al., 
2008; Hyland et al., 2011; McLaughlin-Drubin et al., 2011). An analysis of these effects 
has not been done in any HPV+ oral cavity tumors or on a large scale for any HPV-induced 
tumor site. As such, it remains an open question as to whether these changes in epigenetic 
regulators are specific for distinct subsites of HPV-induced tumors, and how frequently 
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they occur in clinical samples. This information is clearly relevant, considering that 
cancerous cells expressing E7 appear preferentially sensitive to KDM6 inhibition 
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013), which could represent 
a new therapeutic approach for their treatment. 
In this study, we used data from over 800 human cervical (The Cancer Genome Atlas 
Research Network, 2017) and head and neck tumors (The Cancer Genome Atlas Research 
Network, 2015) from The Cancer Genome Atlas (TCGA) to determine how high-risk HPV 
oncogene expression alters expression of H3K27me3 regulators in human tumors. We 
assessed the impact of HPV status on the transcript levels of key regulators of H3K27 
methylation, including EZH2, KDM6A, and KDM6B. We also examined the effect of HPV 
status on gene expression and DNA methylation status across the CDKN2A genomic region 
in these two distinct patient cohorts. We found that HPV+ tumors from both anatomical 
sites exhibited high levels of p16 and p14. Furthermore, HPV+ tumors also expressed 
higher levels of EZH2 and KDM6A. Analysis of CpG methylation also detected two sites 
in the CDKN2A locus with consistently altered methylation in HPV+ tumors versus HPV-
negative (HPV–) samples. Taken together, this data validates conclusions drawn from 
tissue culture studies and identifies remarkable similarities between the effects of HPV on 
gene expression and methylation in both cervical and oral tumors in large human cohorts. 
These results also provide compelling evidence from human tumors that support the current 
model of HPV dysregulation of H3K27 methylation and cognate gene expression via the 
upregulation of KDM6A. 
2.2 Materials and Methods 
2.2.1 RNA expression comparisons and statistical analysis 
Level 3 RNA-Seq by Expectation Maximization (RSEM) normalized Illumina HiSeq RNA 
expression data for the TCGA head and neck cancer (HNSC) and cervical carcinoma 
(CESC) cohorts was downloaded from the Broad Genome Data Analysis Centers Firehose 
server (https://gdac.broadinstitute.org/). The use of mRNA expression data that has 
undergone RSEM normalization via a uniform pipeline allows comparison of samples 
within and between TCGA cohorts (Li and Dewey, 2011). Effectively, these files represent 
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tables listing a quantitative RNA-seq read value for each gene or isoform for each TCGA 
sample. Although rare HPV+ samples have been identified in the TCGA bladder urothelial 
carcinoma (BLCA) and colon adenocarcinoma (COAD) cohorts, they were not present in 
sufficient numbers for any useful comparisons. For all genes except p16 and p14, the gene 
level Firehose dataset was used. For p16 and p14, the gene isoform level Firehose dataset 
was used (uc003zpk.2 and uc003zpl.2, respectively) to adequately discriminate between 
these two different products of the CDKN2A gene. Normalized expression data was 
extracted into Microsoft Excel and the HPV status was manually curated based on 
published datasets (Banister et al., 2017; Bratman et al., 2016; The Cancer Genome Atlas 
Research Network, 2015; The Cancer Genome Atlas Research Network, 2017). For each 
gene analyzed, primary patient samples with known HPV status were grouped as HPV+, 
HPV–, or normal control tissue. Patient samples with unknown HPV status were omitted 
from our calculations, as were samples obtained from secondary metastatic lesions. This 
resulted in 73 HPV+, 442 HPV–, and 43 normal control samples with data available for 
the HNSC gene expression analysis and 278 HPV+, 19 HPV–,  
and 3 normal control samples available for the CESC gene expression analysis.  
Boxplot comparison of gene expression was performed using BoxPlotR 
(http://shiny.chemgrid.org/boxplotr/) and assembled into final form using CorelDRAW. 
For the box plots, center lines show the medians, box limits indicate the 25th and 75th 
percentiles as determined by R software and whiskers extend 1.5 times the interquartile 
range from the 25th and 75th percentiles. Statistical significance was calculated using 
Graphpad Prism v6.01. p-values were assigned using a one-tailed non-parametric Mann-
Whitney U test. Post-hoc power calculations were performed with G*Power software 
version 3.1.9.2 (Faul et al., 2007), using post-hoc t-test family calculations, with effect size 
selected as 0.8 and α = 0.05. All comparisons achieved a power value > 0.8, or 
demonstrated significant differences, unless otherwise noted in the text. 
2.2.2 DNA methylation comparisons and statistical analysis 
Level 3 Infinium Human Methylation450 BeadChip array data for the TCGA HNSC and 
CESC cohorts was downloaded from the Broad Genome Data Analysis Centers Firehose 
server (https://gdac.broadinstitute.org/). There were 14 methylation probes identified to be 
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present in the CDKN2A and adjacent CDKN2B region: cg00718440, cg02400248, 
cg03079681, cg04026675, cg07562918, cg08390209, cg10848754, cg12840719, 
cg13601799, cg13926295, cg14069088, cg14430974, cg19133618, cg19481686. 
Methylation data for all patient samples for these probes were extracted from the Firehose 
files and assembled into a table using Microsoft Excel. HPV status was manually curated 
based on published datasets (Banister et al., 2017; Bratman et al., 2016; The Cancer 
Genome Atlas Research Network, 2015; The Cancer Genome Atlas Research Network, 
2017). For each gene analyzed, primary patient samples with known HPV status were 
grouped as HPV+, HPV–, or normal control tissue. Patient samples with unknown HPV 
status were omitted from our calculations, as were samples obtained from secondary 
metastatic lesions. This resulted in 73 HPV+ tumors, 442 HPV– tumors, and 43 normal 
control samples with data available for the HNSC methylation analysis and 278, 19, and 3 
samples, respectively, available for the CESC methylation analysis. The average 
methylation Beta-value and standard deviation was calculated for each probe for each 
sample type in each cohort. Data was plotted using Excel and assembled into final form 
using CorelDRAW. For statistical analysis, Beta-values were converted to M-values using 
the following equation to improve homoscedasticity of the data: 
𝑀" = log' (
𝐵𝑒𝑡𝑎"
1 − 𝐵𝑒𝑡𝑎"
/ 
where Mi and Betai are the M-value and Beta-value of the ith interrogated CpG site (Du et 
al., 2010). The data was analyzed using Graphpad Prism v6.01. The p-values were assigned 
using non-parametric Kruskal-Wallis test and Dunn’s multiple comparisons test. 
2.3 Results 
2.3.1 Impact of HPV status on CDKN2A and CDKN2B expression 
in human tumors 
The CDKN2A and adjacent cyclin-dependent kinase inhibitor 2B (CDKN2B) loci encode 
three distinct tumor suppressors: p16 INK4A, p14 ARF, and p15 INK4B. This gene cluster 
also encodes a long non-coding RNA transcribed in the antisense direction that is referred 
to as CDKN2B-AS or antisense non-coding RNA in the INK4 locus (ANRIL) (Figure 2.1).  
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Figure 2.1. Organization of the CDKN2A and CDKN2B loci.  
The cyclin-dependent kinase inhibitor 2A (CDKN2A) locus encodes two functionally 
unrelated protein products named p16 INK4A and p14 ARF. The adjacent CDKN2B locus 
encodes p15 INK4B. This gene cluster also encodes a long non-coding RNA transcribed 
in the antisense direction named CDKN2B-AS or antisense non-coding RNA in the INK4 
locus (ANRIL). The position of transcripts (black lines), exons (black vertical bars), coding 
regions (thick black vertical bars), and orientation (direction of arrowheads) of the major 
transcripts in this region of chromosome 9 are indicated.
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Figure 2.2. HPV perturbation of expression of the CDKN2A and CDKN2B genes in 
human head & neck and cervical carcinomas.  
Normalized RNA-Seq data extracted from the TCGA database for the HNSC (A) and 
CESC (B) cohorts for HPV+, HPV–, and normal control tissues. Numbers in brackets refer 
to the number of samples included in each analysis. * p ≤ 0.05, *** p ≤ 0.001, ns – not 
significant.
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Expression of all three coding genes from this cluster is silenced by PRCs during normal 
cell growth (Popov and Gil, 2010). While HPV-induced cancers commonly express high 
levels of the p16 product of the CDKN2A locus (Klaes et al., 2001; Sano et al., 1998), the 
expression levels of p14, p15, and the non-coding CDKN2B-AS RNA have not been studied 
as extensively. We analyzed the TCGA Illumina HiSeq RNA expression data from the 
HNSC and CESC cohorts for expression of all four genes (Figure 2.2). As expected, HPV+ 
samples from both the HNSC and CESC cohorts had greatly increased levels of p16 mRNA 
expression compared to HPV– tumors and normal control tissue. Like p16, a similar 
upregulation of p14, p15, and CDKN2B-AS was observed in HPV+ cancers with respect to 
HPV– cancers (Figure 2.2). These results indicate that PRC-mediated repression is 
abrogated across the entire CDKN2A and CDKN2B regions of the INK4 locus by HPV 
infection. The only major difference appears to be the high level of p15 expression present 
in the normal control samples for the HNSC cohort, which likely reflects some tissue 
specific, HPV-independent regulation. 
2.3.2 Impact of HPV status on expression of PRC2 components 
and BMI1 in human tumors 
The H3K27 methyltransferase activity of PRC2 relies on the catalytic subunit EZH2, as 
well as the embryonic ectoderm development (EED) and suppressor of zeste 12 (SUZ12) 
components. Multiple studies have reported EZH2 upregulation in HPV+ cancer cell lines, 
with similarly higher expression reported in small studies of HPV+ cervical carcinomas 
(Holland et al., 2008; Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Much less is 
known about the effect of HPV status on the other PRC2 core components. Analysis of 
TCGA data reveals significantly elevated expression of all three PRC2 core components 
compared to normal control tissue in both HNSC and CESC (Figure 2.3). All but SUZ12 
in the CESC cohort are similarly elevated as compared to HPV– cancers. Thus, the core 
components of the PRC2 methyltransferase are all consistently transcribed at high levels 
in HPV+ human tumors. This is in stark contrast to the reported decreases in global 
H3K27me3 (Hyland et al., 2011; McLaughlin-Drubin et al., 2011) and the upregulation of 
the CDKN2A and CDKN2B loci we observe in HPV+ tumors. 
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Figure 2.3. HPV perturbation of expression of polycomb components that may 
regulate CDKN2A transcription in human head & neck and cervical carcinomas. 
Normalized RNA-Seq data extracted from the TCGA database for the HNSC (A) and 
CESC (B) cohorts for HPV+, HPV–, and normal control tissues. Numbers in brackets refer 
to the number of samples included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, 
ns – not significant, red bracket indicates a comparison that did not achieve significance 
with a power value < 0.8.
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Tri-methylation of H3K27 by PRC2 is proposed to recruit PRC1 via its B lymphoma Mo-
MLV insertion region 1 (BMI1) component to maintain a transcriptionally repressive state 
(Schwartz and Pirrotta, 2007). A previous study reported that BMI1 expression was 
reduced by transduction of HPV E6 and E7 into human foreskin keratinocytes (HFKs) 
(Hyland et al., 2011). A reduction in BMI1 is consistent with a reduction of repression of 
the CDKN2A locus by PRC1. BMI1 expression in HPV+ CESC tumors was lower than in 
HPV– or normal control tissues (Figure 2.3). However, its expression was generally the 
same or higher in HPV+ HNSC tumors compared to the HPV– or normal control tissues 
(Figure 2.3). The lack of a consistent reduction in BMI1 expression in HPV+ tumors 
suggest that it is not a key factor in HPV activation of CDKN2A and CDKN2B 
transcription. This is supported by a smaller independent study that found no correlation 
between p16 and BMI1 expression in head and neck cancers (Lundberg et al., 2016). 
2.3.3 Impact of HPV status on expression of KDM6A and KDM6B 
in human tumors 
The KDM6A and KDM6B demethylases convert H3K27me3 to the di-methylated or 
mono-methylated forms (Swigut and Wysocka, 2007). Multiple studies have reported that 
upregulation of one or both of the KDM6 demethylases occurs in cell lines when HPV E7 
is expressed. Furthermore, knockdown of KDM6B or treatment with a small molecule 
KDM6 inhibitor reduces p16 expression in these models, suggesting a direct causal 
relationship between KDM6 activity and p16 transcription (McLaughlin-Drubin et al., 
2011; McLaughlin-Drubin et al., 2013). Our analysis of the expression of KDM6A reveals 
that it is significantly upregulated in HPV+ tumors compared to HPV– tumors in both the 
HNSC and CESC cohorts (Figure 2.4). In contrast, KDM6B expression is significantly 
reduced in HPV+ cancers compared to HPV– tumors in both the HNSC and CESC tumor 
types (Figure 2.4). Significant changes in KDM6A and KDM6B expression were similarly 
noted between HPV+ and normal control tissues for the HNSC samples. However, no 
significant differences were observed for the CESC samples, which could reflect the 
limited number of normal control samples in this cohort. Overall, the increased expression 
of KDM6A suggests that it is more likely to play a role in dysregulation of H3K27me3-
mediated regulation of transcription in HPV+ cancers.  
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Figure 2.4. HPV perturbation of expression of the lysine demethylases KDM6A and 
KDM6B in human head & neck and cervical carcinomas. 
Normalized RNA-Seq data extracted from the TCGA database for the HNSC (A) and 
CESC (B) cohorts for HPV+, HPV–, and normal control tissues. Numbers in brackets refer 
to the number of samples included in each analysis. * p ≤ 0.05, *** p ≤ 0.001, ns – not 
significant, red brackets indicate a comparison that did not achieve significance with a 
power value < 0.8.
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2.3.4 Assessment of the DNA methylation status of the CDKN2A 
and CDKN2B loci in human tumors 
HPV-mediated changes in epigenetic regulation of transcription of the CDKN2A and 
CDKN2B genes would be expected to be reflected in methylation status of CpG 
dinucleotide sequences in or adjacent to these loci. Indeed, a previous report identified 
altered methylation at 4 CpG loci in this genomic region that correlated with HPV status 
(Hyland et al., 2011; Schlecht et al., 2015). We analyzed the Infinium 
HumanMethylation450 BeadChip array data for the TCGA HNSC and CESC cohorts for 
consistent alterations in DNA methylation in this region of the genome (Figure 2.5). A 
region of DNA upstream of the p14 transcript (probe cg14069088; see Figure 2.5A for 
location) was consistently identified to be hypomethylated in HPV+ tumors in both the 
HNSC and CESC cohorts compared to HPV– tumors or normal control tissue. No 
differences in methylation were detected in the remainder of the probes across the 
transcribed regions of these loci in HPV+ versus HPV– or normal control samples. In 
contrast, a hypermethylated region of DNA was identified within the 3’-end of the 
CDKN2A locus (probe cg12840719; see Figure 2.5A for location) in HPV+ tumors 
regardless of anatomical location. Thus, altered methylation is detected at the CDKN2A 
locus in HPV+ tumors, which is consistent with an epigenetic mechanism for 
transcriptional activation of this locus by HPV infection. 
2.4 Discussion 
HPV infection and subsequent expression of the E6 and E7 oncogenes leads to a large-
scale reprogramming of gene expression. This is likely further exacerbated in high-risk 
HPV+ tumor cells, which typically express higher levels of these powerful viral regulatory 
proteins compared to levels found in the context of normal infections. Consequently, high-
risk HPV transformed cells exhibit many changes in gene expression that contribute to the 
acquisition and maintenance of cancerous phenotypes unique to viral transformation 
(Doorbar et al., 2012). In particular, dysregulation of H3K27me3 homeostasis by the E7 
proteins from high-risk HPVs contributes to increased expression of loci normally 
repressed by PRCs, including the CDKN2A locus encoding p16 INK4A (McLaughlin  
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Figure 2.5. HPV perturbation of DNA methylation at the CDKN2A and CDKN2B loci 
in human head & neck and cervical carcinomas. 
HPV+ cancers exhibit markedly altered methylation from HPV– tumors or normal control 
tissues at two regions flanking the CDKN2A locus. (A) Location of the transcripts (black 
lines), CpG islands, and methylation probes used in this study. Normalized methylation 
data was extracted from the TCGA database for the HNSC (B) and CESC (C) cohorts. The 
mean methylation levels for HPV+, HPV–, and normal control tissues for all probes located 
in the vicinity of the CDKN2A and CDKN2B loci are shown. ** p ≤ 0.01, *** p ≤ 0.001, 
**** p ≤ 0.0001.
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Drubin et al., 2011; McLaughlin-Drubin et al., 2008; McLaughlin-Drubin et al., 2013). 
Interestingly, while strong p16 expression is a near universal hallmark of high-risk HPV+ 
carcinomas of the cervix or oral cavity (Hoffmann et al., 2010; Klaes et al., 2001; Sano et 
al., 1998), p16 is not expressed in high-risk HPV+ low-grade lesions and variably 
expressed in higher grade precancerous lesions (Mills et al., 2015; Woo et al., 2013) or 
lesions caused by low-risk HPV types (Geissler et al., 2013; Mooren et al., 2014; Sano et 
al., 1998). Thus, expression of high-risk HPV oncogenes alone is not sufficient to activate 
high levels of p16 expression, and additional adaptations acquired during tumor 
development likely contribute to this process. 
While cell culture models have allowed detailed analyses of factors involved in virus-
mediated activation of p16 gene expression from the CDKN2A locus, far less is known 
about how similar these effects are to actual HPV+ tumors. In this study, our goal was to 
determine if the changes in H3K27me3 regulators and their target genes observed in cell 
culture models of HPV transformation are recapitulated in primary HPV+ tumors from 
different anatomical locations. 
Using data from over 800 primary human tumors, we provide evidence that HPV+ tumors 
from both the head and neck and cervical sites exhibit remarkably similar alterations in 
expression of the genes encoded by the CDKN2A locus (Figure 2.2). It is well established 
that HPV induces expression of p16 INK4A in both oropharyngeal and cervical carcinomas 
(Hoffmann et al., 2010; Klaes et al., 2001). While overexpression of the p14 ARF gene 
from this locus has been observed in these cancers (Kanao et al., 2004; Schlecht et al., 
2015), this has not been extensively documented. Our observation that p14 expression, like 
that of p16, is similarly elevated in comparison to HPV– tumors or normal control tissue 
clearly demonstrates that HPV activates expression of the entire CDKN2A locus. 
Furthermore, this activation extends into the adjacent CDKN2B locus, which is also 
regulated by PRCs (Popov and Gil, 2010). Indeed, both the long non-coding RNA, 
CDKN2B-AS ANRIL, and p15 INK4B are induced in HPV+ cervical carcinomas with 
respect to HPV– tumors and normal control tissue; similarly, high levels of both CDKN2B 
encoded genes are expressed in HPV+ head and neck cancers (Figure 2.2). Existing 
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literature from independent cohorts confirms that p15 is expressed at lower levels in normal 
cervical tissue compared to cervical carcinomas (Feng et al., 2007; Zhang et al., 2014), 
supporting our conclusions from the TCGA CESC data. In addition, an independent 
analysis of a subset of the TCGA HNSC cohort used in our analysis observed similarly 
high, albeit variable, levels of p15 in HPV+ and normal control samples (Salyakina and 
Tsinoremas, 2016). Taken together, the similarities between the normalized expression of 
all four gene products from the CDKN2A and CDKN2B gene loci in HPV+ tumors from 
both the cervix and oropharynx is extraordinary. These results clearly demonstrate the 
dominant nature of viral reprogramming of cellular gene expression in these cancers with 
respect to normal control tissue and HPV-negative cancers. 
A simple mechanism to explain the observed increase of CDKN2A and CDKN2B 
expression in HPV+ cells would be a decreased expression of the proteins necessary for 
the H3K27 methyltransferase activity of the PRC2. In tissue culture models, expression of 
the EZH2 methyltransferase is increased by the presence of HPV oncogenes, and no 
significant change is observed for the EED and SUZ12 core proteins also required for 
catalytic activity (Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Similarly, in 
HPV+ tumors from both anatomical sites, we find that these genes are expressed at levels 
equivalent or even higher than normal control tissue and HPV– samples (Figure 2.3). 
Furthermore, an analysis of ten biopsies of normal cervical tissue, HPV+ high-grade 
precancerous lesions, and HPV+ cervical carcinomas detected similarly elevated levels of 
EZH2 protein in the HPV expressing samples (Holland et al., 2008). Thus, there is a 
remarkably close agreement between the finding reported from tissue culture models and 
what is observed in human tumors, confirming that a reduction in the overall level of PRC2 
expression is not likely responsible for CDKN2A and CDKN2B activation. 
Silencing of euchromatin by PRC2 is stabilized and maintained by PRC1. Cell culture 
experiments suggest that expression of BMI1, a core component of PRC1, is reduced in 
E6/E7 transduced HFKs (Hyland et al., 2011) and BMI1 expression is inversely correlated 
with HPV viral load in cervical carcinomas (Kim et al., 2016). Our analysis of primary 
human cervical carcinomas indicates that BMI1 expression is significantly reduced in 
HPV+ tumors with respect to HPV– tumors. However, this is not the case in head and neck 
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tumors, where it is modestly upregulated (Figure 2.3). For this reason, it seems unlikely 
that the induction of CDKN2A and CDKN2B expression observed in both these cancers is 
related to a reduction in expression of the BMI1 component of PRC1. This is further 
supported by a study reporting that BMI1 protein expression was lost in less than half of 
the 40 p16-positive oropharyngeal tumors tested (Lundberg et al., 2016). Thus, a loss of 
BMI1 expression appears unrelated to increased p16 transcription, at least in the context of 
oropharyngeal tumors. 
An alternative method of activating the CDKN2A and CDKN2B loci could be via the 
removal of the repressive H3K27me3 modification catalyzed by the PRC2 complex. This 
histone modification is erased by the KDM6A and KDM6B demethylases. Previous work 
in tissue culture models established that transduction of HPV E7 into HFKs induced 
KDM6A and/or KDM6B mRNA and protein levels (Hyland et al., 2011; McLaughlin-
Drubin et al., 2011). Mechanistically, induction of KDM6B was independent of the 
interaction of E7 with Rb. More importantly, siRNA knockdown of KDM6B antagonized 
p16 induction by E7, suggesting that upregulation of these demethylases is the mechanism 
by which HPV reduces global H3K27me3 levels and activates p16 expression 
(McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). Our analysis of 
primary human tumors indicates that KDM6A expression is significantly increased in 
HPV+ head and neck and cervical carcinoma cells with respect to HPV– tumors and likely 
normal control tissue. However, this is not the case for KDM6B, which is significantly 
reduced (Figure 2.4). These data fully support the model proposed from tissue culture 
experiments, in which enhanced expression of KDM6A, but not KDM6B, by HPV is 
related to the dysregulation of H3K27me3 homeostasis and subsequent activation of 
CDKN2A and likely CDKN2B transcription in both these cancer types. One small study 
reported that expression of both KDM6A and KDM6B is substantially reduced in HPV+ 
mildly dysplastic lesions; however, stepwise increases were observed for both 
demethylases in precancerous lesions and cervical carcinoma, such that the carcinomas 
express both demethylases at levels similar to normal control tissues (Iancu et al., 2015). 
This pattern of re-expression correlates well with the acquisition of p16 expression 
observed during cervical carcinoma progression. 
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Accompanying the global reduction in H3K27me3, HPV+ head and neck cancers and 
cervical carcinomas exhibit numerous alterations in DNA methylation (Lorincz, 2016; van 
Kempen et al., 2014). Indeed, we recently reported a methylation signature that predicts 
HPV status in HNSC samples (Papillon-Cavanagh et al., 2017). Our analysis of 
methylation data for all the probes across the CDKN2A and CDKN2B loci for the TCGA 
HNSC and CESC cohorts revealed that there were two consistent alterations in DNA 
methylation relative to methylation levels present in HPV– tumors and normal tissue 
(Figure 2.5). A hypomethylated region of DNA was identified on the south shore of the 
CpG island located at the start of the p14 transcript in HPV+ tumors in both the HNSC and 
CESC cohorts. Genome-wide studies have clearly shown that methylation in the immediate 
vicinity of the transcription start site blocks initiation (Jones, 2012). As such, the greatly 
reduced methylation in HPV+ samples at this region is fully consistent with enhanced 
CDKN2A expression. In addition, we also observed a hypermethylated region of DNA on 
the north shore of the CpG island closest to the third exon of the p14 and p16 transcripts. 
Hypermethylation at this location has been described in other studies of HPV+ head and 
neck and cervical carcinomas using alternative probes (Ben-Dayan et al., 2017; Schlecht 
et al., 2015; Wijetunga et al., 2016). These studies have established that p16 and p14 
expression in a given tumor sample is strongly correlated with increased methylation at 
this position in the CDKN2A locus (Ben-Dayan et al., 2017; Schlecht et al., 2015). 
Hypermethylation of gene-bodies has recently been shown to occur during elongation 
through a mechanism whereby RNA Polymerase II recruits Su(var)3-9, Enhancer-of-zeste 
and Trithorax domain containing 2 (SETD2), a histone methyltransferase, which then tri-
methylates H3K36. DNA Methyltransferase 3 (DNMT3) recognizes and binds 
H3K36me3, leading to the methylation of CpGs (Baubec et al., 2015; Neri et al., 2017). 
Thus, along with promoter hypomethylation, gene-body methylation correlates well with 
the observed enhanced transcription from the CDKN2A locus, providing further support 
for an epigenetic mechanism as the basis for HPV induction of expression from this locus. 
Taken together, our analysis of over 350 HPV+ head and neck or cervical carcinomas in 
comparison with over 450 HPV– cancers from their respective anatomical sites 
demonstrates that HPV consistently activates expression of both the CDKN2A and 
CDKN2B loci in these cancers. Interestingly, this extends beyond just p16, with most 
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tumors expressing the other gene products from these loci including p14, ANRIL, and p15. 
In these cancers, HPV oncogene expression similarly dysregulates expression of key 
regulators of H3K27me3, including members of PRC2 and the demethylases KDM6A and 
KDM6B. As a likely result of these and other alterations in epigenetic regulation, the levels 
of methylation in the center of the CDKN2A and CDKN2B loci are significantly decreased 
in cells expressing high-risk HPV oncogenes. 
Importantly, epigenetic reprogramming of gene expression induced by HPV should be 
reversible and could represent a unique therapeutic target. Paradoxically, cervical 
carcinoma cell lines or other tumor cell lines expressing HPV E7 from several high-risk 
HPVs appear to require continuous p16 expression for survival. Although p16 normally 
serves as a tumor suppressor, for currently unknown reasons, it becomes necessary for 
continued growth in cells expressing HPV E7. As HPV+ cells require KDM6 demethylase 
activity to maintain p16 expression, they are sensitive to small molecule inhibitors of 
KDM6 in cell culture models (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 
2013). However, it has not been determined if actual primary HPV+ head and neck or 
cervical carcinoma cells will respond similarly. Our analysis of the epigenetic regulators 
that control p16 expression finds many commonalities between the hundreds of tumors 
making up the TCGA CESC and HNSC cohorts and cell culture models, strongly 
suggesting that testing of KDM6 inhibitors should be aggressively pursued as a novel 
therapy of HPV+ cancers. 
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Chapter 3  
3 Analysis of Class I Major Histocompatibility Complex 
Gene Transcription in Human Tumors Caused by Human 
Papillomavirus Infection 
 
3.1 Introduction 
Anti-viral immunity is comprised of multiple levels of defenses that cooperatively block, 
control, and eliminate infection. Intrinsic and innate immunity function as pre-existing 
defenses against viral infection, and serve as the first levels of response (Takeuchi and 
Akira, 2009; Yan and Chen, 2012). In the event that these non-specific immune responses 
are not sufficient to eliminate an infection, subsequent antigen-specific adaptive immune 
responses develop. As such, the recognition of intracellularly-derived viral peptides in the 
context of major histocompatibility complex class I (MHC-I) molecules by cytotoxic T 
lymphocytes (CTLs) triggers the elimination of virally infected cells (Tscharke et al., 
2015), while antibodies specific for virion antigens neutralize viral particles, and block the 
spread of infection (Dorner and Radbruch, 2007). 
Despite the effectiveness of the immune system, many viruses have acquired sophisticated 
methods to evade anti-viral defenses, including the adaptive CTL response. For example, 
several viral proteins have been identified that block MHC-I antigen presentation by 
downregulating the loading of antigen onto MHC-I, the expression of MHC-I itself, and 
the transport of MHC-I to the cell surface. Viral proteins have also been found to trigger 
MHC-I internalization and/or degradation (Hansen and Bouvier, 2009). Collectively, these 
strategies facilitate the evasion of the infected cell from CTL attack, thus allowing the virus 
to persist. 
Human papillomaviruses (HPV) are small, non-enveloped, double-stranded DNA viruses 
that infect mucosal or cutaneous epithelia and induce cellular proliferation (Doorbar et al., 
2015). HPV infections of mucosal tissues are highly prevalent, and infections typically take 
one to two years to resolve (Munoz et al., 2009). Mucosal HPVs are classified as low- or 
high-risk based on the frequency with which they are associated with cancer. High-risk 
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HPVs are causative agents for cancers at multiple distinct anatomical subsites (Doorbar et 
al., 2015), including the cervix (Crosbie et al., 2013), other anogenital tissues (Alemany et 
al., 2016; De Vuyst et al., 2009; Guimera et al., 2017), and the oropharynx (Gillison et al., 
2000; Mehanna et al., 2013; Syrjanen, 2005). Worldwide, mucosal high-risk HPV infection 
is responsible for greater than 5% of all human cancers (Forman et al., 2012). 
HPV encodes two main oncogenes, E6 and E7 (Doorbar et al., 2012), which are 
constitutively expressed in HPV-positive (HPV+) tumors. The E6 and E7 oncoproteins 
perform multiple functions in an infected and/or cancerous cell. They interact with key 
cellular regulatory proteins to dysregulate gene expression and cell growth (Doorbar et al., 
2012). For example, E6 binds to and degrades p53, while E7 targets the retinoblastoma 
protein (Rb) and its family members (Dyson et al., 1992; Scheffner et al., 1990). These 
events contribute to inappropriate cell cycle progression in HPV-infected cells (Boyer et 
al., 1996; Brehm et al., 1998). In high-risk HPV infections, viral oncoproteins uncouple 
cell growth from differentiation. Consequently, this contributes to the formation of 
epithelial dysplasia, which may progress to carcinoma if the infection is not resolved 
(Doorbar et al., 2012). 
Multiple studies have suggested that HPV oncoproteins contribute to the evasion of the 
adaptive immune response, which supports a model by which the establishment of a 
persistent HPV infection contributes to the ability of HPV+ cancers to evade anti-tumor 
CTL responses (Westrich et al., 2017). Although both E5—a third viral oncoprotein—and 
E6 from HPV16 have been reported to block MHC-I expression (Ashrafi et al., 2006; Kim 
et al., 2011), the majority of studies in this area focus on the E7-mediated reduction of 
MHC-I expression. Specifically, transfection of high-risk HPV E7 into various cell lines 
represses MHC-I and/or transporter associated with antigen processing (TAP) expression 
(Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2010). Reciprocal studies have 
shown that the knock-down of E7 in some HPV+ cervical cancer cell lines increases MHC-
I expression (Bottley et al., 2008; Li et al., 2006). In these studies, the repression of MHC-
I appears to be a specific function of high-risk HPV E7 that is not shared by low-risk HPV 
E7 (Georgopoulos et al., 2000; Heller et al., 2011). Mechanistically, the reduction of MHC-
I and TAP expression in these studies occurs at the transcriptional level (Georgopoulos et 
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al., 2000; Heller et al., 2011; Li et al., 2010). The most detailed studies of the HPV-
mediated repression of MHC-I expression report that E7 associates with the promoter of 
the MHC-I HLA-A heavy chain gene, and recruits histone deacetylase activity via residues 
70, 80, and 88 of HPV16 E7 (Heller et al., 2011; Li et al., 2006; Li et al., 2009). In addition 
to repressing the basal transcription of MHC-I, HPV E7 abrogates the interferon regulatory 
factor-1 (IRF-1) response, thus inhibiting interferon-gamma (IFNγ)-mediated 
transcriptional induction of MHC-I expression, antigen presentation, and CTL-induced cell 
death (Park et al., 2000; Perea et al., 2000; Um et al., 2002; Zhou et al., 2013; Zhou et al., 
2011). 
While the majority of published studies using tissue culture models indicate that HPV 
oncoproteins such as E7 repress the expression of the antigen presentation apparatus, 
cognate studies on the effects of HPV in human carcinomas are less consistent. Conflicting 
reports suggest that HPV+ carcinomas/dysplastic lesions display increased (Jochmus et al., 
1993; Torres et al., 1993), decreased (Cromme et al., 1993; Keating et al., 1995; Ritz et al., 
2001; van Esch et al., 2014), or the same levels (Djajadiningrat et al., 2015; Ramqvist et 
al., 2015) of MHC-I or TAP expression when compared with HPV negative (HPV−) 
tumors or normal control tissues. Some of these differences may be related to different 
tissue types, stages, and/or grades. The most comprehensive analysis, which examined 109 
cervical carcinoma samples, concluded that only about 40% of the samples exhibited 
MHC-I downregulation (Mehta et al., 2008). However, many types of tumors that are 
HPV− contain a similar subset that are deficient in MHC-I and/or TAP expression (Garcia-
Lora et al., 2003), which suggests that this reduction is not actually virally-mediated. As 
such, it remains an open question as to whether the E7-mediated changes in the 
transcription of various MHC-I pathway components observed in tissue culture similarly 
occur in the context of actual human HPV+ carcinomas. This information is clearly 
relevant, considering that the activation of an antigen-dependent clearance of tumor cells 
by the immune system is an extraordinarily effective cancer therapy (Gotwals et al., 2017). 
In this study, we used data from over 800 human cervical (The Cancer Genome Atlas 
Research Network, 2017) and head & neck tumors (The Cancer Genome Atlas Research 
Network, 2015) from The Cancer Genome Atlas (TCGA). We set out to determine if high-
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risk HPV oncogene expression alters the expression of MHC-I heavy chain genes, the β2 
microglobulin light chain gene, and other components of the antigen-loading apparatus, 
which includes: TAP1/2, tapasin, ERp57, calreticulin, calnexin, and ERAP1/2 in human 
tumors. We found that HPV+ tumors from both anatomical sites expressed substantial 
levels of mRNA for each of these MHC-I pathway components. Indeed, many of these 
genes were expressed at significantly higher levels than normal control tissues. 
Furthermore, an analysis of mutation frequencies in MHC-I genes indicated that the HPV+ 
and HPV− cancers exhibit similar frequencies of alteration. This is in contrast to TP53 and 
CDKN2A, which are key regulators of pathways known to be targeted by HPV 
oncoproteins and are frequently mutated in HPV− but not HPV+ carcinomas. This suggests 
that the acquisition of somatic mutations in MHC-I genes as a means of evading the anti-
tumor CTL response occurs similarly in HPV+ and HPV− cancers, which would not be 
expected if HPV oncoproteins were effective at repressing MHC-I expression or function. 
Taken together, this data does not entirely validate conclusions drawn from previous tissue 
culture studies. Specifically, HPV oncoprotein expression does not repress the transcription 
of the MHC-I pathway components in cervical carcinomas, although a modest reduction in 
MHC-I mRNA levels was observed in HPV+ vs. HPV− head & neck cancers. 
3.2 Materials and Methods 
3.2.1 RNA expression comparisons and statistical analysis 
Level 3 RNA-Seq by Expectation Maximization (RSEM) normalized Illumina HiSeq RNA 
expression data for the TCGA head & neck cancer (HNSC) and cervical carcinoma (CESC) 
cohorts was downloaded from the Broad Genome Data Analysis Center’s Firehose server 
(https://gdac.broadinstitute.org/). For all of the genes, the gene level Firehose dataset was 
used. Normalized expression data was extracted into Microsoft Excel, and the HPV status 
was manually curated based on published datasets (Banister et al., 2017; Bratman et al., 
2016; The Cancer Genome Atlas Research Network, 2015; The Cancer Genome Atlas 
Research Network, 2017). For each gene analyzed, primary patient samples with known 
HPV status were grouped as HPV+, HPV−, or normal control tissue. Patient samples with 
unknown HPV status were omitted from our calculations, as were samples obtained from 
secondary metastatic lesions. This resulted in 73 HPV+, 442 HPV−, and 43 normal control 
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samples with data available for the HNSC gene expression analysis and 278 HPV+, 19 
HPV−, and 3 normal control samples available for the CESC gene expression analysis. 
Boxplot comparison of gene expression was performed using GraphPad Prism v7.0 
(Graphpad Software, Inc., San Diego, California, USA) and assembled into final form 
using CorelDRAW (Corel, Ottawa, Ontario, Canada). For the boxplots, center lines show 
the medians, box limits indicate the 25th and 75th percentiles as determined by Graphpad 
Prism, and whiskers extend from the minimum to maximum values. Statistical significance 
was calculated using Graphpad Prism. p-values were assigned using a one-tailed non-
parametric Mann–Whitney U test. Post-hoc power calculations were performed with 
G*Power software version 3.1.9.2 (Faul et al., 2007), using post-hoc t-test family 
calculations, with effect size selected as 0.8 and α = 0.05. All comparisons achieved a 
power value > 0.8, or demonstrated significant differences, unless otherwise noted in the 
text. 
3.2.2 Somatic mutation frequency comparisons and statistical 
analysis 
Somatic mutations present in selected genes of the tumor samples in the TCGA, HNSC, 
and CESC cohorts were downloaded as the DNA Mutation Packager Calls  
dataset from the Broad Genome Data Analysis Center’s Firehose server 
(https://gdac.broadinstitute.org/), and manually annotated for HPV status. This resulted in 
67 HPV+ and 431 HPV− samples for the HNSC cohort, and 181 HPV+ and 10 HPV– 
samples for the CESC cohort. Differences in the frequencies of DNA mutations in selected 
genes were calculated between HPV+ and HPV− samples using the maftools package 
(Mayakonda et al., 2018) in R statistical environment (Version 3.4.0). Silent mutations 
were excluded from the analysis, and samples with multiple mutations in a gene were 
counted as one for the calculations. Statistical significance (p < 0.05) was determined using 
Fisher’s exact test. 
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3.3 Results 
3.3.1 Impact of HPV status on MHC-I heavy chain expression in 
human tumors 
MHC-I is a heterodimer comprised of a heavy chain encoded by one of three classical 
(HLA-A, -B, and -C) or non-classical (HLA-E, -F, and -G) genes and the invariant β2 
microglobulin light chain (Hansen and Bouvier, 2009). We analyzed the Illumina HiSeq 
RNA expression data from the TCGA head & neck squamous cell carcinoma (HNSC) and 
cervical carcinoma (CESC) cohorts for expression of HLA-A, HLA-B, and HLA-C, the three 
classical genes (Figure 3.1). Unexpectedly, HPV+ samples from both the HNSC and 
CESC cohorts expressed high levels of mRNA for all three genes, as shown by the 
normalized RNA-seq absolute read count values, which averaged in the range of 25,000–
50,000. The HPV+ samples from the HNSC cohort expressed significantly elevated levels 
of HLA-A, HLA-B, and HLA-C compared with normal control tissue. In the CESC cohort, 
although the median RNA-seq values for the HPV+ samples appeared at least as high as 
those for normal control samples, there was insufficient power to exclude the possibility 
that the expression of HLA-A, HLA-B, or HLA-C was not different. In the HNSC cohort, 
levels in HPV+ samples were slightly lower than HPV− samples, whereas HPV+ samples 
in the CESC cohort had substantially higher levels of expression versus HPV− samples. 
Nevertheless, all tumor subsets expressed high absolute levels of the mRNAs for each of 
the classical MHC-I heavy chain genes. 
Similarly, higher or comparable levels of expression of the non-classical genes, HLA-E, 
HLA-F, and HLA-G, were observed in HPV+ cancers with respect to normal control tissues 
in the HNSC cohort (Figure 3.2). Again, a comparison of the HPV+ samples to normal 
control samples in the CESC cohort was insufficiently powered to allow us to exclude the 
possibility that the expression of HLA-E, HLA-F, or HLA-G was not altered by the presence 
of HPV oncogenes. However, HLA-E and HLA-F were expressed at relatively high levels 
based on the absolute normalized read values. As noted by others (Cicchini et al., 2017), 
HLA-E was expressed at significantly reduced levels in HPV+ samples compared with 
HPV− samples in the HNSC cohort. However, this was not a consistent effect in all HPV+ 
carcinomas, as HLA-E was expressed at much higher levels in the HPV+ samples compared 
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Figure 3.1. Expression of classical MHC-I heavy chain genes in head & neck or 
cervical carcinomas stratified by HPV status. 
Normalized RNA-seq data for the indicated MHC-I heavy chain genes was extracted from 
The Cancer Genome Atlas (TCGA) database for the head & neck cancer (HNSC) (A) and 
cervical carcinoma (CESC) (B) cohorts for HPV+, HPV−, and normal control tissues. 
Numbers in brackets refer to the number of samples included in each analysis. * p ≤ 0.05, 
** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant, red brackets indicate a 
comparison that did not achieve significance with a power value < 0.8. 
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Figure 3.2. Expression of non-classical MHC-I heavy chain genes in head & neck or 
cervical carcinomas stratified by HPV status. 
Normalized RNA-seq data for the indicated MHC-I heavy chain genes was extracted from 
the TCGA database for the HNSC (A) and CESC (B) cohorts for HPV+, HPV−, and normal 
control tissues. Numbers in brackets refer to the number of samples included in each 
analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant, red 
brackets indicate a comparison that did not achieve significance with a power value < 0.8.
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with the HPV− samples in the CESC cohort. Although HLA-G was expressed at lower 
overall levels than the other heavy chain genes, it was also expressed at comparable or 
elevated levels in HPV+ samples versus HPV− or normal control samples (Figure 3.2). 
Collectively, these results indicate that the expression of HPV oncogenes in actual human 
tumors is not correlated with strong repression of the MHC-I loci, in contrast to what is 
reported in tissue culture-based models. Indeed, the average expression of the mRNA for 
these genes is consistently higher or equivalent in HPV+ samples versus the normal 
control. 
3.3.2 Impact of HPV status on the expression of other components 
of the antigen presentation apparatus in human tumors 
The MHC-I heavy chain folds and assembles with the β2 microglobulin light chain within 
the endoplasmic reticulum, in a process dependent on binding to a peptide antigen (Hansen 
and Bouvier, 2009). The MHC-I peptide-loading complex consists of MHC-I, the peptide 
transporter TAP, the bridging factor tapasin, the endoplasmic reticulum aminopeptidase 
(ERAP), and the chaperones: calreticulin, calnexin, and ERp57. Several studies have 
reported the downregulation of TAP in HPV+ cancer cell lines (Georgopoulos et al., 2000; 
Li et al., 2010). Much less is known about the effect of HPV status on the expression of 
the other components necessary for MHC-I antigen presentation, so we examined the 
impact of HPV status on all mRNA expression for all components of the MHC-I peptide-
loading complex. Analysis of TCGA data revealed high levels of transcripts for the B2M 
gene encoding β2 microglobulin, the TAP1 and TAP2 genes encoding the TAP 
heterodimer, and the genes encoding ERAP, tapasin, calreticulin, calnexin, and ERp57 
(ERAP1/2, TAPBP, CALR, CANX, and PDIA3 respectively) in HPV+ samples in head & 
neck (Figure 3.3) and cervical (Figure 3.4) carcinomas. All genes were expressed at higher 
levels in HPV+ samples with respect to normal control tissue in the HNSC cohort, with the 
sole exception of CANX, which was expressed at a comparable level. There were no 
consistent differences in expression with respect to HPV+ and HPV− samples in the HNSC 
cohort. B2M and TAP1 were expressed at equivalent levels; TAP2, CANX, CALR, and 
PDIA3 were reduced; while TAPBP, ERAP1, and ERAP2 were increased (Figure 3.3). In 
the CESC cohort, nearly all of these genes were expressed at elevated or comparable levels 
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Figure 3.3. Expression of the MHC-I light chain and other genes involved in MHC-I-
dependent antigen presentation in head & neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for the indicated genes involved in MHC-I-dependent antigen 
presentation was extracted from the TCGA database for the HNSC cohort for HPV+, 
HPV−, and normal control tissues. Numbers in brackets refer to the number of samples 
included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not 
significant. 
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Figure 3.4. Expression of the MHC-I light chain and other genes involved in MHC-I-
dependent antigen presentation in cervical carcinomas stratified by HPV status. 
Normalized RNA-seq data for the indicated genes involved in MHC-I-dependent antigen 
presentation was extracted from the TCGA database for the CESC cohort for HPV+, 
HPV−, and normal control tissues. Numbers in brackets refer to the number of samples 
included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not 
significant, red brackets indicate a comparison that did not achieve significance with a 
power value < 0.8.
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to normal control tissue or HPV− samples, although some comparisons were limited based 
on insufficient sample numbers. The sole exception was CANX, which was expressed at a 
lower level in HPV+ versus HPV− samples (Figure 3.4). Thus, most components of the 
MHC-I loading complex were transcribed in HPV+ human tumors at levels that appear 
similar or significantly higher than normal control tissue. This again contrasts with the 
reported decreases in TAP transcription reported in tissue culture models. 
3.3.3 Higher levels of lymphocytes and interferon γ are present in 
HPV+ human tumors 
IFNγ, the product of the IFNG locus, can coordinately induce higher levels of transcription 
in many of the genes involved in antigen processing and presentation by MHC-I, and 
provides enhanced immune surveillance under inflammatory conditions (Boehm et al., 
1997). Given our observation that mRNA levels of all MHC-I loading and presentation 
genes were expressed at higher or at least similar levels in HPV+ tumors compared with 
HPV− and normal control tissues, we hypothesized that infiltrating lymphocytes producing 
IFNγ could be present at higher levels in HPV+ tumors versus HPV− tumors or normal 
control tissues. 
We first assessed the relative proportion of T- and NK-cells in these samples, which are 
the primary producers of IFNγ. Similarly to what has been done by others (Becht et al., 
2016), we analyzed the mRNA expression levels of the genes encoding CD3 (CD3D, 
CD3E, and CD3G) and CD16a (FCGR3A), as surrogate markers for T- and NK-cells, 
respectively (Figure 3.5). HPV+ samples from both the HNSC and CESC cohorts showed 
significantly increased expression of all three genes encoding subunits of CD3 versus 
HPV− samples. For the HNSC cohort, CD3 expression in HPV+ samples were also 
consistently higher than normal control tissues. No significant differences in CD3 levels 
were observed between HPV+ samples and normal control tissues in the CESC cohort, but 
this comparison was not powered sufficiently to confirm this result. For the NK-cell marker 
CD16a, expression of FCGR3A was readily detected and significantly higher in HPV+ 
cells versus normal control tissue from both the HNSC and CESC cohorts. No difference 
in FCGR3A levels were apparent between HPV+ and HPV− samples from either cohort, 
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Figure 3.5. Detection of tumor infiltrating T-cells and NK-cells in head & neck and 
cervical carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes indicative of tumor-infiltrating T-cells (CD3D, CD3E, 
and CD3G) or NK-cells (FCGR3A) was extracted from the TCGA database for the HNSC 
(A) and CESC (B) cohorts for HPV+, HPV−, and normal control tissues. Numbers in 
brackets refer to the number of samples included in each analysis. * p ≤ 0.05, *** p ≤ 0.001, 
**** p ≤ 0.0001, ns – not significant, red brackets indicate a comparison that did not 
achieve significance with a power value < 0.8. 
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which indicated that infiltration by NK-cells is similar in both HPV+ and HPV− samples. 
Taken together, these results suggest that there is significant infiltration of both cervical 
and head & neck tumors with T-cells and likely NK-cells, which could be stimulating the 
tumor cells to upregulate MHC-I. Notably, the absolute normalized RNA-seq read levels 
for genes derived from these infiltrating lymphocytes were much lower than any of the 
other genes we analyzed, with the exception of the weakly expressed HLA-G. This was as 
expected, as the lymphocytes are expected to represent only a fraction of the tumor mass 
(Aran et al., 2015). 
We next looked for IFNγ mRNA to determine whether these lymphocytes were producing 
this proinflammatory cytokine (Figure 3.6). Although the expression of IFNγ mRNA in 
these samples was low, it was detectable, and significantly higher in HPV+ samples versus 
HPV− or normal control tissues in both the HNSC and CESC cohorts (Figure 3.6). Taken 
together, these results indicate that HPV+ carcinomas have a significant level of infiltrating 
lymphocytes that appear to be producing some IFNγ. Thus, the upregulated expression of 
the MHC-I loading and presentation genes observed in these carcinomas may be a 
consequence of exposure to IFNγ. 
3.3.4 Genes encoding components of the antigen presentation 
apparatus are frequently mutated in HPV+ human tumors 
Precancerous cells undergo strong selection for properties that are advantageous for growth 
and survival, leading to clonal evolution and cancer formation. As such, tumor cells 
frequently acquire somatic mutations that activate oncogenes or inactivate growth 
inhibitory genes. In HPV-dependent cancers, the expression of virally-derived oncogenes 
should eliminate the need for somatic mutations in the key cellular regulatory pathways 
they target. Thus, if high-risk HPV E7 repressed MHC-I expression and function, the 
frequency of mutations in MHC-I that would allow tumor escape from the immune system 
should be reduced in HPV+ versus HPV− carcinomas. 
To validate this concept, we first analyzed the frequency of mutations in TP53 and 
CDKN2A (Figures 3.7A, B, left panels). TP53 encodes the p53 tumor suppressor protein, 
which is targeted by the E6 oncoproteins of high-risk HPVs. CDKN2A encodes the p16 
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Figure 3.6. Detection of IFNγ mRNA in head & neck and cervical carcinomas 
stratified by HPV status. 
Normalized RNA-seq data for the IFNγ gene produced by tumor-infiltrating lymphocytes 
was extracted from the TCGA database for the HNSC (A) and CESC (B) cohorts for 
HPV+, HPV−, and normal control tissues. Numbers in brackets refer to the number of 
samples included in each analysis. ** p ≤ 0.01, **** p ≤ 0.0001. 
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tumor suppressor, a key regulator of the Rb pathway targeted by the E7 oncoprotein of 
high-risk HPVs (Boyer et al., 1996; Sherr and McCormick, 2002). There were dramatic 
differences in the frequency of somatic mutations in TP53 and CDKN2A in HPV+ versus 
HPV− samples from both the TCGA HNSC and CESC cohorts, although the frequencies 
in the CESC cohort were not statistically different due to a smaller sample size. The 
mutation load for TP53 was much higher in HPV− samples, with a 55-fold (HNSC) and 
5.2-fold (CESC) increase compared with their HPV+ counterparts. For CDKN2A, a fold 
increase could not be calculated for the HNSC cohort, as no mutations were present in the 
HPV+ samples. However, 26% of HPV− HNSC samples contained CDKN2A mutations. 
In the CESC cohort, there was an 18-fold increase in CDKN2A mutations in HPV− 
compared with HPV+, respectively. These observations were expected, as high-risk HPV 
E6 targets p53 for degradation, while high-risk HPV E7 targets Rb. Thus, these viral 
oncoproteins functionally inactivate these critical anti-cancer pathways without the need 
for the somatic mutations acquired by HPV− carcinomas during tumor evolution. 
We next compared the frequency of somatic mutations in all of the genes encoding MHC-
I and the antigen-loading complex in HPV+ samples versus HPV− samples in the TCGA 
HNSC and CESC cohorts (Figures 3.7A, B, right panels). As noted by others (The Cancer 
Genome Atlas Research Network, 2015; The Cancer Genome Atlas Research Network, 
2017), mutations in the genes encoding MHC-I heavy chains were the most frequent. 
However, mutations in B2M, TAP1/2, or other components of the MHC-I loading complex 
were also present at lower frequencies. To simplify this analysis, we compared the mutation 
frequency in both classical and non-classical MHC-I genes as a group, as well as all of the 
components of the MHC-I and associated loading complex, collectively. This second 
comparison should be valid, as the inactivation of any single component of this pathway 
could be sufficient to impair antigen presentation (Hansen and Bouvier, 2009). Indeed, one 
comprehensive study in a small cohort of cervical carcinomas found that 15 out of 16 
tumors exhibited an impaired expression of at least one component of the MHC-I antigen 
presentation apparatus (Ritz et al., 2001). Our inspection of the TCGA data reveals that 
both HPV+ and HPV− carcinomas in the HNSC or CESC cohorts acquire relatively 
frequent somatic mutations in the components of the MHC-I antigen presentation pathway,  
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Figure 3.7. Comparison of the somatic mutation frequency in genes involved in MHC-
I-dependent antigen presentation in head & neck and cervical carcinomas stratified 
by HPV status.  
The presence or absence of somatic mutations in selected genes of the tumor samples in 
the TCGA HNSC and CESC cohorts was obtained from the Broad Genome Data Analysis 
Center’s Firehose server. The frequency of mutations in individual genes or groups of 
genes in HPV+ versus HPV− samples was calculated to determine whether they were 
influenced by HPV status. Analysis of TP53 and CDKN2A (left panels) revealed a 
significantly reduced frequency of somatic mutations in HPV+ versus HPV− samples in 
both the TCGA HNSC (A) and CESC (B) cohorts. No significant decrease was observed 
for somatic mutation frequency in the MHC-I heavy chain genes, or a collective grouping 
of all genes involved in MHC-I-dependent antigen presentation between HPV+ and HPV− 
samples in either the TCGA HNSC (A) or CESC (B) cohorts. Numbers in brackets refer to 
the number of samples included in each analysis. * p ≤ 0.05, ns – not significant.
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presumably as a means of immune escape. There was no difference in the frequency of 
somatic mutations in genes encoding MHC-I or the antigen-loading apparatus between 
HPV+ and HPV− samples in either cohort (Figures 3.7A, B, right panels). Thus, the 
presence of HPV oncogenes has no impact on the frequency of somatic mutations in genes 
related to MHC-I antigen presentation. This is consistent with the conclusion that HPV 
oncogenes do not effectively reduce antigen presentation by MHC-I, which would have 
eliminated the need for HPV+ carcinomas to acquire mutations in this pathway. 
3.4 Discussion 
The stable surface expression of MHC-I requires loading of the heavy chain/light chain 
dimer with an antigenic peptide in the endoplasmic reticulum. The loading complex 
consists of multiple essential factors, including the peptide transporter TAP, the bridging 
factor tapasin, and the chaperones: calreticulin, calnexin, and ERp57. Reduced expression 
or mutation of any of these components can compromise MHC-I-dependent antigen 
presentation, and allow the infected or cancerous cell to escape T-cell recognition and 
clearance (Hansen and Bouvier, 2009). 
HPV infection and subsequent expression of the viral oncoproteins leads to a large-scale 
reprogramming of gene expression. Multiple studies have reported that the high-risk HPV 
E7 oncoprotein contributes to the evasion of the adaptive immune response; this process 
occurs through transcriptional downregulation of the MHC-I heavy chain genes or other 
components necessary for antigen loading and presentation (Georgopoulos et al., 2000; 
Heller et al., 2011; Li et al., 2010). This mechanism has been proposed to support the 
establishment of persistent HPV infection and contribute to the ability of HPV+ cancers to 
evade anti-tumor CTL responses. Additional downregulation of MHC-I is mediated by the 
high-risk HPV E5 oncoprotein. This occurs via a non-transcriptional mechanism in which 
the classical heavy chains are trapped in the Golgi apparatus and not transported to the cell 
surface (Ashrafi et al., 2006). 
While cell culture models have allowed detailed studies on the mechanism of E7-mediated 
transcriptional downregulation of components in the MHC-I antigen presentation 
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apparatus, far less is known about how similar these effects are to actual HPV+ tumors. In 
this study, our goal was to determine whether the transcriptional reduction in MHC-I 
components mediated by E7 is recapitulated in primary HPV+ tumors from different 
anatomical locations. 
Using data from over 800 primary human tumors, we provide evidence that HPV+ tumors 
from both the head & neck and cervical sites display high mRNA levels for MHC-I 
components, including heavy and light chains, as well as all factors required for MHC-I 
loading. Indeed, HPV+ head & neck carcinomas exhibit significant increases, rather than 
decreases, in mRNA levels for many MHC-I components compared with normal control 
tissue, and this trend continues in the cervical carcinoma cohort (Figures 3.1–3.4). These 
unexpected results contradict the existing paradigm of virally-mediated immune evasion 
and suggest that in the context of an in vivo tumor setting, the presence of HPV may 
actually result in enhanced expression of mRNA encoding MHC-I-dependent antigen 
presentation components. 
As our results specifically addressed the question of whether HPV oncoproteins repress 
expression of the MHC-I genes at the transcriptional level, they do not eliminate the 
possibility that other post-transcriptional mechanisms, such as those mediated by high-risk 
HPV E5, can reduce antigen presentation. However, a comprehensive analysis of MHC-I 
protein expression by immunohistochemical detection indicated that only a subset of about 
40% of HPV+ cervical carcinomas have reduced expression of one or more components at 
the protein level (Mehta et al., 2008). As only a minority of carcinomas have reduced 
antigen presentation apparatus, it appears that the HPV-mediated reduction of MHC-I is 
not absolutely necessary for tumorigenesis. 
Our results also do not rule out the possibility that E7 could mediate a reduction in MHC-
I transcription in non-cancerous or pre-cancerous lesions, as all samples in this study are 
carcinomas. However, a purpose for the reacquisition of expression of MHC-I during the 
progression of a non-neoplastic lesion to a carcinoma is difficult to reconcile with current 
models of tumorigenesis. 
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Further evidence supporting our conclusion that HPV oncoproteins are unable to 
functionally antagonize MHC-I-dependent antigen presentation in human carcinomas is 
provided by our comparison of somatic mutation frequencies between HPV+ and HPV− 
samples (Figure 3.7). The anticipated sharp reduction in the occurrence of mutations in 
genes encoding MHC-I or antigen-loading complex components was not observed in 
HPV+ samples. This is in stark contrast to what was observed for TP53, which encodes 
p53, a known target of the high-risk HPV E6 oncoproteins (Scheffner et al., 1990) or 
CDKN2A, which encodes the p16 component of the Rb pathway targeted by high-risk HPV 
E7 oncoproteins (Boyer et al., 1996). 
Furthermore, HPV utilizes multiple other strategies to evade the adaptive immune 
response, which suggests that a simple reduction in MHC-I transcription is unlikely to be 
sufficient to escape surveillance by the immune system. These include the ability of E5 to 
block MHC-I transport to the cell surface (Ashrafi et al., 2006), the preferential utilization 
of low-abundance codons to ensure minimal translation of viral antigens (Zhao and Chen, 
2011), and the induction of the ERAP1 protease to partially degrade and attenuate the 
presentation of viral antigenic epitopes (Steinbach et al., 2017). 
A simple mechanism to explain the lack of MHC-I repression would be a failure of these 
tumors to express the HPV E7 oncogene, which has been reported to be necessary and 
sufficient for the downregulation of transcription from at least some of these genes (Bottley 
et al., 2008; Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2006; Li et al., 2009; 
Li et al., 2010). This is clearly not the case, as all HPV+ samples were reported to express 
detectable levels of E6 and E7 mRNAs (The Cancer Genome Atlas Research Network, 
2015; The Cancer Genome Atlas Research Network, 2017). In addition, a lack of E7 would 
not be expected to lead to the observed increase in MHC-I expression, but rather cause 
equivalent expression to that of HPV− cervical carcinoma samples. 
An alternative method of activating expression of MHC-I and components of the antigen-
loading complex could be via the activation of the JAK/STAT/IRF-1 signal transduction 
pathway by exposure to IFNγ. However, multiple studies done in tissue culture models 
have shown that HPV E7 abrogates the IRF-1 response, thus inhibiting the IFNγ induction 
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of MHC-I expression, antigen presentation, and CTL-induced cell death (Park et al., 2000; 
Perea et al., 2000; Um et al., 2002; Zhou et al., 2013; Zhou et al., 2011). Our analysis 
reveals low but detectable levels of mRNA for IFNγ in HPV+ samples, which are higher 
than HPV− samples or normal control tissue in both TCGA cohorts (Figure 3.6). In 
addition, we searched for the presence of mRNAs that should be unique to infiltrating 
lymphocytes that can express IFNγ (Figure 3.5). Using these surrogate markers, we found 
evidence for significant infiltration by T-cells and NK-cells in both HPV+ and HPV− 
carcinomas. Indeed, the levels of infiltrating lymphocytes were significantly higher in 
HPV+ vs. HPV− samples for both TCGA cohorts, which could have resulted from 
detection of foreign virally-derived antigens. Taken together, the high absolute levels of 
mRNAs encoding MHC-I components expressed in HPV+ head & neck and cervical 
carcinomas provide good evidence that high-risk HPV E7 is unable to efficiently block the 
IFNγ induction of transcription of these genes in actual human tumors. Although this 
contrasts with the results of the studies listed above, our work agrees with other studies 
showing that various cervical cancer cell lines upregulate MHC-I in response to IFNγ 
(Bornstein et al., 1997; Evans et al., 2001; Mora-Garcia Mde et al., 2006), and the treatment 
of HPV+ pre-cancerous cervical lesions in patients increased expression of at least HLA-
B in a majority of cases (Sikorski et al., 2004). It should be noted that the levels of MHC-
I heavy chain mRNAs are statistically lower in HPV+ vs HPV− samples in the HNSC 
cohort (Figure 3.1), despite the increased levels of IFNγ (Figure 3.6). This may indicate 
that HPV is able to modestly impact IFNγ activation in these tissues, but this was not 
observed in the CESC cohort. 
Our analysis of over 350 HPV+ head & neck or cervical carcinomas in comparison with 
over 450 HPV− cancers demonstrates subtle differences in the effect of HPV on MHC-I 
transcription between the two anatomical sites. Specifically, HPV does not repress the 
transcription of MHC-I heavy chain genes in cervical carcinomas, which exhibit high levels 
with respect to both HPV− carcinomas and normal control tissue. In contrast, a statistically 
significant but modest reduction in MHC-I heavy chain mRNA levels was observed in 
HPV+ vs HPV− head & neck cancers. However, transcription of these genes was 
nevertheless substantially elevated with respect to normal control tissues. Interestingly, our 
observations with the MHC-I heavy chain genes extend to many of the other genes 
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involved in MHC-I loading. These results are in sharp contrast to much of the existing 
literature derived from tissue culture-based experiments, possibly because of the complex 
interplay between the MHC-I antigen presentation apparatus and cytokines produced by 
infiltrating lymphocytes present in actual tumors. This differs markedly from our previous 
study on the effects of HPV on numerous regulators of H3K27 methylation and the 
expression of multiple downstream targets of these regulators, in which we showed that 
tissue culture models faithfully recapitulate what is observed in human tumors (Gameiro 
et al., 2017). 
Importantly, MHC-I-dependent antigen presentation is critical for CD8+ T-cell responses, 
which are essential for the control and clearance of virally-infected or cancerous cells. This 
is particularly important as recent advances in cancer immunotherapy using immune 
checkpoint blockades rely on reactivating antigen-dependent clearance of tumor cells 
(Postow et al., 2015). Although we detect high levels of MHC-I mRNA in HPV+ tumors, 
this may not necessarily translate into high levels of expression of these proteins. In 
addition, a functional defect in any component of the MHC-I antigen presentation 
apparatus could compromise the detection and clearance of HPV+ carcinomas by the 
adaptive immune system (Hansen and Bouvier, 2009). Thus, the utility of immune 
checkpoint blockade therapy in HPV-dependent cancers remains to be determined. 
Nevertheless, it is intriguing to speculate that the expression of non-self-derived viral 
antigens, combined with intact MHC-I presentation and increased levels of infiltrating T-
cells, may contribute to the well-established observation that patient outcomes using 
conventional therapies are markedly better for HPV+ versus HPV− carcinomas in both the 
head & neck and cervix (Ang et al., 2010; Gotwals et al., 2017). 
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Chapter 4  
4 Treatment-naïve HPV+ Head and Neck Cancers Display 
a T-cell-inflamed Phenotype Distinct from their HPV– 
Counterparts that has Implications for Immunotherapy 
 
4.1 Introduction 
Recent advances in understanding the basics of tumor immunology have paved the way for 
development of therapies that can induce effective anti-tumor immune responses. Many of 
these are based on immune checkpoint inhibition, in which normal negative regulatory 
mechanisms, which keep immune responses in check, are overcome (Pardoll, 2012; 
Topalian et al., 2015). Current immuno-oncology therapies can demonstrate tremendous 
efficacy and induce long-term remission in patients (Del Paggio, 2018). However, 
responses to immunotherapy are often restricted to a subset of cancers, for reasons that are 
not entirely understood.  
Head and neck squamous cell carcinomas (HNSC) represent the 6th most common human 
cancer type (Ferlay et al., 2010) and are often characterized by aggressive local invasion 
and overall poor prognosis (Baxi et al., 2012). In addition to mortality, both the disease and 
its treatment often result in significant patient morbidity. Indeed, treatments for HNSC 
often impact the most personal characteristics of an individual, including facial appearance 
and the ability to eat and speak.  
Infection with human papillomavirus (HPV) is a major etiological factor for tumors located 
in the oropharynx. Indeed, HPV-positive (HPV+) HNSC is increasing at an epidemic pace 
(Marur et al., 2010; Nichols et al., 2013). Importantly, HPV-negative (HPV–) and HPV+ 
HNSC are molecularly distinct, with a different spectrum of mutations (The Cancer 
Genome Atlas Research Network, 2015). HPV+ HNSC also constitutively express viral 
oncogenes that deregulate cell growth and gene expression (Mittal and Banks, 2017). In 
addition, clinical outcomes for HPV+ HNSC are far superior to those in HPV– cases (Ang 
et al., 2010; Fakhry et al., 2008).  
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Both HPV+ and HPV– HNSC display a comparable frequency of somatic mutations, a 
major source of tumor specific neoantigens that can be recognized and targeted by anti-
tumor immunity (The Cancer Genome Atlas Research Network, 2015). However, HPV+, 
but not HPV–, HNSC express exogenous antigenic viral proteins that may be the source of 
a key difference in the tumor immune landscape between these two types of HNSC and 
may contribute to the superior clinical outcomes associated with HPV+ HNSC. Several 
studies have compared various immunological parameters between HPV+ and HPV– 
HNSC and have commonly concluded that HPV+ HNSC are immune “hot” tumors, with 
markedly more immune infiltration and higher levels of CD8+ T-cell activation than HPV– 
HNSC (Mandal et al., 2016; Solomon et al., 2018). These and other studies suggest that a 
detailed comparison of the immunological differences between HPV+ and HPV– HNSC 
provides an opportunity to identify immunological determinants that contribute to 
successful treatment in HNSC that may be broadly applicable to cancer treatment in general 
(Feng et al., 2017; Lyford-Pike et al., 2013; Montler et al., 2016).  
In this study, we used RNA-sequencing data from over 500 HNSC samples from The 
Cancer Genome Atlas (TCGA) to compare the immune landscape between HPV+, HPV–, 
and normal-adjacent control tissue. Importantly, these samples were treatment-naïve prior 
to surgical resection, avoiding any confounding effects of exposure to chemotherapy or 
radiation on the immune-status of these tumors. Such analysis can provide scientific 
rationale for treating HNSC patients with immune checkpoint inhibitors (ICIs) as first-line 
therapy.  
We determined that HPV+ HNSC tumors exhibit a strong Th1 response, characterized by 
increased infiltration with dendritic cells (DCs), CD4+ and CD8+ T-cells. HPV+ HNSC 
also expressed higher levels of CD39 and multiple T-cell exhaustion markers including 
LAG3, PD1, TIGIT, and TIM3 compared to HPV– HNSC. This gene expression profile is 
consistent with a “T-cell-inflamed” phenotype, one that is dominated by T-cell markers 
and chemokines associated with effector T-cell recruitment (Gajewski et al., 2013). 
Importantly, higher expression of these T-cell exhaustion genes correlated with markedly 
improved patient survival in HPV+, but not HPV–, HNSC. These results illustrate the 
profound differences between the immune landscape of HPV+ and HPV– HNSC tumors 
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and its association with patient outcome. Furthermore, the presence of high expression 
levels of multiple immune inhibitory genes in HPV+ HNSC suggests that these cancers 
will exhibit strong beneficial responses to immunotherapy, providing a strong rationale for 
using ICIs as single treatment or combination therapies in first-line treatment of HPV+ 
HNSC. This would save patients from disfiguring surgery, or the toxicities associated with 
conventional chemotherapy or radiation treatment. 
4.2 Materials and Methods 
4.2.1 Data collection 
Patient data from The Cancer Genome Atlas (TCGA), including Merged Clinical data 
(build 2016012800) and Level 3 RSEM-normalized Illumina HiSeq RNA expression data 
(build 2016012800) for the HNSC cohort, was downloaded from the Broad Genome Data 
Analysis Centers Firehose server (https://gdac.broadinstitute.org/). Written informed 
consents were obtained from the patients (or their families) by the TCGA project. 
CIBERSORT immune fraction data (TCGA.Kallisto.fullIDs.cibersort.relative.tsv) and 
Leukocyte Fraction (TCGA_all_leuk_estimate.masked.20170107.tsv) data from the Pan-
Cancer Atlas was downloaded from the National Cancer Institute Cancer Genome 
Commons (https://gdc.cancer.gov/about-data/publications/panimmune). 
4.2.2 RNA expression comparisons 
RNA-Seq by Expectation Maximization (RSEM)-normalized expression data was 
extracted into Microsoft Excel and the HPV status was manually curated based on 
published datasets as described (Gameiro et al., 2017a). Primary patient samples with 
known HPV status were grouped as HPV+, HPV–, or normal control tissue. This 
classification agrees completely with work done by others (Chakravarthy et al., 2016), with 
the exception of sample TCGA-BB-7862‐01A. That sample had minimal reads aligning to 
the HPV genome, none of which aligned to the HPV16 E6 or E7 oncogenes, and we 
classified this sample as HPV– rather than HPV+. Patient samples with unknown HPV 
status were omitted from our calculations, as were samples obtained from secondary 
metastatic lesions. This resulted in 73 HPV+, 442 HPV–, and 43 normal control samples 
with data available for the HNSC gene expression analysis. This surgically managed cohort 
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was considered treatment-naïve, as only 9 patients received neoadjuvant radiation or 
chemotherapy treatment (2 HPV+, 7 HPV–). Boxplot comparison of gene expression was 
performed using GraphPad Prism v7.0 (Graphpad Software, Inc., San Diego, California, 
USA) and assembled into final form using Adobe Illustrator. For the boxplots, center lines 
show the medians, box limits indicate the 25th and 75th percentiles as determined by 
Graphpad Prism, and whiskers extend 1.5 times the interquartile range from the 25th and 
75th percentiles. Statistical significance was calculated using Graphpad Prism. p-values 
were assigned using a one-tailed non-parametric Mann-Whitney U test. Selected genes 
were compared in a pairwise fashion and concordance calculated using Spearman’s Rho 
analysis. Differences were considered to be statistically significant for p < 0.05. 
4.2.3 Immune fraction estimates 
The relative fractions of 22 leukocyte types as calculated using CIBERSORT (Newman et 
al., 2015) was previously reported for all TCGA samples as part of the Pan-Cancer Atlas 
(Thorsson et al., 2018). Only those HNSC samples with a CIBERSORT p < 0.01 were 
included in our analysis, which resulted in 28 HPV+, 209 HPV–, and 17 normal control 
samples used in this analysis. The total leukocyte fraction was also previously reported for 
all TCGA samples as part of the Pan-Cancer Atlas. The HNSC values were extracted from 
this data and annotated for HPV status as described above. 
4.2.4 Survival analysis 
Five-year overall survival outcomes and disease-free progression were compared in both 
HPV+ and HPV– subsets of patients as dichotomized by median expression of LAG3, PD1, 
TIGIT, TIM3, or CD39. A second set of survival outcomes were done to compare tumors 
expressing high levels of each combination of two of these markers. Log-rank statistical p-
values were calculated for each Cox survival model. Univariate survival analysis was done 
through R statistical environment (version 3.4.0) based on a Cox Proportional Hazard 
Model using survival package (version 2.41-3). Stepwise bidirectional multivariate 
analysis was then carried out with clinical variables (sex, age, smoking history, subsite, T 
stage, N stage, Overall stage, and HPV type), LAG3, PD1, TIGIT, TIM3, and CD39 
expression. The p-values derived from the Wald test on survival coefficients were reported 
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for investigated variables. The derived log-rank p-values for all tested genes (Table 4.1) 
were assessed for significance after correcting for false discovery rate (FDR) using the 
Benjamini–Hochberg method, and an FDR threshold of 0.1 was set for significance. 
4.3 Results 
4.3.1 HPV+ and HPV– head & neck carcinomas exhibit differences 
in some leukocyte populations 
To identify and understand differences in the immune landscape between HPV+ and HPV– 
HNSC, we conducted a preliminary analysis using the CIBERSORT deconvolution 
algorithm in order to elucidate the immune cell populations present in each sample 
(Newman et al., 2015). This computational method is based on the differential expression 
of 547 genes to estimate the relative fraction of 22 leukocyte populations in each of the 
samples for the TCGA HNSC cohort (Figure 4.1). Our comparison of the HPV+ and HPV– 
samples revealed a number of differences, including an increased percentage of CD8+ T-
cells and CD4+ T-regulatory cells (Tregs) in HPV+ samples compared to HPV– samples. 
HPV+ samples were also estimated to contain a greatly decreased level of uncommitted 
(M0) and anti-inflammatory (M2) macrophages as compared to HPV– samples. Increased 
levels of follicular helper CD4+ T-cells, but not other types of CD4+ T-cells, were present 
in HPV+ versus HPV– HNSC samples, as well increased levels of naïve and memory B-
cells, but not plasma cells. These data indicate a difference between the immune landscape 
of HPV+ and HPV– HNSC tumors that requires further investigation. 
Given the observed differences in the various leukocyte populations, we also compared the 
total leukocyte fraction between the HPV+ and HPV– samples in the TCGA HNSC cohort 
using a previously defined DNA methylation signature that is highly specific for leukocytes 
(Hoadley et al., 2018). However, no significant differences were detected between the 
overall leukocyte fraction of HPV+ versus HPV– HNSC (Figure 4.2). 
4.3.2 HPV+ head & neck carcinomas exhibited a Th1 CD4+ helper 
T-cell phenotype 
CIBERSORT identified a number of differences between HPV+ and HPV– HNSC samples 
for multiple classes of T-cells, however, cancer-induced dysregulations and immune 
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Table 4.1. Analysis of significance between gene expression and survival (overall and 
disease-free) after correcting for false discovery rate (FDR). 
Gene 
All HNSC HPV+ HNSC HPV– HNSC 
Overall 
Survival 
Disease-free 
Survival 
Overall 
Survival 
Disease-free 
Survival 
Overall 
Survival 
Disease-free 
Survival 
p 
value FDR 
p 
value FDR 
p 
value FDR 
p 
value FDR 
p 
value FDR 
p 
value FDR 
CD8A 0.031 0.091 0.620 0.730 0.023 0.087 0.821 0.937 0.481 0.795 0.955 0.955 
CD8B 0.118 0.208 0.426 0.566 0.009 0.058 0.614 0.912 0.538 0.795 0.653 0.912 
FOXP3 0.014 0.052 0.007 0.093 0.039 0.115 0.380 0.912 0.154 0.454 0.016 0.209 
TBX21 0.277 0.367 0.927 0.927 0.004 0.047 0.814 0.937 0.280 0.634 0.777 0.935 
CD6 0.002 0.014 0.204 0.403 0.027 0.090 0.647 0.912 0.011 0.200 0.696 0.912 
CD3D 0.015 0.052 0.488 0.623 0.069 0.164 0.711 0.912 0.136 0.449 0.917 0.955 
CD3E 0.001 0.014 0.091 0.269 0.005 0.047 0.576 0.912 0.042 0.343 0.429 0.846 
CD3G 0.002 0.014 0.264 0.463 0.076 0.165 0.582 0.912 0.091 0.449 0.881 0.954 
SH2D1A 0.010 0.043 0.202 0.403 0.035 0.107 0.603 0.912 0.145 0.449 0.726 0.912 
TRAT1 0.028 0.087 0.055 0.210 0.003 0.047 0.383 0.912 0.517 0.795 0.724 0.912 
XCL1 0.755 0.805 0.659 0.752 0.271 0.385 0.423 0.912 0.536 0.795 0.499 0.854 
XCL2 2.4e-04 0.005 0.278 0.463 0.073 0.164 0.432 0.912 0.021 0.267 0.484 0.854 
NCR1 0.008 0.037 0.144 0.325 0.095 0.175 0.694 0.912 0.111 0.449 0.186 0.626 
KIR2DL3 0.091 0.169 0.078 0.263 0.498 0.589 0.044 0.912 0.336 0.693 0.158 0.626 
KIR3DL1 0.005 0.026 0.009 0.093 0.258 0.381 0.923 0.968 0.049 0.357 0.261 0.678 
KIR3DL2 0.025 0.082 0.042 0.171 0.020 0.083 0.385 0.912 0.979 0.982 0.671 0.912 
IL21R 0.032 0.091 0.013 0.093 0.049 0.127 0.365 0.912 0.283 0.634 0.239 0.675 
FPR1 0.726 0.786 0.067 0.241 0.690 0.729 0.068 0.912 0.804 0.886 0.291 0.701 
NCAM1 0.005 0.026 0.178 0.385 0.701 0.729 0.364 0.912 0.034 0.316 0.179 0.626 
MS4A2 0.002 0.014 0.017 0.113 0.405 0.510 0.734 0.912 0.004 0.200 0.009 0.203 
CD84 0.357 0.446 0.095 0.269 0.004 0.047 0.569 0.912 0.888 0.962 0.036 0.293 
LAG3 0.245 0.346 0.227 0.433 0.047 0.127 0.343 0.912 0.706 0.846 0.927 0.955 
CD19 2.1e-05 0.001 0.042 0.171 0.134 0.229 0.630 0.912 0.012 0.200 0.405 0.823 
CD103 0.693 0.763 0.008 0.093 0.257 0.381 0.219 0.912 0.622 0.843 0.009 0.203 
ITGB7 0.015 0.052 0.314 0.495 0.028 0.090 0.277 0.912 0.025 0.271 0.156 0.626 
KLRB1 1.2e-04 0.004 0.028 0.139 0.006 0.048 0.847 0.947 0.012 0.200 0.322 0.720 
CD4 0.057 0.126 0.007 0.093 0.073 0.164 0.598 0.912 0.500 0.795 0.033 0.293 
TIM3 0.875 0.903 0.081 0.263 0.019 0.083 0.151 0.912 0.582 0.822 0.498 0.854 
PDCD1 0.076 0.160 0.818 0.872 0.013 0.075 0.265 0.912 0.399 0.740 0.816 0.936 
GATA3 0.496 0.608 0.367 0.508 0.305 0.421 0.744 0.912 0.691 0.846 0.330 0.720 
STAT6 0.561 0.663 0.114 0.296 0.397 0.510 0.525 0.912 0.763 0.885 0.186 0.626 
XCR1 0.085 0.167 0.001 0.048 0.512 0.594 0.530 0.912 0.132 0.449 0.003 0.163 
CD141 0.258 0.357 0.577 0.708 0.415 0.510 0.472 0.912 0.798 0.886 0.291 0.701 
IRF8 0.316 0.402 0.140 0.325 0.097 0.175 0.621 0.912 0.716 0.846 0.254 0.678 
CD137 0.088 0.168 0.012 0.093 0.416 0.510 0.422 0.912 0.778 0.886 0.090 0.534 
FCGR3A 0.952 0.964 0.272 0.463 0.134 0.229 0.100 0.912 0.635 0.843 0.484 0.854 
IL6R 0.238 0.346 0.243 0.450 0.082 0.172 0.953 0.968 0.454 0.795 0.353 0.741 
IL10RB 0.244 0.346 0.351 0.495 0.706 0.729 0.729 0.912 0.161 0.455 0.196 0.626 
IL12A 0.192 0.297 0.489 0.623 0.898 0.898 0.996 0.996 0.510 0.795 0.744 0.912 
IL12B 0.042 0.104 0.703 0.788 0.272 0.385 0.289 0.912 0.532 0.795 0.870 0.954 
CD11A 0.034 0.092 0.205 0.403 0.016 0.081 0.701 0.912 0.662 0.846 0.689 0.912 
CD11B 0.646 0.737 0.093 0.269 0.089 0.175 0.081 0.912 0.958 0.982 0.090 0.534 
CD11C 0.124 0.212 0.398 0.539 0.345 0.458 0.335 0.912 0.177 0.472 0.736 0.912 
IDO1 0.040 0.104 0.122 0.304 0.664 0.729 0.233 0.912 0.524 0.795 0.946 0.955 
BIN1 0.820 0.860 0.629 0.730 0.340 0.458 0.441 0.912 0.697 0.846 0.707 0.912 
IFNG 0.047 0.112 0.787 0.855 0.095 0.175 0.930 0.968 0.141 0.449 0.801 0.936 
TNF 0.079 0.160 0.789 0.855 0.015 0.079 0.807 0.937 0.182 0.472 0.675 0.912 
RORC 0.102 0.185 0.102 0.275 0.554 0.632 0.111 0.912 0.070 0.449 0.036 0.293 
RORA 0.148 0.247 0.009 0.093 0.694 0.729 0.107 0.912 0.338 0.693 0.015 0.209 
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Table 4.1. (continued). Analysis of significance between gene expression and survival 
(overall and disease-free) after correcting for false discovery rate (FDR). 
Gene 
All HNSC HPV+ HNSC HPV– HNSC 
Overall 
Survival 
Disease-free 
Survival 
Overall 
Survival 
Disease-free 
Survival 
Overall 
Survival 
Disease-free 
Survival 
p 
value FDR 
p 
value FDR 
p 
value FDR 
p 
value FDR 
p 
value FDR 
p 
value FDR 
CXCR3 0.002 0.014 0.011 0.093 0.005 0.047 0.664 0.912 0.215 0.537 0.143 0.626 
STAT4 0.658 0.738 0.342 0.495 0.685 0.729 0.254 0.912 0.692 0.846 0.202 0.626 
CCR5 0.058 0.126 0.145 0.325 0.002 0.047 0.720 0.912 0.579 0.822 0.709 0.912 
CCL3 0.532 0.641 0.312 0.495 0.189 0.313 0.395 0.912 0.610 0.843 0.126 0.626 
CCL4 0.964 0.964 0.845 0.885 0.043 0.122 0.097 0.912 0.930 0.975 0.556 0.912 
CXCL1 0.182 0.288 0.332 0.495 0.096 0.175 0.546 0.912 0.397 0.740 0.332 0.720 
CXCR6 0.001 0.014 0.267 0.463 0.007 0.048 0.950 0.968 0.093 0.449 0.955 0.955 
CXCL2 0.200 0.303 0.022 0.127 0.020 0.083 0.537 0.912 0.923 0.975 0.112 0.606 
TIGIT 0.005 0.026 0.351 0.495 0.027 0.090 0.581 0.912 0.127 0.449 0.726 0.912 
CD39 0.011 0.043 0.038 0.171 0.001 0.047 0.649 0.912 0.100 0.449 0.078 0.534 
GZMA 0.157 0.255 0.913 0.927 0.218 0.346 0.860 0.947 0.366 0.720 0.821 0.936 
GZMB 0.306 0.398 0.624 0.730 0.237 0.366 0.245 0.912 0.135 0.449 0.737 0.912 
PRF1 0.052 0.120 0.538 0.672 0.192 0.313 0.909 0.968 0.260 0.625 0.626 0.912 
PDL1 0.591 0.686 0.862 0.890 0.430 0.518 0.355 0.912 0.341 0.693 0.457 0.854 
IL23A 0.005 0.026 0.027 0.139 0.051 0.127 0.390 0.912 0.097 0.449 0.230 0.675 
EBI3 0.266 0.360 0.330 0.495 0.813 0.826 0.800 0.937 0.982 0.982 0.845 0.947 
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Figure 4.1. The relative fraction of immune cell populations in head & neck 
carcinomas stratified by HPV status. 
The relative population of 22 leukocyte types present in the tumor microenvironment was 
determined by the CIBERSORT algorithm and compared between HPV+, HPV–, and 
normal control samples. Four leukocyte types (neutrophils, eosinophils, naïve CD4+ T-
cells, and gamma delta T-cells) are not shown, as they were undetectable in this cohort.  
* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant. 
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Figure 4.2. No differences in total leukocyte fraction were detected between HPV+ 
and HPV– HNSC samples. 
Total leukocyte fraction as estimated by a DNA methylation signature was extracted for 
all HNSC samples in the TCGA dataset and annotated for HPV status. Numbers in brackets 
refer to the number of samples included in each analysis. ns – not significant.
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cell phenotypic plasticity can limit the ability of CIBERSORT to accurately characterize 
immune components of the tumor microenvironment (Newman et al., 2015). Therefore, 
we began a detailed and mechanistically oriented comparison of the immune responses in 
HPV+ versus HPV– HNSC. CD4+ helper T-cells are instrumental in establishing the type 
of response triggered by immune activation, whether it be a cell-mediated Th1 response, a 
humorally-biased Th2 response, or the proinflammatory Th17 response necessary to 
maintain the immunological integrity of mucosal barriers (Mucida and Salek-Ardakani, 
2009). Each of the CD4+ subsets are characterized by a distinct transcriptional program 
regulated by specific master regulatory transcription factors (Fang and Zhu, 2017). To 
examine the tumor immune landscape of HPV+ and HPV– HNSC, we analyzed the TCGA 
Illumina HiSeq RNA expression data from the HNSC cohort for expression of TBX21 
(Th1), GATA3 and STAT6 (Th2), and RORA and RORC (Th17) (Figure 4.3). As expected, 
a strong Th17 signature was observed in normal control samples, and that signature 
expression profile was markedly reduced in HPV+ and HPV– carcinomas (Figure 4.3A). 
HPV+ samples had significantly increased levels of TBX21 as compared to HPV– and 
normal control samples, indicative of a polarization toward a Th1 response (Figure 4.3B). 
A modest increase in GATA3 accompanied by a reduction in STAT6 was observed in HPV+ 
samples versus normal control samples (Figure 4.3C). Taken together, these results 
indicate that a strong shift in the normal Th17 bias towards Th1 occurred in HNSC, with a 
significantly accentuated Th1 signature in HPV+ versus HPV– carcinomas. 
4.3.3 Higher levels of CD4+ and CD8+ T-cells were present in HPV+ 
head & neck carcinomas 
We next assessed the relative proportion of CD4+ and CD8+ T-cells in these samples, based 
on relative expression of the lineage defining CD4 and CD8A/CD8B marker genes, 
respectively (Figures 4.4A and B). HPV+ samples showed significantly increased 
expression of all three genes versus HPV– HNSC or normal control samples, confirming 
that enhanced T-cell infiltration is a common feature of HPV+ HNSC. We also observed 
significantly higher FOXP3 expression in HPV+ HNSC compared to HPV– HNSC and 
normal control samples. FOXP3 is associated with Tregs infiltrating into these tumor 
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Figure 4.3. Expression of marker genes indicating CD4+ helper T-cell subsets present 
in head & neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for RORA and RORC (Th17) (A), TBX21 (Th1) (B), and GATA3 
and STAT6 (Th2) (C) was extracted from The Cancer Genome Atlas (TCGA) database for 
the head & neck cancer (HNSC) cohort for HPV+, HPV−, and normal control tissues. 
Numbers in brackets refer to the number of samples included in each analysis. * p ≤ 0.05, 
** p ≤ 0.01, **** p ≤ 0.0001, ns – not significant. 
 
 
106 
(Figure 4.4C). Furthermore, analysis of the expression of CD137 (4-1BB), an activation-
induced costimulatory molecule present primarily on CD8+ T-cells, detected significantly 
higher levels in HPV+ versus HPV– or normal control samples, suggesting a higher overall 
level of T-cell activation and effector function in HPV+ disease (Figure 4.4D).  
Activated cytotoxic CD8+ T-cells produce various effector molecules, including IFNγ and 
TNF. Although expression of IFNγ mRNA (IFNG) in these samples was low, it was 
detectable at significantly higher levels in HPV+ samples versus HPV– HNSC or normal 
control tissues. No significant difference was observed for TNF (Figure 4.4E). HPV+ 
HNSC tumors also expressed significantly higher levels of cytotoxic mediators, including 
granzyme A (GRZA), granzyme B (GRZB), and perforin (PRF1) compared to both HPV– 
HNSC or normal control tissues (Figure 4.5A). Taken together, these results indicate CD8+ 
T-cells are not only present at higher levels in HPV+ HNSC, but are concomitantly more 
active and producing effector molecules such as IFNγ, granzyme A, granzyme B, and 
perforin, but not TNF. We also observed low—but significantly higher than in HPV– 
HNSC or normal control tissues—expression levels of genes associated with natural killer 
(NK)-cells (SH2D1A, XCL2, NCR1, KIR2DL3, KIR3DL1, and KIR3DL2) and B-cells 
(IL21R and CD19) in HPV+ tumors indicating higher infiltration of these immune cells 
into HPV+ HNSC (Figures 4.5B and C, respectively). While many of these observations 
agree with the CIBERSORT estimations (Figure 4.1), there are some differences. In some 
cases, this may be related to the use of different marker genes, or to the fact that 
CIBERSORT divides some classes of leukocytes into multiple subcategories based on a 
gene signature that can be affected by disease dysregulation. 
4.3.4 Interferon γ-induced immunomodulatory genes are expressed 
at higher levels in HPV+ head & neck carcinomas 
An expected consequence of higher levels of infiltrating CD8+ T-cells producing IFNγ 
would be induction of expression of interferon response genes in tumor cells in close 
proximity to the infiltrating T-cells. Indeed, we previously reported that multiple interferon 
responsive components of the MHC-I antigen presentation apparatus were upregulated in 
HPV+ HNSC (Gameiro et al., 2017b). We extended those studies to PDL1 and IDO1, two 
immunomodulatory genes known to be expressed by tumor cells in response to IFNγ 
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Figure 4.4. Detection of tumor infiltrating T-cells and their activation status in head 
& neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes indicative of tumor infiltrating CD4+ (CD4) (A), 
CD8+ (CD8A and CD8B) (B), or regulatory (C) T-cells and their activation status (CD137, 
IFNG, and TNF) (D, E) was extracted from the TCGA database for the HNSC cohort for 
HPV+, HPV–, and normal control tissues. Numbers in brackets refer to the number of 
samples included in each analysis. **** p ≤ 0.0001, ns – not significant. 
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Figure 4.5. Detection of immune effector molecules and tumor-infiltrating NK-cells 
and B-cells in head & neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes indicative of tumor infiltrating: Effector molecules 
(GZMA, GZMB, and PRF1) (A), NK-cells (SH2D1A, XCL2, NCR1, KIR2DL3, KIR3DL1, 
and KIR3DL2) (B), and B-cells (IL21R and CD19) (C) was extracted from the TCGA 
database for the HNSC cohort for HPV+, HPV–, and normal control tissues. Numbers in 
brackets refer to the number of samples included in each analysis. **** p ≤ 0.0001.
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(Figure 4.6). Both PDL1 and IDO1 were significantly upregulated in HPV+ HNSC 
compared to normal control samples. While IDO1 was also significantly upregulated 
compared to HPV– HNSC, no significant difference was observed between PDL1 
expression in HPV+ versus HPV– carcinomas. Interestingly, BIN1 expression was 
significantly downregulated in HPV+ compared to both HPV– HNSC and normal control 
samples (Figure 4.6). As BIN1 is a negative regulator of IDO expression and deletion of 
BIN1 increases IFNγ stimulation of IDO1 gene expression, these results are consistent with 
the higher levels of IDO1 observed in both HPV+ and HPV– HNSC (Muller et al., 2005). 
Taken together, these data (Figures 4.4–4.6) indicate that HPV+ HNSC, in treatment-naïve 
patients, shows a T-cell-inflamed phenotype (Gajewski et al., 2013). 
4.3.5 Dendritic cell signatures are elevated in HPV+ head & neck 
carcinomas 
Because HPV+ HNSC displayed a T-cell-inflamed phenotype and DCs play a key role as 
professional antigen-presenting cells to stimulate T-cell function, we performed an analysis 
of DC signatures in these tumors. Using the expression of mRNA encoding CD103 and 
CD11C to detect DCs in tumor samples, we found that both genes are expressed at higher 
levels in HPV+ HNSC compared to normal control samples (Figure 4.7A). While CD103 
was expressed at significantly higher levels in HPV+ versus HPV– carcinomas, CD11C 
was not. We also determined that there was a modest but significant correlation between 
CD103 and CD11C in individual tumors (Figure 4.7A; r = 0.56, p = 2.6e-07). This 
suggested that these markers tended to be coordinately expressed, although the link was 
not strong enough to lead to increased CD11C expression in HPV+ carcinomas in accord 
with increased CD103.  
A key anti-tumor role for DCs is to express effector cytokines such as IL12 and IL23 that 
mediate CD8+ T-cell activation and IFNγ production. While IL12A mRNA levels in HPV+ 
samples were not significantly induced versus normal control tissue, they were elevated 
compared to HPV– HNSC (Figure 4.7B). IL12 activates STAT4 signaling, which is 
critical for anti-tumor immunity (Lund et al., 2004). Notably, STAT4 expression levels 
were higher in HPV+ HNSC tumors (Figure 4.7B). Activated DCs also produce IL23— 
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Figure 4.6. Transcript levels of tumor-derived IFNg-responsive immunomodulatory 
genes in head & neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes associated with tumor cell mediated immune-
modulation including IDO1, its negative regulator BIN1, and PDL1 was extracted from the 
TCGA database for the HNSC cohort for HPV+, HPV–, and normal control tissues. 
Numbers in brackets refer to the number of samples included in each analysis. ** p ≤ 0.01, 
**** p ≤ 0.0001, ns – not significant. 
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Figure 4.7. Detection of dendritic cells and their effector cytokines in head & neck 
carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes indicative of tumor infiltrating dendritic cells (CD103 
and CD11C) (A) and genes encoding cytokines indicative of dendritic cell activation status 
(IL12A, STAT4, IL23A, and EBI3) (B) was extracted from the TCGA database for the 
HNSC cohort for HPV+, HPV–, and normal control tissues. Numbers in brackets refer to 
the number of samples included in each analysis. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001, ns – not significant. 
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a proinflammatory cytokine—that induces IFNγ secretion from activated CD4+ T-cells 
(Shi et al., 2015). IL23A levels were higher in HPV+ HNSC than HPV– tumors and normal 
control samples (Figure 4.7B). Moreover, Epstein-Barr virus-induced gene 3 (EBI3) 
transcripts that encode a component of IL27—a cytokine that synergizes with IL12 and 
induces IFNγ production by naïve CD4+ T-cells (Pflanz et al., 2002)—were significantly 
higher in HPV+ than HPV– tumors and normal control samples (Figure 4.7B). We were 
not able to analyze the other two genes within the IL12 family of cytokines—IL12B and 
IL27A—because their RNA transcripts were not detectable in the majority of tumor and 
normal control samples. Finally, we looked at a number of inflammatory chemokines and 
chemokine receptors that are crucial for DC and T-cell recruitment to tumors (Castellino 
et al., 2006; Chen et al., 2018a; Mikucki et al., 2016; Mitchell et al., 2015). CCR5, CCL4, 
and CXCR3 were highly expressed in HPV+ HNSC compared to HPV– tumors and normal 
control samples, while CCL3 expression was elevated in HPV+ HNSC compared to normal 
control samples (Figure 4.8). Overall, these results indicate a higher level of DC 
involvement in HPV+ than in HPV– HNSC, with higher levels of effector cytokines that 
could be responsible for the elevated levels of T-cell infiltration of these samples. 
4.3.6 HPV+ head & neck carcinomas expressed high levels of 
multiple T-cell exhaustion markers 
Once activated, T-cells upregulate expression of multiple cell surface receptors that 
negatively regulate their proliferation and moderate their level of activation. These so-
called “exhaustion markers” include LAG3, PD1, TIGIT, and TIM3 (Anderson et al., 
2016). They are important targets for immune checkpoint blockade therapies that are 
approved or under development. Notably, all four of these checkpoint genes were 
significantly upregulated in HPV+ compared with HPV– HNSC or normal control samples 
(Figure 4.9). We also determined that individual tumors expressing high levels of any one 
of these T-cell inhibitory genes generally co-expressed high levels of the other exhaustion 
markers (r values ranging from 0.78 to 0.9), suggesting that these genes are coordinately 
expressed (Figure 4.10). We also examined the expression of the immunosuppressive 
molecule CD39 (Jie et al., 2013) in this cohort of patients. CD39 was recently shown to be 
exclusively expressed on tumor antigen-specific CD8+ T-cells and not bystander CD8+  
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Figure 4.8. Detection of dendritic cell-associated chemokines and receptors in head & 
neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes indicative of dendritic cell-associated chemokines and 
receptors (CCR5, CCL3, CCL4, and CXCR3) was extracted from the TCGA database for 
the HNSC cohort for HPV+, HPV–, and normal control tissues. Numbers in brackets refer 
to the number of samples included in each analysis. *** p ≤ 0.001, **** p ≤ 0.0001, ns – 
not significant. 
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Figure 4.9. Transcript levels of T-cell exhaustion marker genes and CD39 in head & 
neck carcinomas stratified by HPV status. 
Normalized RNA-seq data for genes associated with T-cell exhaustion (LAG3, PD1, 
TIGIT, and TIM3) and CD39 was extracted from the TCGA database for the HNSC cohort 
for HPV+, HPV–, and normal control tissues. Numbers in brackets refer to the number of 
samples included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001.
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Figure 4.10. HPV+ head & neck carcinomas concordantly express multiple markers 
of T-cell exhaustion. 
Normalized RNA-seq data for LAG3, PD1, TIGIT, and TIM3 was compared in a pairwise 
fashion in HPV+ HNSC samples and concordance calculated by Spearman’s Rho analysis. 
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T-cells in colorectal and lung tumors (Simoni et al., 2018). Notably, CD39 showed 
significantly higher RNA expression levels in HPV+ HNSC tumors compared to HPV– 
HNSC samples (Figure 4.9). Interestingly, individual tumors expressing high levels of 
CD39 also co-expressed high levels of the four exhaustion markers (r values ranging from 
0.37 to 0.62), suggesting that these genes are coordinately expressed (Figure 4.11). Taken 
together, HPV+ HNSC display a markedly different immune signature from HPV– HNSC, 
indicative of sustained CD8+ T-cell activation in HPV+ HNSC. 
4.3.7 High levels of T-cell exhaustion markers correlated with 
improved survival of HPV+ head & neck carcinomas 
High CD8+ T-cell infiltration into HNSC tumors has been previously linked to better 
patient outcome (de Ruiter et al., 2017). Moreover, expression of checkpoint molecules 
such as PD1 on circulating CD8+ T-cells is a biomarker of tumor antigen specificity (Gros 
et al., 2016). We therefore dichotomized the HPV+ HNSC data set based on median LAG3, 
PD1, TIGIT, or TIM3 expression and calculated the impact of high versus low expression 
on overall patient survival (Figure 4.12, black and red curves). Higher than median 
expression of any of these genes predicted markedly improved survival in HPV+ HNSC 
over those patients with tumors expressing these markers at levels below the median. This 
sharp overall increase in clinical outcome was also statistically significant following 
correction for multiple testing in all the assessed genes, with the exception of LAG3 (Table 
4.1). In contrast, a similar analysis did not reveal any survival advantage for HPV– samples 
expressing higher levels of LAG3, PD1, TIGIT, or TIM3 (Figure 4.12, green and purple 
curves).  
Given our observation that HPV+ tumors expressing high levels of LAG3, PD1, TIGIT, or 
TIM3 transcripts generally displayed higher levels of at least one more of these exhaustion 
markers (Figure 4.10), we repeated the survival analysis by comparing HPV+ HNSC 
samples that were above the median expression for each combination of two markers to 
those below the median for both markers (Figure 4.13, black and red curves). 
Remarkably, overall survival for patients with high expression of any combination of two 
of the T-cell exhaustion markers identified individuals with a virtual certainty of long-term  
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Figure 4.11. HPV+ head & neck carcinomas express CD39 concordantly with multiple 
markers of T-cell exhaustion. 
Normalized RNA-seq data for CD39 was compared in a pairwise fashion to LAG3, PD1, 
TIGIT, and TIM3 in HPV+ HNSC samples. Concordance was calculated by Spearman’s 
Rho analysis.  
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Figure 4.12. High LAG3, PD1, TIGIT, or TIM3 gene transcript levels are strongly 
associated with improved survival in treatment naïve patients with HPV+ but not 
HPV– head & neck carcinomas. 
Overall survival of patients within the HPV+ cohort dichotomized by median expression 
of LAG3, PD1, TIGIT, or TIM3. Comparison between groups was made by the 2-sided log-
rank test. Red = low expression of the indicated gene in HPV+ samples, Black = high 
expression of the indicated gene in HPV+ samples, Purple = low expression of the indicated 
gene in HPV– samples, Green = high expression of the indicated gene in HPV– samples.
 
 
119 
Figure 4.13. Concordant levels of multiple markers of T-cell exhaustion is strongly 
associated with survival in patients with HPV+ head & neck carcinomas.  
Overall survival of patients within the HPV+ cohort dichotomized by median transcript 
levels of the indicated pairs of T-cell exhaustion markers. Comparison between groups was 
made by the 2-sided log-rank test. Red = low expression of the indicated gene in HPV+ 
samples, Black = high expression of the indicated gene in HPV + samples, Purple = low 
expression of the indicated gene in HPV– samples, Green = high expression of the 
indicated gene in HPV– samples. 
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survival. No improvement was seen when a similar analysis was performed using the 
HPV– HNSC cohort (Figure 4.13, green and purple curves). These results suggest that 
the co-expression of high levels of LAG3, PD1, TIGIT, and TIM3 in HPV+ HNSC reflect 
the successful development of T-cell-based anti-tumor immunity and a T-cell-inflamed 
phenotype, which contributed to long-term remission. This immune signature could be 
used as a predictive biomarker of HPV+ HNSC patient outcome after surgery. 
4.3.8 High levels of CD39 correlated with improved survival of 
HPV+ head & neck carcinomas 
We also dichotomized the HPV+ and HPV– HNSC data set based on median CD39 
expression and calculated the impact of high versus low expression on overall patient 
survival (Figure 4.14). Higher than median expression of CD39 predicted markedly 
improved survival in HPV+ HNSC over those patients with tumors expressing this marker 
at levels below the median. This sharp overall increase in clinical outcome was also 
statistically significant. Similar to our previous analysis (Figure 4.13), a combination of 
CD39 and any of the T-cell exhaustion markers identified long-term survivors in HPV+ 
HNSC (Figure 4.14). 
We next applied the Cox Proportional Hazards model to identify clinical variables and 
immunological markers predictive of overall survival (Table 4.2). By univariate analysis 
high expression of TIGIT, TIM3, PD1, and CD39 were correlated with favorable prognosis 
(HzR = 0.29, 0.24, 0.22, and 0.15 respectively, p < 0.05), while an HPV type other than 
HPV16 was associated with a markedly poorer survival (HzR = 3.22, p = 0.03). Oral cavity 
tumors had significantly worse survival compared those in the oropharyngeal subsite (HzR 
= 3.05, p = 0.03). There was a trend towards improved outcome with high expression of 
LAG3 (HzR = 0.32, p = 0.06). Stepwise regression analysis was used to identify the best 
multivariate model of survival, and the final model included N stage, HPV type, and CD39. 
Notably, CD39 (HzR = 0.07, p = 0.0007), and HPV type (HzR = 9.23, p = 0.001) remained 
as significant predictors of survival in the multivariate model. 
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Figure 4.14. High CD39 gene transcript level is strongly associated with improved 
survival in treatment naïve patients with HPV+ head & neck carcinomas. 
Overall survival of patients within the HPV+ and HPV– cohorts were dichotomized by 
median expression of CD39 (A). Concordant levels of CD39 and multiple markers of T-
cell exhaustion was strongly associated with survival in patients with HPV+ head & neck 
carcinomas (B). Overall survival of patients within the HPV+ cohort dichotomized by 
median transcript levels of the indicated pairs of T-cell exhaustion markers with CD39. 
Comparison between groups was made by the 2-sided log-rank test. Red = low expression 
of the indicated gene in HPV+ samples, Black = high expression of the indicated gene in 
HPV+ samples, Purple = low expression of the indicated gene in HPV– samples, Green = 
high expression of the indicated gene in HPV– samples. 
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Table 4.2. Univariate and multivariate analysis of the association of clinical 
characteristics and LAG3, PD1, TIGIT, TIM3, and CD39 expression and overall 
survival in HPV+ HNSC. 
Variables 
Univariate Analysis Multivariate Analysis 
HzR (95% CI) p value HzR (95% CI) 
p 
value 
Sex Male vs Female 0.95 (0.21 – 4.29) 0.95   
Age per every additional year 0.99 (0.94 – 1.05) 0.77   
Smoking Light vs Non-Smoker 0.84 (0.16 – 4.39) 0.84   Heavy vs Non-Smoker 1.99 (0.54 – 7.38) 0.30   
Subsite 
Oral cavity vs Oropharynx 3.05 (1.09 – 8.49) 0.03   
Larynx vs Oropharynx 1.46e-08 (0 – Inf) Inf   
Hypopharynx vs Oropharynx 1.57e-08 (0 – Inf) Inf   
T Stage T3-4 vs T1-2 1.06 (0.37 – 2.99) 0.92   
N Stage N2b-N3 vs N0-N2a 0.35 (0.12 – 1.05) 0.06 0.24 (0.08 – 0.81) 0.02 
Overall Stage IV vs I-III 0.80 (0.27 – 2.36) 0.69   
HPV Type Other vs 16 3.22 (1.10 – 9.45) 0.03 9.23 (2.45 – 34.7) 0.001 
LAG3 High vs Low Expression 0.32 (0.10 – 1.04) 0.06   
PD1 High vs Low Expression 0.22 (0.06 – 0.81) 0.02   
TIGIT High vs Low Expression 0.29 (0.09 – 0.93) 0.04   
TIM3 High vs Low Expression 0.24 (0.07 – 0.87) 0.03   
CD39 High vs Low Expression 0.15 (0.04 – 0.56) 0.004 0.07 (0.02 – 0.34) 0.0007 
 
 
125 
4.4 Discussion 
Although evading anticancer immunity is one of the hallmarks of cancer, 
immunotherapy—also referred to as immuno-oncology—harnesses the power of the 
immune system to destroy cancer cells. Durable responses to immunotherapy among 
cancer patients are what sets immunotherapy apart from conventional oncology therapies, 
including chemotherapy, radiotherapy, and targeted therapy. Cancer immunotherapy is 
now widely recognized as having the potential to revolutionize cancer treatment. Despite 
the recent “tsunami of immunotherapy in oncology” and many reports of immunotherapy 
treatment resulting in near-miraculous cures in cases of highly refractory cancers, in 
general only a subset of patients respond to these treatments. The underlying reasons for 
response, or lack thereof, remain an intense area of investigation (Routy et al., 2018).  
Based on their somatic mutation prevalence (Sadelain et al., 2017), tumors can be 
categorized as immunologically “cold” or immunologically “hot”. Immunologically hot 
tumors such as melanoma and smoking-induced lung cancer, often respond more favorably 
to immune checkpoint inhibition therapy than cold tumors. Therefore, a partial explanation 
for immune checkpoint inhibitor response appears to be related to high mutation burden, 
which leads to higher levels of tumor-derived neoantigens. Indeed, a significant correlation 
exists between immune checkpoint inhibitor response and mutational load across cancer 
sites (Yarchoan et al., 2017).  
A variety of studies have compared various immunological parameters between HPV+ and 
HPV– HNSC and generally concluded that HPV+ HNSC are immune “hot” tumors, with 
markedly more immune infiltration and higher levels of CD8+ T-cell activation than HPV– 
HNSC (Chen et al., 2018b; Keck et al., 2015; Mandal et al., 2016; Solomon et al., 2018). 
Although this is thought to contribute to the improved prognosis of HPV+ HNSC, the 
mutational loads in HPV+ and HPV– HNSC are similar therefore the immune hot and cold 
model cannot explain the survival differences observed among HNSC patients. However, 
HPV+, but not HPV–, HNSC express exogenous antigenic viral oncoproteins that may 
represent a key difference in the tumor immune landscape between these two types of 
HNSC, giving HPV+ HNSC a T-cell-inflamed phenotype that can at least partially explain 
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the better patient outcome in HPV+ HNSC compared to HPV– HNSC. Furthermore, HPV+ 
HNSC tumors are different from HPV– HNSC tumors at the epigenetic and genomic levels, 
but viral etiology alone may not be sufficient to confer favorable outcome in HNSC 
(Chakravarthy et al., 2016). Therefore, the substantial differences observed in anti-tumor 
immunity between HPV+ and HPV– cancers could be the major source of improved 
prognosis in HPV+ tumors.  
In this study, for the first time, we report the detailed immune characteristics of T-cell-
inflamed HPV+ HNSC compared to non-T-cell-inflamed HPV– HNSC. We performed a 
mechanistic analysis of the tumor immune landscape in treatment-naïve HNSC using the 
TCGA cohort, which allows a detailed and direct comparison between HPV+ and HPV– 
HNSC and normal-adjacent control tissue. However, examination of only the RNA 
expression levels limits the ability to accurately confirm expression levels on each cell 
type. To address this limitation, we primarily used immune lineage-specific markers or 
examined co-expression correlations for markers that are expressed by more than one cell 
type. We found that HPV+ HNSC has a predominant Th1 immune phenotype (Figure 4.3) 
with a significant increase in CD8+ and CD4+ T-cell infiltration compared to HPV– HNSC 
(Figure 4.4). Interestingly, higher T-cell infiltration into HPV+ tumors was accompanied 
with greater T-cell activation, as shown by high CD137 (4-1BB) gene transcript levels. 
Mononuclear cells isolated from patients with advanced head and neck cancer have been 
reported to be defective in IFNγ production in vitro (Conti-Freitas et al., 2012). Given the 
high CD137 RNA levels in HPV+ HNSC samples, we expected higher effector cytokine 
production by T-cells in these samples. Indeed, HPV+ HNSC expressed significantly 
higher levels of IFNγ, granzyme A, granzyme B, and perforin compared to HPV– HNSC 
or normal control samples, indicating that there remains some T-cell effector functionality 
in these tumors. Moreover, the higher levels of CD137 and multiple effector molecules in 
HPV+ HNSC could be a consequence of higher infiltration of these tumors with antigen-
specific tumor-infiltrating lymphocytes (TILs). In contrast, we did not observe differences 
in TNF transcript levels—a critical cytokine for anti-tumor immunity (Calzascia et al., 
2007)—between HPV+ and HPV– HNSC, indicating T-cell dysfunction in these samples. 
Given the role of IFNγ in inducing MHC-I expression in tumor cells, these findings explain 
 
 
127 
our previous observation that HPV+ HNSC tumors had significantly higher levels of 
expression of MHC-I apparatus (Gameiro et al., 2017b). Furthermore, high IFNγ transcript 
levels in HPV+ HNSC were associated with significantly higher levels of IFN-responsive 
gene transcripts, including IDO and PD-L1 (Figure 4.6). These observations provide a 
scientific rationale for combining immunotherapy of HPV+ HNSC with ICIs and IDO 
inhibitors in treatment-naïve patients. Currently the only phase II study of such a 
combination (NCT03325465) has been canceled in light of the recent failure of combined 
IDO inhibition and pembrolizumab in showing advantage in progression-free survival over 
pembrolizumab monotherapy in melanoma patients. However, that study (NCT03325465) 
was not focused specifically on HPV+ HNSC, which we show here express higher levels 
of IDO compared to HPV– HNSC.  
The observed increased numbers of CD8+ and CD4+ T-cells in HPV+ HNSC can likely be 
explained by the ability of DCs to migrate to these tumors, pick up antigens, and present 
those antigens to T-cells (Spranger et al., 2015). Indeed, we observed not only high levels 
of transcripts from DC-associated genes, but also molecules expressed by activated DCs, 
including chemokines that attract DCs and T-cells into tumors (Figure 4.7 and Figure 
4.8). We also observed less M2 macrophages in HPV+ HNSC samples (Figure 4.1) 
indicative of less immunosuppressive activity in these tumors compared to HPV– HNSC. 
These observations provide a mechanistic insight into the processes that shape the immune 
structure of HPV+ HNSC as a T-cell-inflamed tumor. 
T-cell-inflamed tumors show high levels of immune regulatory genes including IDO and 
PD-L1, and high infiltration of FoxP3+ Tregs (Gajewski et al., 2017), secondary to 
cytotoxic T-cell infiltration into those tumors. The presence of these immunosuppressive 
events in a T-cell-inflamed microenvironment is often accompanied by increased levels of 
multiple T-cell immune checkpoint molecules and T-cell anergy (Gajewski et al., 2017). 
Our findings show that HPV+ HNSC, but not HPV– HNSC, have similarly high levels of 
multiple immune checkpoint molecules (LAG3, TIM3, PD1, and TIGIT; Figure 4.9), 
suggesting that combined immunotherapy with drugs that target more than one of these 
inhibitory molecules can be effective in overcoming resistance to anti-tumor immunity in 
HPV+ HNSC tumors. There are no such trials currently under way, but these findings 
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strongly indicate that initiation of such clinical studies is justified. CD39 is an 
immunosuppressive molecule that can be expressed on intratumoral Tregs (Jie et al., 2013) 
and tumor-specific CD8+ TILs, but not bystander CD8+ T-cells (Simoni et al., 2018). CD39 
RNA expression was higher in both HPV+ and HPV– HNSC tumors compared to normal 
control samples (Figure 4.9). Of note, CD39 expression in HPV+ HNSC was significantly 
higher than HPV– tumors. CD39 alone or in combination with any of the T-cell exhaustion 
markers analyzed above was also a predictive biomarker of survival in HPV+ HNSC 
(Figure 4.14). Therefore, CD39 may represent a useful biomarker of survival in HPV+ 
HNSC. Our findings warrant the initiation of prospective trials in determining the 
predictive value of this gene as a potential genomic biomarker correlated with improved 
overall survival in HPV+ HNSC. 
High T-cell infiltration into HNSC, regardless of HPV status, has been reported as a 
positive prognostic factor (Nguyen et al., 2016). We observed that high levels of transcripts 
from one or any combination of two genes expressing immune checkpoint molecules (PD1, 
TIM3, TIGIT, LAG3) in HPV+, but not HPV–, HNSC can predict patient survival after 
surgery. These findings require confirmation by prospective clinical studies to—we 
anticipate—pave the way for the development of immune-predictive biomarkers for HPV+ 
HNSC patients that will ultimately lead to treatment deintensification in this patient 
population.  
Taken together, this study provides clear evidence, for the first time, that the immune 
landscape of HPV+ HNSC represents a T-cell-inflamed phenotype that is very different 
from HPV– HNSC. Of prime importance, we demonstrate that multiple mechanisms that 
negatively regulate the anti-tumor immune response are significantly upregulated in the 
majority of HPV+ HNSC cases, that is secondary to CD8+ T-cell infiltration and IFNγ 
production in HPV+ HNSC. Therefore, high levels of such gene transcripts—PD1, TIM3, 
LAG3, and TIGIT—correlate strongly with improved clinical outcome. Crucially, many of 
these negative regulators of the immune response are targets of clinically-approved 
immune checkpoint inhibitors or inhibitors under investigation in current clinical trials. 
Thus, HPV+ HNSC has many immunological features that suggest that it would be highly 
amenable to immune checkpoint inhibition therapy. Based on these data, we propose that 
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HPV+ HNSC is a T-cell-inflamed disease and should be treated differently in the clinic 
than HPV– HNSC, specifically with combinations of immune checkpoint inhibitors. 
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Chapter 5  
5 High Level Expression of MHC-II in HPV+ Head and 
Neck Cancers Suggests that Tumor Epithelial Cells 
Serve an Important Role as Accessory Antigen 
Presenting Cells 
 
5.1 Introduction 
High-risk human papillomaviruses (HPVs) are small, non-enveloped, double-stranded 
DNA viruses that are responsible for an estimated 5% of all human cancers (Doorbar et al., 
2015; Forman et al., 2012). These biological carcinogens are the causative agents of 
virtually all cervical cancers and a subset of head and neck squamous cell carcinomas 
(HNSC) (Doorbar et al., 2015). HNSC are a heterogenous group of malignancies caused 
by multiple distinct etiologies. Infection with high-risk HPVs is responsible for 
approximately 85,000 of the 600,000 global annual cases of HNSC, making it the second 
most common cause of HPV-induced cancers (Gillison et al., 2014; Gillison et al., 2000; 
Syrjanen, 2005). HPV-positive (HPV+) tumors are distinct from their HPV-negative 
(HPV−) counterparts from a molecular perspective, with distinct genetic, epigenetic, and 
protein expression profiles (Gameiro et al., 2018; Gameiro et al., 2017a; Gameiro et al., 
2017b; Seiwert et al., 2015; Sepiashvili et al., 2015; Worsham et al., 2013). Interestingly, 
patients with HPV+ HNSC tumors have markedly better clinical outcomes compared to 
those with HPV− tumors, leading to the recognition of HPV+ HNSC as unique clinical 
entities (Ang et al., 2010; Fakhry et al., 2008; Psyrri et al., 2014).  
We and others have noted significant differences in the immune landscape between the 
tumor microenvironments of HPV+ and HPV− HNSC (Baruah et al., 2019; Chen et al., 
2018; Gameiro et al., 2018; Gameiro et al., 2017b; Mandal et al., 2016; Nguyen et al., 
2016; Solomon et al., 2018). Specifically, HPV+ tumors express higher levels of class I 
major histocompatibility complex (MHC-I) compared to their HPV− counterparts, which 
could be a consequence of the higher intratumoral levels of interferon-gamma (IFNg) 
observed in the tumors of the HPV+ cohort (Gameiro et al., 2017b). Utilizing an 
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immunogenomic approach, we have also shown that HPV+ HNSC tumors exhibited a 
strong Th1 response characterized by increased infiltration with multiple types of T-cells—
CD4+, CD8+, and regulatory T-cells—and expression of their effector molecules (Gameiro 
et al., 2018). In addition, HPV+ HNSC also expressed higher levels of CD39 and multiple 
T-cell exhaustion markers including LAG3, PD1, TIGIT, and TIM3 compared to HPV− 
HNSC. Importantly, patients with higher expression of these exhaustion markers—
indicative of a T-cell-inflamed tumor—exhibited markedly improved survival in HPV+, 
but not HPV−, HNSC (Gameiro et al., 2018). 
In order for an effective T-cell-specific anti-tumor response to occur, a tumor associated 
antigen must be presented in either the context of MHC-I or class II MHC (MHC-II) (Rock 
et al., 2016). This process is dependent on the initial acquisition of specific antigenic 
peptides by surveilling antigen presenting cells (APCs). APCs present these exogenous 
peptides on their cell surface in the context of major histocompatibility complex-II (MHC-
II) to activate cognate CD4+ helper T-cells in an antigen-specific fashion (Roche and 
Furuta, 2015). This crosslinking of T-cell receptor (TCR) with its cognate antigen-MHC-
II complex is the initial step in the activation of T-cells. The next step is the crosslinking 
of co-stimulatory molecules between T-cell and APCs that will provide the appropriate 
signals to initiate T-cell proliferation and survival (Chen and Flies, 2013). Once activated, 
CD4+ T-cells then stimulate the proliferation of CD8+ cytotoxic T-cells (CTLs) that 
recognize and respond to the initial antigenic peptide. CTLs subsequently target tumor cells 
for lysis based on presentation of the cognate endogenously derived antigenic peptides on 
the tumor cell surface in the context of MHC-I (Luckheeram et al., 2012; Zhang and Bevan, 
2011). 
Although the ability of HPV to suppress MHC-I expression in cell culture systems is well 
known (Ferris, 2015; Heller et al., 2011), this is not likely the case in actual human tumors. 
Indeed, we previously reported that HPV+ head and neck cancers express higher levels of 
MHC-I than HPV− tumors (Gameiro et al., 2017b). Thus, HPV+ tumor cells may be more 
effective at displaying endogenously derived viral or neo-antigenic peptides, making them 
more easily targeted for CTL lysis. Expression of MHC-II molecules is typically restricted 
to professional APCs, such as dendritic cells (DCs), macrophages, and B-cells (van den 
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Elsen et al., 2004). However, epithelial cells can be stimulated by proinflammatory 
cytokines—specifically IFNg—to express MHC-II and function as accessory APCs to 
stimulate T-cell responses (Boss and Jensen, 2003; Collins et al., 1984; Kim et al., 2009). 
As mentioned above, MHC-II proteins play a key role in presenting exogenously-derived 
peptide antigens that ultimately lead to an effective CTL response, and it is likely that the 
induced tumor-specific MHC-II expression on epithelial cells may accentuate this process. 
Indeed, the role of tumor cell-derived MHC-II in anti-tumor immunity has become 
increasingly appreciated (Axelrod et al., 2019), with accumulating evidence suggesting 
that tumor-specific MHC-II expression is correlated with favorable outcomes in 
melanoma, classic Hodgkin’s lymphoma, breast cancer, and oropharyngeal cancers 
(Axelrod et al., 2019; Cioni et al., 2019; Forero et al., 2016; Johnson et al., 2016; Roemer 
et al., 2018). 
In this study, we used RNA-seq data from over 500 human head and neck tumors from The 
Cancer Genome Atlas (TCGA) to determine if the presence of oncogenic HPV is associated 
with altered expression of all classical MHC-II genes and other key genes involved in their 
regulation, antigen presentation, and T-cell co-stimulation. We found that expression of 
virtually all classical MHC-II genes was significantly upregulated in HPV+ tumors 
compared to their HPV− counterparts or normal control tissue. Similarly, genes that encode 
products that are fundamental to proper antigen loading and presentation were also 
significantly upregulated in HPV+ tumors. Importantly, the relative level of expression of 
these inducible MHC-II genes was far beyond those genes associated with professional 
APCs. Furthermore, the expression of class II major histocompatibility complex 
transactivator (CIITA) and regulatory factor X5 (RFX5)—essential master regulators of 
the MHC-II transcriptional control system—were significantly upregulated in the HPV+ 
cohort. This coordinated upregulation of the mRNA levels of genes involved in the MHC-
II antigen presentation pathway and their regulation were correlated with the higher 
intratumoral levels of IFNg observed in HPV+ carcinomas. In addition, genes that encode 
various T-cell co-stimulatory molecules involved in T-cell activation and survival were 
found to be significantly upregulated in HPV+ tumors compared to HPV− tumors and 
normal control tissue. Taken together, these results suggest a previously unappreciated role 
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for epithelial cells in antigen presentation that functionally contributes to the highly 
immunogenic tumor microenvironment observed in HPV+ HNSC. This further illustrates 
the profound differences in the immune landscape between the tumor microenvironments 
of HPV+ and HPV− HNSC and may in part contribute to the superior clinical outcomes 
that are associated with HPV+ HNSC. 
5.2 Materials and Methods 
5.2.1 TCGA RNA-seq boxplot comparisons 
Level 3 RNA-Seq by Expectation Maximization (RSEM)-normalized Illumina HiSeq 
RNA expression data for the TCGA head and neck cancer (HNSC) cohort was  
downloaded from the Broad Genome Data Analysis Centers Firehose server 
(https://gdac.broadinstitute.org/). The normalized, gene level Firehose dataset was utilized 
for all the genes analyzed. RSEM-normalized RNA-Seq data was extracted into Microsoft 
Excel and the HPV status was determined based on published datasets (Banister et al., 
2017; Bratman et al., 2016; The Cancer Genome Atlas Research Network, 2015; The 
Cancer Genome Atlas Research Network, 2017). For all genes analyzed in this study, 
patient samples from primary tumors with known HPV status were grouped as HPV+, 
HPV−, or normal control samples. Patient samples with undetermined HPV status or 
samples from secondary metastatic lesions were omitted from our calculations. This 
resulted in 73 HPV+, 442 HPV−, and 43 normal control samples with RNA-Seq data 
available for gene expression analysis. Oropharynx-only gene reanalysis was performed 
by utilizing patient samples that were isolated from the tissues of the oropharynx (tonsils, 
base of tongue, or oropharynx) for both HPV+ and HPV− samples. This resulted in 53 
HPV+ and 26 HPV− samples with RNA-Seq data available for gene expression analysis. 
Graphpad Prism v7.0 (Graphpad Software, Inc., San Diego, California, USA) was used to 
generate boxplot comparisons of gene expression between the indicated HPV+, HPV−, and 
normal control samples as well as the oropharynx-only reanalysis between HPV+ and 
HPV− samples. For each boxplot, the center line indicates the median, the lower and upper 
box limits represent Q1 (25th percentile) and Q3 (75th percentile), respectively, and the 
whiskers extend 1.5 times the interquartile range (IQR) from Q1 (lower whisker) and Q3 
(upper whisker). An unpaired, two-tailed non-parametric Mann–Whitney U test was 
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utilized to assign p-values. G*Power Software version 3.1.9.2 (Faul et al., 2007) was used 
to perform post-hoc power calculations, with effect size selected as 0.8 and α = 0.05. All 
boxplot comparisons achieved a power value > 0.8. Figures were assembled into final form 
using Adobe Illustrator CS6. 
5.2.2 Correlation matrix 
Level 3 RSEM-normalized RNA-seq data for the genes listed above were extracted from 
the TCGA database and processed as detailed above. For the HPV+ (upper triangle) and 
HPV− samples (lower triangle), pairwise spearman correlation was performed for each 
gene involved in the MHC-II transcriptional control system. Hierarchical clustering was 
utilized to group genes based on strength of correlation. Correlations and clustering were 
performed using R statistical environment (version 3.4.0) utilizing packages ggplot2 and 
reshape2. Correlation matrix figure was assembled into final form using Adobe Illustrator. 
5.3 Results 
5.3.1 Classical MHC class II α- and β-chain genes are expressed at 
higher levels in HPV+ head & neck carcinomas 
Constitutive expression of classical MHC-II molecules is typically restricted to 
professional antigen presenting cells—DCs, macrophages, and B-cells (van den Elsen et 
al., 2004). However, in non-immune cells that lack constitutive expression, such as those 
of the epithelia, their expression can be induced through exposure to proinflammatory 
cytokines (Boss and Jensen, 2003; Collins et al., 1984; Steimle et al., 1994). In humans, 
the genes that encode the three classical polymorphic MHC-II molecules HLA-DP, HLA-
DQ, and HLA-DR are expressed as α- and β-chains that form heterodimers on the cell 
surface (van den Elsen et al., 2004). We began by analyzing the Illumina HiSeq RNA 
expression data from the TCGA HNSC cohort for expression of HLA-DPA1, -DPB1, -
DQA1, -DQA2, -DQB1, -DQB2, -DRA, -DRB1, -DRB5, and -DRB6 genes, encoding the 
various α- and β-chains for all three classical isotypes (Figure 5.1). Uniformly, all HPV+ 
patient samples expressed significantly higher levels of mRNA for all 10 MHC-II genes 
analyzed compared to HPV− patient samples and virtually all normal control tissues—with 
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Figure 5.1. Expression of classical MHC-II α- and β-chain genes in head & neck 
squamous cell carcinomas stratified by high-risk HPV status. 
RSEM-normalized RNA-seq data for the indicated MHC-II genes was extracted from the 
TCGA database for the HNSC cohort for HPV+, HPV–, and normal control tissues. 
Numbers in brackets refer to the number of samples included in each analysis. Statistical 
analysis was performed using a two-tailed non-parametric Mann–Whitney U test. ** p ≤ 
0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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the exception of HLA-DQB2 (HPV+ versus Normal). As the majority of the HPV+ samples 
are from the oropharynx subsite, we repeated this analysis with HPV+ and HPV− samples 
that occur only in the oropharynx. Similarly, to the analysis including all subsites, HPV+ 
oropharyngeal tumors expressed significantly higher levels of MHC-II α- and β-chain 
genes compared to their HPV− oropharyngeal tumor counterparts (Figure 5.2). 
Collectively, these results indicate that HPV+ head and neck tumors express high levels of 
the mRNAs encoding the α- and β-chain heterodimers of the classical MHC-II molecules 
versus HPV− tumors or normal control tissues. It is noteworthy that based on the 
normalized read levels, all of these genes are expressed at levels several orders of 
magnitude above any markers of professional APCs, such as CD19 (B-cells) (Wang et al., 
2012), CCL13 (DCs) (Danaher et al., 2017), and CD84 (macrophages) (Zaiss et al., 2003) 
(Figure 5.3A). However, these normalized read levels are comparable to that of an 
established epithelial cell marker, E-cadherin (CDH1) (Gall and Frampton, 2013) (Figure 
5.3B). Thus, it is likely that these genes are being expressed by epithelial cells within the 
actual tumor. 
5.3.2 Genes encoding key components of the MHC-II antigen 
presentation pathway are expressed at higher levels in HPV+ 
head & neck carcinomas 
In the endoplasmic reticulum, newly synthesized MHC-II α- and β-chains form a trimeric 
complex with a non-polymorphic protein called the invariant chain (Ii), which is encoded 
by the HLA-DR antigens-associated invariant chain or Cluster of Differentiation 74 
(CD74) gene (Cresswell, 1996). This association with the Ii chain prevents premature 
peptide loading and also dictates the trafficking of the Ii-MHC-II complex to the 
endosomal-lysosomal antigen-processing compartments, which contain the antigenic 
peptides (Roche and Cresswell, 1990; Roche and Furuta, 2015). Once in this compartment, 
Ii is proteolytically cleaved, leaving only a small fragment in the peptide-binding groove 
called the class II-associated invariant chain peptide (CLIP). Similarly, to the genes 
encoding the classical MHC-II α- and β-chains, CD74 was found to be significantly 
upregulated in HPV+ HNSC compared to their HPV− counterparts or normal control 
tissues (Figure 5.4).
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Figure 5.2. Gene expression reanalysis in the oropharynx.  
RSEM-normalized RNA-seq data for tumors occurring in the oropharynx was extracted 
from the TCGA database for the HNSC cohort for HPV+ (53) and HPV– (26) samples. 
Statistical analysis was performed using a two-tailed non-parametric Mann-Whitney U 
test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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Figure 5.3. Expression of markers associated with APCs or epithelia. 
RSEM-normalized RNA-seq data for genes associated with APCs (A) or epithelia (B) was 
extracted from the TCGA database for the HNSC cohort for HPV+, HPV–, and normal 
control tissues. Statistical analysis was performed using a two-tailed non-parametric Mann-
Whitney U test. Numbers in brackets refer to the number of samples included in each 
analysis. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns – not significant.
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Figure 5.4. Expression of the invariant chain and MHC class II-like genes in head & 
neck carcinomas stratified by HPV status. 
RSEM-normalized RNA-seq data for the indicated genes involved in MHC-II-dependent 
antigen processing and presentation was extracted from the TCGA database for the HNSC 
cohort for HPV+, HPV–, and normal control tissues. Numbers in brackets refer to the 
number of samples included in each analysis. Statistical analysis was performed using a 
two-tailed non-parametric Mann–Whitney U test. ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 
0.0001.
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In order for antigenic peptide-binding to occur, CLIP must be removed from the peptide-
binding groove (Cresswell, 1996; Roche and Furuta, 2015). The enzymatic removal of 
CLIP is mediated by the MHC class II-like heterodimer, HLA-DM. After HLA-DM-
mediated removal of CLIP, the class II molecules can now bind lysosomally generated 
antigenic peptides (Busch et al., 2005; Roche, 1995). The binding of antigenic peptides is 
influenced by another MHC class II-like heterodimer, HLA-DO, which regulates the 
MHC-II peptide repertoire by modulating the activity of HLA-DM (Denzin et al., 2005; 
Poluektov et al., 2013). The α- and β-chains of these dimeric class II-like molecules are 
encoded by the HLA-DMA, HLA-DMB, HLA-DOA, and HLA-DOB genes. Like the 
classical MHC-II genes, all four genes encoding the class II-like MHC molecules are 
similarly upregulated in HPV+ HNSC versus HPV− tumors or normal control tissues 
(Figure 5.4). 
When repeated only considering the oropharynx subsite, HPV+ oropharyngeal tumors 
expressed significantly higher levels of the invariant chain and MHC-II-like genes 
compared to their HPV− oropharyngeal tumor counterparts (Figure 5.2). Taken together, 
the upregulation of the genes encoding the MHC-II invariant chain and class II-like genes, 
suggests that key components of the MHC-II antigen presentation pathway are transcribed 
in HPV+ HNSC at levels that are significantly higher than observed in HPV− tumors or 
normal control tissues. Furthermore, these genes are also expressed at very high levels, 
with the exception of HLA-DOB, that are indicative of being expressed by epithelial cells 
within the actual tumor. 
5.3.3 Impact of HPV status on the expression of transcriptional 
regulators of MHC-II gene expression 
Transcriptional control of MHC-II genes and the related genes that encode key components 
of the MHC-II antigen presentation pathway is among one of the best understood systems 
in mammals. It is a complex transcriptional system with a unique method of regulation that 
is completely dependent on the master transcriptional regulator CIITA (Boss and Jensen, 
2003; van den Elsen, 2011). In agreement with the high levels of MHC-II genes and related 
genes, analysis of the TCGA data reveals significantly higher levels of CIITA in HPV+ 
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samples compared to HPV− or normal control tissues (Figure 5.5). In addition, RFX5—
another important transcriptional regulator of MHC-II genes (Boss and Jensen, 2003)—
was similarly expressed at significantly higher levels in HPV+ samples with respect to 
HPV− tumors or normal control tissues (Figure 5.5). Again, these differences were also 
observed when only considering the expression of these genes in the oropharynx (Figure 
5.2). 
Expression of MHC-II genes and related genes are restricted to APCs, however non-
hematopoietic cells such as fibroblasts, endothelial cells, and epithelial cells can be 
stimulated by IFNγ to express MHC-II molecules and related proteins involved in the 
antigen presentation pathway (Boss and Jensen, 2003; Collins et al., 1984; Steimle et al., 
1994). We analyzed the expression level of the IFNγ gene (IFNG) (Figure 5.5). As 
expected, the relative level of IFNG expression was similar in magnitude to that of other 
leukocyte specific genes (Figure 5.3A). However, IFNG was expressed at significantly 
higher levels in HPV+ tumors compared to its HPV– counterpart or normal control tissues 
(Figure 5.5). In addition, when only considering the oropharynx, the expression of the 
IFNγ gene was significantly higher in HPV+ samples compared to HPV− oropharyngeal 
tumors (Figure 5.2). 
To further illustrate the IFNγ-specific coordinated upregulation of MHC-II genes and 
related genes that encode products essential for antigen processing and presentation, we 
generated a correlation matrix for both HPV+ (Figure 5.6: upper triangle) and HPV− 
samples (Figure 5.6: lower triangle). As expected, regardless of HPV status, we found 
that expression of all MHC-II antigen presentation-specific genes were correlated in a 
pairwise fashion in each patient sample. 
Thus, the upregulated expression of CIITA, RFX5, and subsequent expression of all the 
classical MHC-II genes and related genes required for antigen loading and presentation 
observed in HPV+ head and neck carcinomas are likely a consequence of IFNγ exposure. 
Furthermore, the correlation matrix illustrates the unique simultaneous coordination of the 
MHC-II transcriptional control system that has been shown to be dictated by the master 
transcriptional regulator CIITA (Boss and Jensen, 2003; van den Elsen, 2011).
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Figure 5.5. Expression of CIITA, RFX5, and IFNG mRNA in head & neck carcinomas 
stratified by HPV status. 
RSEM-normalized RNA-seq data for the CIITA, RFX5, and IFNG genes were extracted 
from the TCGA database for the HNSC cohort for HPV+, HPV−, and normal control 
tissues. Numbers in brackets refer to the number of samples included in each analysis. 
Statistical analysis was performed using a two-tailed non-parametric Mann–Whitney U 
test. **** p ≤ 0.0001.
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Figure 5.6. Correlation matrix of genes involved in the MHC-II antigen presentation 
pathway in head & neck carcinomas stratified by HPV status. 
RSEM-normalized RNA-seq data for the genes listed above were extracted from the TCGA 
database for the HNSC cohort for HPV+ (upper triangle) and HPV− samples (lower 
triangle). Pairwise spearman correlation was performed followed by hierarchical clustering 
to group based on correlation. Number in boxes indicate Spearman’s rank correlation 
coefficient of analyzed gene pairs.
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5.3.4 Impact of HPV status on the expression of T-cell co-
stimulatory molecules in HPV+ head & neck carcinomas 
Co-stimulation of T-cells occurs through the interaction of its constitutively expressed 
CD28 receptor with either CD80 or CD86 on APCs (Chen and Flies, 2013). Utilizing RNA 
expression data for the levels of each of these co-stimulatory molecules, we found higher 
levels of CD28 in HPV+ tumors compared to HPV− or normal control tissues (Figure 5.7). 
While the levels of both CD80 and CD86 in HPV+ tumors were not significantly different 
compared to their HPV− counterparts, they were significantly higher compared to normal 
control tissues (Figure 5.7). In addition, we found that the mRNA levels of CD152, which 
encodes for CTLA-4, a marker of T-cell activation (Rudd et al., 2009), was significantly 
upregulated in HPV+ tumors compared to HPV− and normal control tissues (Figure 5.7). 
Again, these differences were also observed when only considering the expression of these 
genes in the oropharynx (Figure 5.2). These results suggest that, like the MHC-II genes 
and the genes involved in antigen loading and presentation, co-stimulatory molecules are 
similarly present at higher levels in HPV+ tumors and this is correlated with a higher level 
of T-cell activation. 
5.3.5 Impact of HPV status on the expression of inducible T-cell 
survival signal molecules in HPV+ head & neck carcinomas 
Utilizing the RNA-seq HNSC dataset from the TCGA, we looked at genes that encode for 
inducible, T-cell activation-dependent, survival signal molecules and their respective 
ligands (Beier et al., 2007; Chen and Flies, 2013). We found that CD137 (4-1BB, 
TNFRSF9) was significantly upregulated in HPV+ tumors compared to HPV− or normal 
control tissues (Figure 5.8). However, its ligand TNFSF9 (CD137L, 4-1BBL) was found 
to be significantly downregulated in HPV+ tumors compared to HPV− and not 
significantly different compared to normal control tissues (Figure 5.8). Next, we looked at 
the genes that encode for the inducible T-cell co-stimulator (ICOS) and its ligand ICOSLG 
and found that both were significantly upregulated in HPV+ tumors compared to HPV−, 
but only ICOS was significantly upregulated in comparison to normal control tissues 
(Figure 5.8). Finally, we looked at OX40 (TNFRSF4, CD134) and its ligand OX40L 
(TNFSF4, CD252) and found that both genes were significantly upregulated in HPV+  
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Figure 5.7. Expression of genes that encode for T-cell co-stimulatory molecules in 
head & neck carcinomas stratified by HPV status. 
RSEM-normalized RNA-seq data for genes that encode T-cell specific co-stimulatory 
molecules was extracted from the TCGA database for the HNSC cohort for HPV+,  
HPV–, and normal control tissues. Statistical analysis was performed using a two-tailed 
non-parametric Mann–Whitney U test. Numbers in brackets refer to the number of samples 
included in each analysis. **** p ≤ 0.0001, ns – not significant.
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Figure 5.8. Expression of inducible T-cell survival signal molecules in head & neck 
carcinomas stratified by HPV status. 
RSEM-normalized RNA-seq data for inducible genes that encode for T-cell survival 
molecules was extracted from the TCGA database for the HNSC cohort for HPV+, HPV−, 
and normal control tissues. Statistical analysis was performed using a two-tailed non-
parametric Mann–Whitney U test. Numbers in brackets refer to the number of samples 
included in each analysis. * p ≤ 0.05, ** p ≤ 0.01, **** p ≤ 0.0001, ns – not significant.
 
 
150 
tumors compared to their HPV− counterparts and normal control tissues (Figure 5.8). 
Again, these differences were also observed when only considering the expression of these 
genes in the oropharynx with the exception of TNFSF4 (Figure 5.2). Taken together, these 
results suggest that T-cells are activated and proliferating within the HPV+ tumor 
microenvironment via the observation of an increase in expression of genes that encode for 
survival signal molecules that are only induced following TCR-mediated antigen-specific 
T-cell activation and/or CD28 co-stimulation (Beier et al., 2007; Chen and Flies, 2013). 
5.4 Discussion 
Expression of MHC-II is typically associated with professional APCs, which are 
considered essential for the initiation of the adaptive immune response. They function by 
sampling their local environment via phagocytosis, acquiring particles and processing them 
internally in order to present them on their cell surface to CD4+ T-cells in the context of an 
antigen-MHC-II complex (Roche and Furuta, 2015). The crosslinking of the CD4+ TCR 
and antigen-MHC-II complex initiates the T-cell activation protocol that, in conjunction 
with co-stimulatory signals, can ultimately lead to an effective adaptive immune response 
against a threat of internal or external origin, such as cancerous cells or bacteria and viruses, 
respectively (Chen and Flies, 2013). 
In non-hematopoietic cells, such as epithelia, MHC-II expression can be induced through 
exposure to the proinflammatory cytokine IFNγ (Boss and Jensen, 2003; Collins et al., 
1984; Steimle et al., 1994). This induction of MHC-II on epithelial cells bestows on them 
the ability to act as accessory APCs, and this can accentuate the presentation of antigens to 
CD4+ T-cells (Kim et al., 2009). However, the ability of epithelial cells to function as 
accessory APCs is generally underappreciated, with most existing information related to 
the gastrointestinal and respiratory tracts (Wosen et al., 2018). Interestingly, cancerous 
tissues can retain tumor-specific MHC-II expression, and this has the potential to increase 
recognition of a tumor by the immune system (Axelrod et al., 2019). Indeed, tumor specific 
MHC-II expression has been associated with superior prognosis and/or improved response 
to immune checkpoint inhibitor therapy in several human cancers, as well as increased 
tumor rejection in murine models (Axelrod et al., 2019; Cioni et al., 2019; Forero et al., 
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2016; Johnson et al., 2016; Roemer et al., 2018). The importance of the immune response 
for successful resolution of cancers cannot be understated. Indeed, mouse models have 
shown that neither chemotherapy nor radiation treatment functioned effectively in the 
absence of a functional immune system, at least in HPV+ HNSC (Spanos et al., 2009). 
While MHC-II expression has been reported in head and neck tumors (Cioni et al., 2019), 
existing studies have been limited to individual classical isotypes, such as HLA-DR, based 
on limitations in available antibodies (Johnson et al., 2018). Cell culture models based on 
established head and neck cancer lines have also demonstrated MHC-II expression, often 
in response to IFNγ, or following transfection with CIITA—master regulator of MHC-II 
transcription (Arosarena et al., 1999; Meissner et al., 2009). However, no existing studies 
have comprehensively assessed the transcriptional status of the entire MHC-II antigen 
presentation system in head and neck cancers. In this study, our goal was to determine if 
MHC-II components were widely expressed in human head and neck cancers and whether 
expression was influenced by HPV status. 
Using data from over 500 primary human head and neck tumors, we provide evidence that 
HPV+ head and neck carcinomas display high mRNA levels for virtually all MHC-II 
genes, including the classical and non-classical α- and β-chains, the invariant γ chain, as 
well as factors required for MHC-II loading and trafficking (Figures 5.1 and 5.4). 
Increased expression of these genes was observed whether the comparison included all 
head and neck cancer subsites or was restricted to just the oropharynx, where the majority 
of HPV+ head and neck cancers arise (Figure 5.2). These results are in good agreement 
with the concurrent detection of high levels of expression of CIITA and RFX5, important 
global regulators of MHC-II transcription (Boss and Jensen, 2003; van den Elsen, 2011), 
in HPV+ tumors. HPV+ head and neck carcinomas express significantly higher levels of 
these genes as compared to normal control tissues, and these levels are generally higher 
than in HPV– carcinomas (Figure 5.5). This likely reflects the T-cell inflamed nature of 
HPV+ cancers (Gameiro et al., 2018), and specifically the higher levels of IFNγ expressed 
in these tumors (Figure 5.5). This IFNγ-dependent coordinated upregulation of MHC-II 
genes and related genes involved in antigen processing and presentation was further 
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illustrated in Figure 5.6, where we observed a strong global correlation with all genes 
analyzed in the MHC-II transcriptional control system. 
After generation and programming in the thymus, CD8+ and CD4+ T-cells circulate in the 
body until they encounter their specific antigen presented on either class I or class II MHC 
molecules, respectively (Luckheeram et al., 2012; Pennock et al., 2013; Zhang and Bevan, 
2011). This interaction between TCR and antigen-loaded MHC complex represents signal 
1, which triggers the activation of T-cells. However, in order for the activated T-cell to 
fully respond to the presented threat, and not enter a state of unresponsiveness, it requires 
a secondary signal through co-stimulatory molecules (Chen and Flies, 2013). We found 
higher levels of CD28 in HPV+ tumors compared to their HPV− counterparts and normal 
control tissues (Figure 5.7). The binding of CD28 with either CD80 or CD86 leads to 
clonal expansion of the T-cell pool that is specific to the recognized antigen (Beier et al., 
2007; Chen and Flies, 2013). In order to attenuate this response, the aforementioned 
interaction leads to the induction of the co-inhibitory molecule CTLA-4, which is encoded 
by the gene CD152. This co-inhibitory molecule will compete with CD28 for binding to 
either CD80 or CD86 to attenuate the T-cell response (Chen and Flies, 2013; Rudd et al., 
2009). We found that CD152 was significantly upregulated in the HPV+ cohort (Figure 
5.7). Collectively, this data indirectly illustrates the higher number of infiltrating T-cells 
within the tumor microenvironments of HPV+ HNSC through the identification of 
significantly higher levels of the constitutively expressed T-cell-specific CD28 marker. In 
addition, it provides good evidence that the interaction of co-stimulatory molecules in 
HPV+ HNSC is effective, given that we detected significantly higher levels of expression 
of CD152 mRNA, which encodes for the inducible co-inhibitory molecule CTLA-4. 
In order for proliferating T-cells to persist and survive after antigen-recognition and 
subsequent stimulation with co-stimulatory molecules, they require survival signals that 
are delivered through the cross-linking of various molecules (Beier et al., 2007; Chen and 
Flies, 2013). Interestingly, unlike other co-stimulatory molecules—such as CD28—that 
can be found constitutively expressed on T-cells, the molecules that convey these survival 
signals are encoded by genes that are only expressed following TCR-mediated antigen-
specific T-cell activation and/or CD28 co-stimulation (Beier et al., 2007; Chen and Flies, 
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2013). We found that all inducible T-cell survival genes analyzed, with the exception of 
TNFSF9, were expressed at significantly higher levels in HPV+ tumors compared to HPV− 
and normal control tissues (Figure 5.8). TNFSF9 was significantly downregulated in 
HPV+ tumors compared to its HPV− counterpart (Figure 5.8). This downregulation of 
TNFSF9 is indicative of a mechanistic response to excessive CD137-mediated signaling 
(Eun et al., 2015; Ho et al., 2013; Kwon, 2015). This data indirectly illustrates that the 
HPV+ tumor microenvironment contains increased levels of activated and proliferating T-
cells via the observation of an increase in expression of genes that encode for survival 
signal molecules that are induced following TCR-mediated antigen-specific T-cell 
activation and/or CD28 co-stimulation. These results agree well with previous reports by 
our group and others that HPV+ tumors contain more T-cells (Chen et al., 2018; Gameiro 
et al., 2018; Mandal et al., 2016; Nguyen et al., 2016; Solomon et al., 2018), but goes 
further in that it indirectly provides evidence of productive MHC-II-dependent tumor-
antigen recognition. 
HPV+ HNSC tumors are remarkably different from their HPV− counterparts in that they 
express high levels of all components of the MHC-II antigen presentation apparatus. 
Importantly, while some of this signal can be attributed to professional APCs, the 
extremely high relative level of expression supports a model whereby the T-cell inflamed 
environment in HPV+ HNSC induces a functionally effective MHC-II presentation system 
based on tumor epithelial cells. As MHC-II-dependent antigen presentation is critical for 
CD4+ help in CD8+ T-cell responses, which are essential for the control and clearance of 
cancerous cells, it is likely that the expression of non-self-derived viral antigens or tumor-
derived neoantigens, combined with intact MHC-II presentation and appropriate co-
stimulation, contributes to the markedly better patient outcomes for HPV+ versus HPV– 
head and neck carcinomas. As immune checkpoint inhibition therapy in other cancers has 
been reported to be most effective for tumors with high MHC-II levels, suggesting that 
stratification based on MHC-II levels may help predict those likely to respond to 
checkpoint inhibition therapy. 
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Chapter 6  
6 General Discussion 
 
6.1 Thesis Summary 
Much of the existing literature that encompasses the foundation for this body of work 
utilizes relatively artificial in vitro model systems. These earlier and current approaches 
attempt to phenocopy complex malignancies under conditions that can be manipulated, to 
gain insight into mechanistic processes. Indeed, these approaches have several advantages 
such as infinite growth, amenability to high-throughput screening, and formation of 
xenograft tumors for in vivo testing. However, their lack of heterogeneity, tumor 
microenvironment, and infiltrating immune cells severely limit their ability to recapitulate 
actual human cancers (Namekawa et al., 2019). Therefore, my thesis research capitalizes 
on genomic and transcriptomic “big” data acquired through next-generation “-omics” 
technologies from actual human tumors. This in silico approach allows for an insightful 
elucidation of mechanistic processes under the influence of a native heterogeneous 
environment. Utilizing computational methods, I explored and profiled the epigenetic and 
immune landscapes between the tumor microenvironments of HPV-positive (HPV+) and 
HPV-negative (HPV–) carcinomas present in actual human malignancies. True to my 
proposed hypothesis, my studies have identified strikingly profound differences in the 
epigenetic and immune landscapes of the tumor microenvironments (TMEs) of these 2 
etiologically-distinct carcinomas, regardless of their tissue of origin. Furthermore, they 
also provided insight into the validity of 2 important models of HR HPV-mediated sabotage 
of intracellular epigenetic and immune networks that were previously proposed from 
artificial in vitro culture studies. In addition, these studies identified potentially useful 
therapeutic targets and advocated for the utility of novel immunotherapy treatment 
modalities. Notably, the expression of immune checkpoint molecules was shown, in HPV+ 
head and neck patients, to be potentially predictive biomarkers of clinical outcomes that 
could have implications for treatment deintensification. 
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6.2 Epigenetic Landscape of HPV+ Tumor Microenvironments 
The E7 oncoprotein from HR HPVs have been shown to mediate global changes on the 
epigenome of the infected host cell (Durzynska et al., 2017). One prime example of an E7-
mediated epigenetic change is the global reduction in the levels of tri-methylated lysine 27 
on histone 3 (H3K27me3), which is a universal mark of transcriptionally silenced 
chromatin. (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2008; Schwartz 
and Pirrotta, 2007). Furthermore, HPV has also been shown to increase the expression of 
the catalytic enzymes responsible for creating and removing methyl groups on lysine 27 of 
histone 3. Indeed, these in vitro studies have shown that HPV induces an increase in the 
expression level of the EZH2 core component of the PRC2 methyltransferase (Popov and 
Gil, 2010; Schwartz and Pirrotta, 2007), and the lysine demethylases 6A (KDM6A) and 
6B (KDM6B) (Hyland et al., 2011; McLaughlin-Drubin et al., 2011). 
Mechanistic studies of HPV-dependent effects on epigenetic regulators have primarily 
focused on altered expression of the p16 product of the CDKN2A locus, which is commonly 
found to be upregulated in HPV+ carcinomas (Klaes et al., 2001; Sano et al., 1998). Indeed, 
this HPV-specific upregulation of p16 is a clinically important surrogate marker of HPV 
status (Burd, 2016; Hoffmann et al., 2010; Klaes et al., 2001). The CDKN2A locus encodes 
for p16 and p14 which are negative regulators of the cell cycle (Zhang et al., 1998). 
Importantly, transcription from this locus is tightly regulated at the epigenetic level, with 
the methyltransferase PRC2 serving a key role in its repression by catalyzing the tri-
methylation (me3) of H3K27 across the entire genomic region. This is followed by the 
subsequent recruitment of another methyltransferase, PRC1, that maintains the chromatin 
in a transcriptionally repressive state by increasing local DNA methylation (Popov and Gil, 
2010). Therefore, this well-characterized locus serves as an important model of HPV-
induced epigenetic dysregulation (Kanao et al., 2004; Schlecht et al., 2015). 
As indicated above, the detailed series of experiments that have mechanistically unraveled 
the epigenetic changes induced by HPV E7 on the tightly regulated CDKN2A and adjacent 
CDKN2B loci have been elucidated in 2-dimensional in vitro culture systems (McLaughlin-
Drubin et al., 2011; McLaughlin-Drubin et al., 2013). While these cell culture-based 
experiments have allowed for a detailed elucidation of the biological factors involved in 
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HPV-mediated upregulation of p16, an analysis of these HPV-specific epigenetic effects 
has not been done in any HPV+ head and neck carcinomas or on large cohorts of any HPV-
induced cancers. Therefore, my objective was to determine if the epigenetic changes 
involved in p16 upregulation observed in artificial culture systems were recapitulated in 
actual primary HPV+ tumors from different anatomical locations. 
I began this work by developing an initial database of genomic and transcriptomic data that 
would serve as the basis for this and subsequent studies presented within my thesis. I 
downloaded normalized RNA expression data for the TCGA head and neck cancer (HNSC) 
and cervical carcinoma (CESC) cohorts from the Broad Genome Data Analysis Centers 
Firehose server. Importantly, HPV status was manually curated based on published datasets 
(Banister et al., 2017; Bratman et al., 2016; The Cancer Genome Atlas Research Network, 
2015; The Cancer Genome Atlas Research Network, 2017). Primary patient samples with 
known HPV status were grouped as HPV+, HPV–, or normal-adjacent control tissue. 
Patient samples with unknown HPV status were omitted from my calculations, as were 
samples obtained from secondary metastatic lesions. This resulted in 73 HPV+, 442  
HPV–, and 43 normal-adjacent control samples for the HNSC cohort and 278 HPV+, 19 
HPV–, and 3 normal-adjacent control samples for the CESC cohort. For all genes analyzed 
in this thesis, with the exception of p16 and p14, the gene level Firehose dataset was used. 
For p16 and p14, the gene isoform level Firehose dataset was used to discriminate between 
these two different products of the CDKN2A locus. 
In Chapter 2, I began by analyzing the entire CDKN2A and adjacent CDKN2B loci that 
encode for the tumor suppressors p16, p14, p15, and the non-coding RNA CDKN2B-AS. 
During normal cell growth and development, expression of genes from this cluster are 
silenced by PRCs through their catalyzation of methyl groups on lysine 27 of histone 3 
(Popov and Gil, 2010). As mentioned above, HPV-induced cancers commonly express 
high levels of p16 (Klaes et al., 2001; Sano et al., 1998). In contrast, the expression levels 
of the other products of this locus, and the adjacent CDKN2B locus—p14, p15, and the 
non-coding CDKN2B-AS—have not been studied as extensively. I therefore utilized my 
curated database of transcriptomic data from the TCGA to analyze the expression of the 4 
genes from the aforementioned loci in both the HNSC and CESC cohorts. As expected, 
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HPV+ samples from both cohorts had greatly increased levels of p16 mRNA expression 
compared to HPV– tumors and normal control tissue. Like p16, a similar upregulation of 
p14, p15, and CDKN2B-AS was observed in HPV+ cancers with respect to their HPV– 
counterparts. These results led me to conclude that PRC-mediated repression was 
abrogated across the entire CDKN2A and adjacent CDKN2B genomic regions as a result of 
infection by HPV. 
Based on the above observations, I wanted to analyze the impact of HPV oncogene 
expression on the core components of the methyltransferases, PRC2 and PRC1. A 
straightforward mechanistic explanation of the observed increase of expression from the 
CDKN2A and CDKN2B loci in HPV+ cells would be a decreased expression of the core 
proteins necessary for mediating the methyltransferase activity of PRC2 and PRC1 on 
H3K27. Interestingly, tissue culture experiments have shown that expression of EZH2 to 
be increased by the presence of HPV oncogenes, while no significant changes were 
observed for the EED and SUZ12 core component proteins (Hyland et al., 2011; 
McLaughlin-Drubin et al., 2011). Furthermore, other cell culture experiments have shown 
that BMI1, a core component of PRC1, is reduced in human foreskin keratinocytes (HFKs) 
transduced with E6 and E7. My analysis revealed that all 4 core components of both PRC2 
and PRC1 were expressed at levels higher or equivalent to HPV– samples or normal control 
tissues, with the exception of BMI1 in the CESC cohort. These results led me to conclude 
that the increased expression observed in the HPV+ cohorts from the CDKN2A and 
CDKN2B loci were not due to a reduction in the overall levels of the core components that 
form the PRC2 and PRC1 methyltransferases, respectively. 
I next looked for an alternative method of activating the CDKN2A and CDKN2B loci. Since 
I previously looked at the enzymes responsible for catalyzing the repressive methyl groups 
onto lysine 27 of histone 3, I therefore wanted to look at the enzymes responsible for the 
removal of the repressive H3K27me3 modification catalyzed by PRCs. Indeed, these 
histone modifications are erased by the KDM6A and KDM6B demethylases (Dawson and 
Kouzarides, 2012). Previous work in tissue culture models established that transduction of 
HPV E7 into HFKs induced increases in the levels of KDM6A and/or KDM6B mRNA and 
protein (Hyland et al., 2011; McLaughlin-Drubin et al., 2011). Importantly, siRNA 
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knockdown of KDM6B antagonized p16 induction by E7, suggesting that upregulation of 
these demethylases is the mechanism by which HPV reduces global H3K27me3 levels and 
activates p16 expression (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 
2013). My analysis concluded that KDM6A expression was significantly increased in 
HPV+ samples from both the HNSC and CESC cohorts with respect to their HPV– 
counterparts and normal control samples. However, this was not the case for KDM6B, 
which was found to be reduced in HPV+ samples compared to HPV– and normal control 
tissues from both cohorts. These results support the model proposed from tissue culture 
experiments, in which enhanced expression of KDM6A, but not KDM6B, by HPV is 
correlated with the dysregulation of H3K27me3 homeostasis and subsequent activation of 
transcription from the CDKN2A and CDKN2B loci in both these cancer types. 
Since HPV-mediated changes in epigenetic regulation of transcription of genes encoded 
by CDKN2A and CDKN2B would be reflected in the methylation-status of CpG 
dinucleotide sequences in or adjacent to these loci. I therefore sought to analyze the 
Infinium Human Methylation450 BeadChip array data for the TCGA HNSC and CESC 
cohorts for consistent alterations in DNA methylation in this region of the genome. My 
analysis of methylation data revealed that there were two consistent alterations in DNA 
methylation relative to methylation levels present in HPV– tumors and normal control 
tissues. Specifically, a region of DNA upstream of the p14 transcript was consistently 
identified to be hypomethylated in HPV+ carcinomas of both cohorts. Importantly, 
genome-wide studies have clearly indicated that methylation in the immediate vicinity of 
the transcription start site blocks initiation (Jones, 2012). As such, the greatly reduced 
methylation in HPV+ samples at this region is fully consistent with enhanced CDKN2A 
expression. In contrast, I also observed a hypermethylated region of DNA within the 3’-
end of the CDKN2A locus in HPV+ tumors regardless of their anatomical origins. Indeed, 
hypermethylation at this location has been described in other studies of HPV+ head and 
neck and cervical carcinomas using alternative probes (Ben-Dayan et al., 2017; Schlecht 
et al., 2015; Wijetunga et al., 2016). These studies have established that p16 and p14 
expression in a given tumor sample is strongly correlated with increased methylation at 
this position in the CDKN2A locus (Ben-Dayan et al., 2017; Schlecht et al., 2015). 
Therefore, along with promoter hypomethylation, gene-body methylation correlates well 
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with the observed enhanced transcription from the CDKN2A locus, providing further 
support for an epigenetic mechanism as the basis for HPV-mediated induction of 
expression from this locus. 
Epigenetic reprogramming induced by HPV should be reversible and could represent a 
unique and useful therapeutic target. Indeed, cervical carcinoma cell lines or other tumor 
cell lines expressing HPV E7 from HR HPVs appear to require continuous p16 expression 
for survival (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). Although 
p16 normally serves as a tumor suppressor, it becomes necessary for continued growth in 
cells expressing E7. Since HPV+ cells require KDM6 demethylase activity to maintain p16 
expression, therefore they are sensitive to small molecule inhibitors of KDM6 in cell 
culture models (McLaughlin-Drubin et al., 2011; McLaughlin-Drubin et al., 2013). 
Notably, it has not been determined if actual primary HPV+ head and neck or cervical 
carcinomas will respond similarly. My analysis of the epigenetic regulators that control 
p16 expression finds many commonalities between the hundreds of tumors making up the 
TCGA HNSC and CESC cohorts compared to in vitro cell culture models. Therefore, these 
observations strongly suggest that testing of KDM6 inhibitors should be aggressively 
pursued as a novel therapy against HPV+ cancers. 
Taken together, my analysis of over 350 HPV+ head and neck or cervical carcinomas in 
comparison with over 450 HPV– cancers from their respective anatomical sites validates 
conclusions drawn from artificial 2-dimensional in vitro culture models and identifies 
remarkable similarities between the effects of HPV on gene expression and methylation in 
large human cohorts from two anatomically distinct regions. Furthermore, these results 
also showcase the profound differences in the epigenetic landscape between the tumor 
microenvironments of HPV+ and HPV− carcinomas. In addition, the findings in this study 
strongly advocate for the testing of KDM6 inhibitors in actual human malignancies caused 
by infection with HPV. 
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6.3 Immune Landscape of HPV+ Tumor Microenvironments 
6.3.1 Impact of HPV on the MHC-I antigen presentation network 
In Chapter 3, I wanted to use the same computational methodology utilized in Chapter 2 to 
validate another important model of HPV-mediated sabotage that was proposed from 
artificial in vitro tissue culture studies. Indeed, multiple studies have suggested that HPV 
oncoproteins contribute to the evasion of the adaptive immune response, which supports a 
model by which the establishment of a persistent HPV infection contributes to the ability 
of HPV+ cancers to evade antitumor immune responses (Westrich et al., 2017). 
Specifically, transfection of HR HPV E7 into various cell lines has been shown to repress 
MHC-I and/or TAP expression (Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 
2010). Furthermore, reciprocal studies have also shown that the knockdown of E7 in some 
HPV+ cervical cancer cell lines increases MHC-I expression (Bottley et al., 2008; Li et al., 
2006). Mechanistically, these in vitro studies proposed that the reduction of MHC-I and 
TAP occur at the transcriptional level (Georgopoulos et al., 2000; Heller et al., 2011; Li et 
al., 2010).  
While the majority of published studies using tissue culture models indicate that HPV E7 
represses the expression of MHC-I, related studies on the effects of HPV in actual human 
carcinomas are less consistent. Indeed, conflicting reports have suggested that HPV+ 
carcinomas and/or precancerous lesions display increased, decreased, or the same levels of 
MHC-I or TAP when compared to their HPV− counterparts or normal control tissues. 
(Cromme et al., 1993; Djajadiningrat et al., 2015; Jochmus et al., 1993; Keating et al., 
1995; Ramqvist et al., 2015; Ritz et al., 2001; Torres et al., 1993; van Esch et al., 2014). I 
therefore utilized my curated database of transcriptomic data from over 800 human cervical 
and head and neck carcinomas, to assess the impact of HPV status on the expression of 
MHC-I heavy chain genes, the β2 microglobulin light chain gene, and other components 
of the MHC-I antigen presentation network. 
I began by analyzing the expression of both the classical (HLA-A, -B, and -C) and non-
classical (HLA-E, -F, and -G) heavy chain genes, as well as the invariant β2 microglobulin 
light chain (B2M) that comprises the MHC-I heterodimer (Hansen and Bouvier, 2009). 
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Unexpectedly, the expression levels of the 3 classical heavy chain genes were significantly 
higher compared to normal control tissues in the HNSC cohort. However, those levels were 
significantly lower than those observed in the HPV– samples. Furthermore, the expression 
levels of the non-classical heavy chain genes were higher or comparable to normal control 
tissues. As noted by others (Cicchini et al., 2017), HLA-E was expressed at significantly 
reduced levels in HPV+ samples compared with HPV− samples in the HNSC cohort only. 
Moreover, the classical and non-classical heavy chain genes in the CESC cohort were 
expressed at levels significantly higher in HPV+ samples compared to their HPV– 
counterparts. However, the comparison between HPV+ and normal control samples in the 
CESC cohort were insufficiently powered to allow for proper conclusions. In addition, the 
B2M light chain gene in both cohorts was expressed in HPV+ carcinomas at levels higher 
or comparable to HPV– samples. Collectively, these results indicate that the expression of 
HPV oncogenes in actual human tumors is not correlated with strong repression of genes 
encoded by the MHC-I loci, which is in stark contrast to what has been reported in tissue 
culture-based models. Indeed, the average expression of the mRNA for these genes was 
consistently higher or equivalent in HPV+ samples versus their respective controls. 
Next, I wanted to analyze the expression of key components involved in MHC-I-specific 
antigen loading and presentation that includes the heterodimer peptide transporter TAP 
(TAP1/2), the bridging factor tapasin (TAPBP), the endoplasmic reticulum aminopeptidase 
(ERAP1/2), and the chaperones: calreticulin (CALR), calnexin (CANX), and ERp57 
(PDIA3). As mentioned above, several studies have reported the downregulation of TAP 
in HPV+ cancer cell lines (Georgopoulos et al., 2000; Li et al., 2010). However, much less 
is known about the effect of HPV on the expression of these other components. In the 
HNSC cohort, all genes were expressed at higher levels in HPV+ samples with respect to 
normal control tissues, with the exception of CANX. In the CESC cohort, nearly all of these 
genes were expressed at elevated or comparable levels to HPV– or normal control tissues, 
although some comparisons were limited due to being insufficiently powered. Therefore, 
most components of the MHC-I antigen loading and presentation complex were transcribed 
in HPV+ human tumors at levels that appear similar or significantly higher than normal 
control tissues. This again contrasts with the reported decreases in TAP transcription 
reported in tissue culture models. 
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These unexpected results contradict the existing paradigm of HPV-mediated immune 
evasion and suggest that in the context of an actual human tumor setting, the presence of 
HPV may actually result in enhanced expression of mRNA encoding MHC-I-specific 
antigen loading and presentation components. Notably, these results illustrate the 
limitations of utilizing tissue culture systems to infer on complex networks. The use of in 
vitro 2-dimensional approaches are useful as a launching point into many hypothesis-
driven research initiatives; however, their utility in tumor virology—as exposed in this 
study—can be limited, primarily due to the platforms lack of cellular heterogeneity. Indeed, 
this cellular heterogeneity that exemplifies tumor microenvironments is a fundamental 
characteristic of actual human cancers and plays a significant role in influencing the 
complex interacting biochemical systems of these malignant cells. Specifically, expression 
of MHC-I and related genes can be induced by proinflammatory mediators that are 
produced by infiltrating immune cells that create an inflammatory state within the tumor 
microenvironment (Boehm et al., 1997). However, this would never be recapitulated in 
studies that simply transfect cell lines with HR HPV oncogenes without exposing them to 
proinflammatory mediators (Georgopoulos et al., 2000; Heller et al., 2011; Li et al., 2010). 
Given my observation that mRNA levels of all MHC-I antigen loading and presentation 
genes were expressed at higher or at least similar levels in HPV+ tumors compared with 
HPV− and normal control tissues, I hypothesized that infiltrating lymphocytes producing 
IFNγ—a proinflammatory cytokine—could be present at higher levels in HPV+ tumors 
compared to HPV− tumors or normal control tissues. Utilizing an immunogenomic 
approach with surrogate markers, I found evidence for significant infiltration by T- and 
NK-cells in both HPV+ and HPV− carcinomas. Indeed, the levels of infiltrating T-cells 
were significantly higher in HPV+ compared to their HPV– counterparts in both cohorts. 
In addition, my analysis also revealed significantly higher levels of IFNγ in HPV+ samples 
in both the HNSC and CESC cohorts. Taken together, these results indicate that HPV+ 
carcinomas have a significant level of infiltrating lymphocytes that appear to be producing 
IFNγ, which may explain the upregulated expression of the genes involved in MHC-I 
antigen loading and presentation observed in these carcinomas. 
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Taken together, the high absolute levels of mRNAs encoding MHC-I components 
expressed in HPV+ head & neck and cervical carcinomas provide good evidence that HR 
HPV E7 is unable to efficiently block the IFNγ induction of transcription of these genes in 
actual human tumors. Although this contrasts with the results of the studies listed above, 
my work agrees with other studies showing that various cervical cancer cell lines 
upregulate MHC-I in response to IFNγ (Bornstein et al., 1997; Evans et al., 2001; Mora-
Garcia Mde et al., 2006). Importantly, it should be noted that the levels of MHC-I heavy 
chain mRNAs are statistically lower in HPV+ compared to HPV− samples in the HNSC 
cohort, despite the increased levels of IFNγ. This may indicate that HPV is able to modestly 
impact IFNγ activation in these tissues, but this was not observed in the CESC cohort. In 
addition, this work differs markedly from my previous study in Chapter 2, in which I 
showed that tissue culture models faithfully recapitulate what is observed in actual human 
tumors. This may be due to the intrinsic nature of the pathways analyzed, with the MHC-I 
network being amenable to influence by immune cells infiltrating into the local 
environment. 
6.3.2 Impact of HPV on the immune status of head and neck tumor 
microenvironments  
Given the observation in Chapter 3 of higher levels of intratumoral IFNγ and increased 
infiltration by T- and NK-cells into the HPV+ TME, a mechanistic and detailed 
characterization of immune cell presence and status between the 2 anatomically-similar, 
etiologically-different head and neck cancer types were warranted. In Chapter 4, I used 
transcriptional data from my curated dataset of over 500 HNSC samples from the TCGA 
to compare the immune landscape between HPV+ and HPV– samples. Importantly, the 
corresponding analysis could not be done in the TCGA CESC cohort because of limitations 
in the number of HPV– and normal control samples in this dataset. In addition, these 
samples were treatment-naïve prior to surgical resection, avoiding any confounding effects 
of exposure to chemotherapy or radiation on the immune-status of these tumors. 
Both HPV+ and HPV– HNSC display a similar frequency of somatic mutations, a major 
source of tumor specific neoantigens that can be recognized and targeted by antitumor 
immunity (The Cancer Genome Atlas Research Network, 2015). However, unlike HPV– 
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HNSC, HPV+ carcinomas express exogenous antigenic viral proteins that may contribute 
to the initial differences observed in Chapter 3 in the levels of infiltrating immune cells 
between these 2 types of HNSC. Indeed, several studies have compared various 
immunological parameters between HPV+ and HPV– HNSC and have commonly 
concluded that HPV+ HNSC are immune “hot” tumors, with markedly more immune 
infiltration and higher levels of CD8+ T-cell activation than HPV– HNSC (Mandal et al., 
2016; Solomon et al., 2018). Importantly, these and other studies suggest that a detailed 
comparison of the immunological differences between HPV+ and HPV– HNSC provides 
an opportunity to identify immunological determinants that contribute to successful 
treatment in HNSC that may be broadly applicable to cancer treatment in general (Feng et 
al., 2017; Lyford-Pike et al., 2013; Montler et al., 2016).  
I began my investigation by comparing the type of immune response generated in HPV+ 
HNSC compared to its HPV– counterpart. Specifically, CD4+ helper T-cells are 
instrumental in establishing the type of response triggered by immune activation, whether 
it be a cell-mediated Th1 response, a humorally-biased Th2 response, or the 
proinflammatory Th17 response necessary to maintain the immunological integrity of 
mucosal barriers (Mucida and Salek-Ardakani, 2009). Each of the CD4+ subsets is 
characterized by a distinct transcriptional program regulated by specific master regulatory 
transcription factors (Fang and Zhu, 2017). Therefore, I analyzed my HNSC cohort from 
the TCGA for the expression of the following master regulatory transcription factors and 
the immune response they dictate: TBX21 (Th1), GATA3 and STAT6 (Th2), and RORA and 
RORC (Th17). I found that HPV+ samples had significantly increased levels of TBX21 
compared to HPV– and normal control tissues, which was indicative of a predominant Th1 
immune phenotype. 
Based on the observation that the HPV+ HNSC tumor microenvironment was 
characterized by a predominant Th1 cellular-mediated response and the observation in 
Chapter 3 of increased infiltration by T-cells into the HPV+ TME, I wanted to assess the 
relative proportion of CD4+ and CD8+ T-cells in these samples. Utilizing an 
immunogenomic approach, I analyzed the lineage-defining markers CD4 and 
CD8A/CD8B. As expected, HPV+ samples showed significantly increased expression of 
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all 3 genes compared to HPV– or normal control samples, confirming that enhanced T-cell 
infiltration is a common feature of HPV+ HNSC. Furthermore, I also observed 
significantly higher FOXP3 expression—associated with regulatory T-cells (Tregs)—in 
HPV+ HNSC. Moreover, analysis of the expression of CD137 (4-1BB), an activation-
induced costimulatory molecule present primarily on CD8+ T-cells, detected significantly 
higher levels in HPV+ compared to their HPV– counterparts or normal control samples, 
suggesting a higher overall level of T-cell activation and effector function in HPV+ 
malignancies. In addition, given the high levels of CD137 RNA in HPV+ HNSC samples, 
I expected higher effector cytokine production by T-cells in these samples. Indeed, as 
previously shown in Chapter 3, HPV+ HNSC expressed significantly higher levels of IFNγ. 
Furthermore, HPV+ HNSC tumors also expressed significantly higher levels of cytotoxic 
mediators, including granzyme A (GRZA), granzyme B (GRZB), and perforin (PRF1) 
compared to both HPV– HNSC or normal control tissues. Taken together, these results 
indicate that T-cells are not only present at higher levels in HPV+ HNSC, but also appear 
more active and likely producing effector molecules. 
An expected consequence of higher levels of infiltrating CD8+ T-cells producing IFNγ 
would be induction of expression of interferon-responsive genes in tumor cells in close 
proximity to the infiltrating T-cells. Indeed, in Chapter 3, I reported that multiple interferon 
responsive components of the MHC-I antigen presentation apparatus were upregulated in 
HPV+ HNSC. I therefore wanted to extend my studies to PDL1 and IDO1, which are 
immunomodulatory genes known to be expressed by tumor cells in response to IFNγ. Both 
PDL1 and IDO1 were significantly upregulated in HPV+ HNSC compared to normal 
control samples. Notably, these observations provide a scientific rationale for combining 
immunotherapy of HPV+ HNSC with immune checkpoint and IDO inhibitors in treatment-
naïve patients.  
Based on the observed increase in the number of infiltrating CD8+ and CD4+ T-cells into 
the TME of HPV+ HNSC, I hypothesized that this could be explained by the presence of 
a dendritic cell (DC) signature in these tumors. Indeed, DCs play an important role in 
migrating into these tumors, phagocytosing antigens, and presenting them to T-cells in the 
context of MHC-II (Spranger et al., 2015). Therefore, I performed an analysis of DC 
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signatures in these tumors, utilizing mRNA associated with DCs, as well as molecules 
expressed by activated DCs that include chemokines that are pivotal in attracting them into 
the TME. In my analysis, I observed high levels of transcripts from DC-associated genes, 
but also high levels of molecules expressed by activated DCs, such as chemokines, in 
HPV+ HNSC. Overall, these results indicate a higher level of DC involvement in HPV+ 
compared to HPV– HNSC, with higher levels of effector cytokines that could be 
responsible for the elevated levels of T-cell infiltration into the TME of these samples. 
T-cell-inflamed tumors show high levels of immune regulatory genes including IDO1 and 
PDL1, and high infiltration of FoxP3+ Tregs (Gajewski et al., 2017), secondary to 
cytotoxic T-cell infiltration into the TME. The presence of these immunosuppressive 
events in a T-cell-inflamed microenvironment is often accompanied by increased levels of 
multiple T-cell immune checkpoint molecules indicative of T-cell anergy. Indeed, once 
activated, T-cells upregulate expression of multiple cell surface receptors that negatively 
regulate their proliferation and moderate their level of activation. These so-called 
“exhaustion markers” include LAG3, PD1, TIGIT, and TIM3 (Anderson et al., 2016). 
Notably, they are important targets for immune checkpoint blockade therapies that are 
currently approved or under development. My analysis revealed that all 4 of these 
checkpoint genes were significantly upregulated in HPV+ HNSC compared to HPV– or 
normal control samples. In addition, I also examined the expression of the 
immunosuppressive molecule CD39 (Jie et al., 2013), which was recently shown to be 
exclusively expressed on tumor antigen-specific CD8+ T-cells and not bystander CD8+ T-
cells in colorectal and lung tumors (Simoni et al., 2018). My analysis showed significantly 
higher CD39 RNA expression levels in HPV+ HNSC tumors compared to HPV– or normal 
control samples. Collectively, my results indicate that HPV+ HNSC display a markedly 
different immune signature from HPV– HNSC, revealing sustained CD8+ T-cell activation 
in HPV+ HNSC. Furthermore, these observations provide a mechanistic insight into the 
processes that shape the immune structure of HPV+ HNSC as a T-cell-inflamed tumor. 
Moreover, they also suggest that combined immunotherapy with drugs that target more 
than one of these inhibitory molecules have potential to be effective in overcoming 
resistance to antitumor immunity in HPV+ HNSC tumors. Interestingly, there are no such 
trials currently under way, but these findings strongly indicate that initiation of such 
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clinical studies are justified once elevated protein levels are confirmed in a secondary 
validation cohort. 
High T-cell infiltration into HNSC, regardless of HPV status, has been reported as a 
positive prognostic factor (Nguyen et al., 2016). Moreover, expression of checkpoint 
molecules such as PD1 on circulating CD8+ T-cells is a biomarker of tumor antigen 
specificity (Gros et al., 2016). I therefore analyzed 5-year overall survival outcomes in both 
HPV+ and HPV– subsets of patients dichotomized by median expression of LAG3, PD1, 
TIGIT, TIM3, or CD39. Furthermore, a second set of survival outcomes were done to 
compare tumors expressing high levels of each combination of 2 of these markers. I 
observed that high levels of transcripts from 1 or any combination of 2 genes expressing 
immune checkpoint molecules (PD1, TIM3, TIGIT, LAG3) or CD39 in HPV+, but not 
HPV–, HNSC can predict patient survival after surgery. Collectively, these results suggest 
that the co-expression of high levels of CD39, LAG3, PD1, TIGIT, and TIM3 in HPV+, but 
not HPV–, HNSC reflect the successful development of T-cell-based antitumor immunity 
and a T-cell-inflamed phenotype, which contributed to long-term remission. This immune 
signature could be used as a predictive biomarker of HPV+ HNSC patient outcome after 
surgery. However, these findings require confirmation by prospective clinical studies to 
pave the way for the development of immune-predictive biomarkers for HPV+ HNSC 
patients that may ultimately lead to treatment deintensification in this patient population. 
I next applied the Cox Proportional Hazards Model to identify clinical variables (sex, age, 
smoking history, subsite, T stage, N stage, Overall stage, and HPV type) and 
immunological markers predictive of overall survival. By univariate analysis, high 
expression of TIGIT, TIM3, PD1, and CD39 were correlated with favorable prognosis 
(HzR = 0.29, 0.24, 0.22, and 0.15 respectively, p < 0.05), while an HPV type other than 
HPV16 was associated with a markedly poorer survival (HzR = 3.22, p = 0.03). 
Furthermore, oral cavity tumors had significantly worse survival compared to those in the 
oropharyngeal subsite (HzR = 3.05, p = 0.03). In addition, stepwise bidirectional 
multivariate analysis was used to identify the best multivariate model of survival, and the 
final model included N stage, HPV type, and CD39. Notably, CD39 (HzR = 0.07, p = 
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0.0007), and HPV type (HzR = 9.23, p = 0.001) remained as significant predictors of 
survival in this multivariate model. 
Taken together, this study provides comprehensive evidence that the immune landscape of 
HPV+ HNSC represents a T-cell-inflamed phenotype that is very different from HPV– 
HNSC. Importantly, I demonstrate that multiple mechanisms that negatively regulate the 
antitumor immune response are significantly upregulated in the majority of HPV+ HNSC 
cases. Furthermore, high levels of gene transcripts from these negative regulators—CD39, 
PD1, TIM3, LAG3, and TIGIT—correlate strongly with improved clinical outcome. 
Notably, many of these negative regulators of the immune response are targets of 
clinically-approved immune checkpoint inhibitors or inhibitors currently under 
investigation in clinical trials. Therefore, HPV+ HNSC has many immunological features 
that suggest that it would be highly amenable to immune checkpoint inhibition therapy. 
Based on this study, I propose that HPV+ HNSC is a T-cell-inflamed disease and should 
be treated differently in the clinic compared to HPV– HNSC, specifically with 
combinations of immune checkpoint inhibitors. 
6.3.3 Impact of HPV on the MHC-II antigen presentation network 
In the previous chapters, I have noted significant differences in the epigenetic and immune 
landscapes between the tumor microenvironments of HPV+ and HPV− carcinomas. 
Furthermore, other studies have also concluded that HPV+ tumors are distinct from their 
HPV– counterparts from a molecular perspective, with distinct genetic, epigenetic, and 
protein expression profiles (Seiwert et al., 2015; Sepiashvili et al., 2015; Worsham et al., 
2013). Moreover, in Chapter 4, I have also shown that HPV+ HNSC is a T-cell-inflamed 
malignancy, with increased infiltration by T-cells that express high levels of CD39 and 
multiple exhaustion markers that correlated with improved survival. In order for an 
effective T-cell-specific antitumor response to occur, a tumor associated antigen must be 
presented in the context of either MHC-I or MHC-II (Rock et al., 2016). Indeed, in Chapter 
3, I reported that HPV+ cancers express high levels of MHC-I and that this observation 
could be a consequence of the increased levels of intratumoral IFNg present in the HPV+ 
TME. While expression of MHC-II molecules is typically restricted to professional APCs, 
such as DCs, macrophages, and B-cells (van den Elsen et al., 2004), epithelial cells can be 
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stimulated by IFNg to express MHC-II and function as accessory APCs to stimulate T-cell 
responses (Boss and Jensen, 2003; Collins et al., 1984; Kim et al., 2009). In this final 
chapter, I sought to determine the impact of HPV status on the expression of MHC-II genes 
and related genes involved in their regulation, antigen presentation, and T-cell co-
stimulation by analyzing my large HNSC cohort from the TCGA. 
I began by analyzing my large HNSC transcriptomic dataset for expression of the α- and 
β-chain genes that form the classical MHC-II heterodimers on the cell surface (van den 
Elsen et al., 2004). Uniformly, all HPV+ patient samples expressed significantly higher 
levels of mRNA for all MHC-II genes analyzed compared to HPV− patient samples and 
virtually all normal control tissues. Notably, the normalized read levels of these genes were 
expressed at levels several orders of magnitude above any lineage-defining markers of 
professional APCs, such as CD19 (B-cells) (Wang et al., 2012), CCL13 (DCs) (Danaher et 
al., 2017), and CD84 (macrophages) (Zaiss et al., 2003). However, these normalized read 
levels were comparable to that of an established epithelial cell marker, E-cadherin (CDH1) 
(Gall and Frampton, 2013). Therefore, it is likely that these MHC-II genes are being 
expressed by epithelial cells within the actual tumor. Collectively, these results indicate 
that HPV+ head and neck tumors express high levels of the mRNAs encoding the α- and 
β-chain heterodimers of the classical MHC-II molecules, providing key evidence that 
epithelial cells could be functioning as accessory APCs. 
Next, I wanted to analyze the genes encoding key components of the MHC-II presentation 
pathway. Specifically, I analyzed the non-classical α- and β-chains and the invariant γ chain 
that are required for proper MHC-II antigen loading and trafficking. Similar to the classical 
MHC-II genes, HPV+ samples expressed significantly higher levels of the invariant chain 
and MHC-II-like genes compared to their HPV− counterparts and normal control tissues. 
Collectively, the upregulation of these genes suggests that key components of the MHC-II 
antigen presentation pathway are transcribed in HPV+ HNSC at levels that are significantly 
higher than observed in HPV− tumors or normal control tissues. Furthermore, these genes 
are also expressed at very high levels, indicative of being expressed by epithelial cells 
within the actual tumor. 
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Based on the observations that HPV+ head and neck carcinomas display high mRNA levels 
for virtually all MHC-II genes analyzed above, I wanted to assess the impact of HPV on 
the expression of transcriptional regulators of MHC-II gene expression. Transcriptional 
control of MHC-II genes and the related genes that encode key components of the MHC-
II antigen presentation pathway is among one of the best understood systems in mammals. 
It is a complex transcriptional system with a unique method of regulation that is completely 
dependent on the master transcriptional regulator CIITA (Boss and Jensen, 2003; van den 
Elsen, 2011). Analysis of the TCGA data revealed significantly higher levels of CIITA in 
HPV+ samples compared to HPV− or normal control tissues. In addition, RFX5—another 
important transcriptional regulator of MHC-II genes (Boss and Jensen, 2003)—was 
similarly expressed at significantly higher levels in HPV+ samples with respect to HPV− 
tumors or normal control tissues. 
In Chapters 3 and 4, I showed that HPV+ carcinomas had increased levels of intratumoral 
IFNγ, which as mentioned above, is able to stimulate the expression of MHC-II genes in 
epithelial cells. To illustrate this IFNγ-specific coordinated upregulation of MHC-II genes 
and related genes that encode products essential for antigen processing and presentation, I 
generated a correlation matrix for both HPV+ and HPV− samples. As expected, regardless 
of HPV status, I found that expression of all MHC-II antigen presentation-specific genes 
were statistically correlated in a pairwise fashion in each patient sample. Therefore, the 
upregulated expression of CIITA, RFX5, and subsequent expression of all the classical 
MHC-II genes and related genes required for antigen loading and presentation observed in 
HPV+ head and neck carcinomas are likely a consequence of IFNγ exposure. Furthermore, 
the correlation matrix illustrates the unique simultaneous coordination of the MHC-II 
transcriptional control system that has been shown to be dictated by the master 
transcriptional regulator CIITA (Boss and Jensen, 2003; van den Elsen, 2011). 
Next, I wanted to assess the impact of HPV on the expression of T-cell co-stimulatory 
molecules. After generation and programming in the thymus, CD8+ and CD4+ T-cells 
circulate in the body until they encounter their specific antigen presented on either class I 
or class II MHC molecules. (Luckheeram et al., 2012; Pennock et al., 2013; Zhang and 
Bevan, 2011). This interaction between TCR and antigen-loaded MHC complex represents 
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signal 1, which triggers the activation of T-cells. However, in order for the activated T-cell 
to fully respond to the presented threat, it requires a secondary signal mediated by co-
stimulatory molecules (Chen and Flies, 2013). My analysis found higher levels of CD28 in 
HPV+ tumors compared to their HPV− counterparts and normal control tissues. It is well 
established that the binding of T-cell-specific CD28 with either CD80 or CD86 leads to the 
clonal expansion of the T-cell pool that is specific to the recognized antigen (Beier et al., 
2007; Chen and Flies, 2013). In order to attenuate this response, the aforementioned 
interaction leads to the induction of the co-inhibitory molecule CTLA-4, which is encoded 
by the gene CD152. This co-inhibitory molecule will then compete with CD28 for binding 
to either CD80 or CD86 to attenuate the T-cell response (Chen and Flies, 2013; Rudd et 
al., 2009). I found that CD152 was significantly upregulated in the HPV+ cohort. 
Collectively, this data indirectly illustrates and further confirms what has been shown in 
previous chapters, that HPV+ tumor microenvironments have a higher number of 
infiltrating T-cells. In addition, it provides good evidence that the interaction of co-
stimulatory molecules in HPV+ HNSC is effective, given that I detected significantly 
higher levels of expression of CD152 mRNA, which encodes for the inducible co-
inhibitory molecule CTLA-4. 
Finally, I wanted to look at the impact of HPV on the expression of activation-inducible T-
cell survival molecules. In order for proliferating T-cells to persist and survive after 
antigen-recognition and subsequent stimulation with co-stimulatory molecules, they 
require survival signals that are delivered through the cross-linking of various molecules 
(Beier et al., 2007; Chen and Flies, 2013). Importantly, unlike CD28 that is found 
constitutively expressed on T-cells, the molecules that convey these survival signals are 
encoded by genes that are only expressed following TCR-mediated antigen-specific T-cell 
activation (Beier et al., 2007; Chen and Flies, 2013). Utilizing my HNSC dataset, I looked 
at these genes that encode for the inducible, T-cell activation-dependent, survival signal 
molecules. I found that all inducible T-cell survival genes analyzed, with the exception of 
TNFSF9, were expressed at significantly higher levels in HPV+ tumors compared to HPV− 
and normal control tissues. This data indirectly illustrates that the HPV+ tumor 
microenvironment contains increased levels of activated and proliferating T-cells via the 
observation of an increase in expression of genes that encode for survival signal molecules 
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that are only induced following TCR-mediated antigen-specific T-cell activation. 
Furthermore, these results agree with my previous work on the immune landscape 
(Chapters 3 and 4) and with previous reports by others that HPV+ tumor 
microenvironments contain more T-cells (Chen et al., 2018; Mandal et al., 2016; Nguyen 
et al., 2016; Solomon et al., 2018). 
In summary, this final chapter provided further evidence that the HPV+ HNSC tumor 
microenvironments are remarkably different from their HPV− counterparts. Importantly, 
while some of this MHC-II signal can be attributed to professional APCs, the extremely 
high relative level of expression supports a model whereby the T-cell inflamed 
environment in HPV+ HNSC induces a functionally effective MHC-II presentation system 
based on tumor epithelial cells. As MHC-II-dependent antigen presentation is critical for 
CD4+ help in CD8+ T-cell responses, which are essential for the control and clearance of 
cancerous cells (Pluhar et al., 2015), it is likely that the expression of non-self-derived viral 
antigens or tumor derived neoantigens, combined with intact MHC-II presentation and 
appropriate co-stimulation, contributes to the markedly better patient outcomes observed 
for those with HPV+ head and neck carcinomas. 
Taken together, the aforementioned studies profiled the immune landscape of HPV+ TMEs 
(Chapters 3–5) and illustrated a microenvironment that consisted of increased MHC-I and 
MHC-II expression that seemed to be induced from exposure to the proinflammatory 
cytokine IFNγ that is mainly produced by infiltrating T- and NK-cells. Furthermore, we 
observed an HPV+ TME that exhibited a strong bias towards a Th1 response which was 
characterized by increased infiltration with multiple types of immune cells and expression 
of their effector molecules. In addition, the HPV+ TME also expressed higher levels of 
multiple T-cell exhaustion markers that were indicative of a T-cell-inflamed phenotype. 
This predominantly immune “hot” HPV+ tumor microenvironment is summarized in the 
following proposed schematic model (Figure 6.1). 
6.4 Limitations of Study Design 
The use of transcriptomic “big” data acquired through next-generation “-omics” 
technologies from bulk tumor samples is a powerful approach that allows for an insightful 
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Figure 6.1. Proposed schematic model of an HPV+ tumor microenvironment. 
Schematic of an immune “hot” HPV+ tumor microenvironment that is characterized by an 
increase in expression of the MHC-I and MHC-II antigen presentation systems, infiltration 
with various immune cell subtypes, abundance of effector molecules, and upregulation of 
T-cell exhaustion markers. Created with BioRender.
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elucidation of mechanistic processes under the influence of a native heterogeneous 
environment. However, this in silico method that has been employed in this body of work 
contains unavoidable limitations. The first limitation is the use of RNA-seq data acquired 
through bulk tissue RNA sequencing platforms. This bulk tissue method measures the 
mRNA expression levels of genes from an admixture of cells that include cancerous cells, 
fibroblasts, immune cells, endothelial cells, and normal-adjacent cells (The Cancer 
Genome Atlas Research Network et al., 2013). This could lead to confounding results 
where you have expression of certain genes that can be expressed by different cell types. 
However, in our study design, we looked at genes that have been shown to be expressed 
by specific cell types, such as those of the immune system. In terms of tumor purity, the 
TCGA consortium set a quality threshold that required tumor samples to be composed of 
at least 60% tumor nuclei, as determined by visual analysis (Aran et al., 2015). Another 
limitation is the lack of protein data in the TCGA cohorts to corroborate our mRNA 
analyses, which is important because mRNA expression does not always mirror their 
respective protein levels (Fortelny et al., 2017). Finally, as with any high throughput 
analysis, the cohorts used are susceptible to batch effects that result from data processing 
(Leek et al., 2010). 
6.5 Concluding Remarks 
In conclusion, these analyses provide significant insight into the validity of epigenetic and 
immunological models of HPV-mediated sabotage, which have been proposed from 
experiments conducted on relatively artificial in vitro culture systems. Importantly, these 
studies have illustrated, in great detail, the strikingly profound differences in both the 
epigenetic and immune landscapes between the tumor microenvironments of HPV+ and 
HPV– carcinomas. In addition, this body of work has also identified a potentially useful 
therapeutic target in KDM6A, and strongly advocates for the use of promising 
immunotherapy strategies in the treatment of HPV+ HNSC. Furthermore, I also show that 
expression of negative regulators of T-cell responses could potentially serve as predictive 
biomarkers of clinical outcomes that could allow for treatment deintensification for patients 
with favorable prognosis. Notably, the novel hypotheses that have been generated by this 
work can also feedback into the laboratory and allow for further exploration in an 
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experimental setting where relevant models, based on these studies, can be generated and 
biologically manipulated. Lastly, it is in my hope that the accumulated knowledge gained 
from this thesis will help advance the field of tumor virology and provide a positive clinical 
impact on patients who live their daily lives with the burden of these devastating HPV-
induced malignancies. 
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Market, London, Ontario, Canada. February 4, 2018 
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The Epigenetic dysregulation of p16 by HPV in head and neck cancers is a potential target 
for therapy. Presented at the Oncology Grand Rounds, held at Victoria Hospital, London 
Regional Cancer Program, London, Ontario, Canada. December 5, 2017 
 
Surgical Management of Aortic Dissection—A Patient’s Perspective. Presented at the 
Canadian Society of Vascular Nursing (London Chapter) held at the Four Points Sheraton 
in London, Ontario, Canada. November 2, 2011 
 
 
POSTER PRESENTATIONS 
 
Human papillomavirus-positive head and neck cancers express high levels of class II major 
histocompatibility complex. Abstract and poster presented at the Molecular Biology of 
DNA Tumor Viruses Conference, held in Trieste, Italy. July 9-14, 2019 
 
*Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype 
distinct from their HPV- counterparts that has implications for immunotherapy. Abstract 
and poster presented at Oncology Research and Education Day, held in London, Ontario, 
Canada. June 8, 2018 
 
*HPV16 intratypic variants in head & neck cancers: A Southwestern Ontario perspective. 
Abstract and poster presented at Oncology Research and Education Day, held in London, 
Ontario, Canada. June 17, 2016 
 
HPV16 intratypic variants in head & neck cancers: A Southwestern Ontario perspective. 
Abstract and poster presented at the Infection and Immunity Research Forum (IIRF), held 
in London, Ontario, Canada. November 6, 2015 
 
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Abstract and poster 
presented at the Molecular Biology of DNA Tumor Viruses Conference, held in Trieste, 
Italy. July 21-26, 2015 
 
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Abstract and poster 
presented at the Infection and Immunity Research Forum (IIRF), held in London, Ontario, 
Canada. November 6, 2014 
 
Reduction of MHC I by HPV16 E7 and its role in head & neck cancers. Abstract and poster 
presented at the Molecular Biology of DNA Tumor Viruses Conference, held in Madison, 
Wisconsin, USA. July 21-26, 2014 
 
Elucidating the mechanism by which HPV16 E7 modulates MHC I and defining its role in 
OSCC. Abstract and poster presented at the London Health Research Day (LHRD), held 
in London, Ontario, Canada. March 18, 2014 
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Elucidating the mechanism by which HPV16 E7 modulates MHC I and defining its role in 
OSCC. Abstract and poster presented at the Infection and Immunity Research Forum 
(IIRF), held in London, Ontario, Canada. November 1, 2013 
 
*Denotes award-winning presentation 
 
 
SCHOLARLY ACTIVITIES 
 
Chair                                                                                     October 2017 – August 2018 
Translational Seminar Speaker Selection Committee 
Cancer Research and Technology Transfer Program 
• Act as liaison between the selection committee and administrative staff 
 
Student Representative                                                   September 2017 – August 2019 
American Society for Virology 
Department of Microbiology and Immunology 
• Convey information regarding the annual general meeting, funding opportunities, 
and other relevant information from the society to M&I graduate students 
 
Student Representative                                                   September 2015 – August 2017 
Seminars Committee 
Department of Microbiology and Immunology 
• Responsible for attending meetings throughout the year to discuss potential 
speakers for the R.G.E Murray Seminar Series 
 
Grad Coordinator                                                                    January 2014 – May 2015 
Microbiology & Immunology Student Association (MISA) 
• Mentor in the MISA mentorship program 
• Aid in organizing events to educate undergraduate students about graduate studies 
in the Microbiology and Immunology program at The University of Western 
Ontario 
 
Organizing Committee Member                                     November 2013 – August 2018 
Infection and Immunity Research Forum (IIRF) 
• The IIRF is an annual scientific conference that is organized and run by the 
graduate students of The University of Western Ontario in the department of 
Microbiology and Immunology. This conference showcases undergraduate, 
graduate, and post-doctoral research in the fields of microbiology, immunology, 
and virology 
 
Committee Member                                                             October 2013 – August 2016 
Microbiology and Immunology Social Committee 
• Organizing and running social events, including fundraising for the department of 
Microbiology and Immunology 
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MEMBERSHIPS 
 
American Society for Virology Student Member                   February 2017 – Present 
 
 
VOLUNTEER WORK 
 
Research Information Outreach Team                                  September 2017 – Present 
Canadian Cancer Society—London Chapter 
• Help plan and organize annual activities such as: World Cancer Day and Let’s 
Talk Cancer 
• Spread the word about progress and promise in cancer research through a monthly 
column in The Londoner and through social media postings 
 
Undergraduate Science Case Competition Judge                                        March 2016 
SciNapse Science—The University of Western Ontario 
• Evaluated undergraduate poster presentations and their understanding of the 
research project 
 
The American Society for Virology (ASV) Volunteer                                     June 2015 
34th annual ASV meeting—The University of Western Ontario 
• Organized and ran oral presentation workshops 
 
Outreach Volunteer                                                        December 2012 – January 2015 
Let’s Talk Science -The University of Western Ontario  
• Deliver science learning programs and services that turn children and youth on to 
science 
 
Volunteer Speaker               December 2012 – March 2014 
Canadian Blood Services Volunteer Speakers’ Bureau Program 
• Share my personal story at organized events to expand Canadian Blood Services’ 
capacity to recruit blood donors and help raise awareness of the increasing need 
for blood and new blood donors 
 
In-Community Volunteer                                                    November 2012 – May 2013 
Canadian Blood Services 
• Sign up blood donors for upcoming clinics 
• Monitor donors after they have given blood 
• Promote public awareness about the importance of blood donation through 
handing out flyers 
